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In the last few years we have entered an important new chapter in the story of hepatitis C 
virus (HCV) infection. Troublesome interferon-based treatment regimens with severe side 
effects and moderate success rates are left behind. The advent of effective and well-tolerated 
therapies with cure rates above 95% in most patient groups has been a game-changer for the 
disease and made HCV infection, theoretically, an eliminable disease. Clinicians can offer 
treatment to potentially all HCV infected persons, regardless of the degree of liver disease, 
somatic or psychiatric comorbidities. In the last years, data on optimal regimens have been 
rapidly emerging and treatment guidelines subsequently rapidly changing. During the work 
with this thesis, I have been fortunate to witness this major breakthrough in modern medicine 
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Chronic hepatitis C virus (HCV) infection can progress to cirrhosis and end-stage liver 
disease in a substantial proportion of patients. The infection is frequently asymptomatic, 
leaving many infected individuals unaware of the diagnosis until complications occur. 
Worldwide, the total number of HCV infections is projected to remain stable or to decline, but 
the burden of the disease is expected to increase. The availability of potent direct-acting 
antiviral therapies (DAAs) provides an opportunity to reverse the rising burden of HCV-
disease. However, viral resistance to DAAs has emerged as an important consideration in 
optimization of HCV-treatment.  
There is an uncertainty regarding the prevalence of HCV infection in Norway due to limited 
availability of population-based data. The first aim of this thesis is to assess the prevalence of 
HCV infection and the proportion of undiagnosed HCV infection in a general adult 
population. In a cross-sectional study based on data from the Tromsø 7 Study, we found a low 
prevalence (0.2%) of viraemic HCV infection in the general population. A substantial number 
(13/33) of individuals with viraemic disease were unaware of their status. 
Second, we aim to estimate future complications of chronic HCV infection towards 2050 in 
our presumed low-prevalence area by using a Markov cohort simulation model based on data 
from the Hepatitis C Study in Northern Norway. In this modelling approach, we estimated a 
stable low incidence of HCV infections towards 2050. The model predicted an almost three-
fold increase in the prevalence of cirrhosis (68 per 100,000), of decompensated cirrhosis (21 
per 100,000) and of hepatocellular carcinoma (4 per 100,000) by 2050, as well as a six-fold 
increase in the cumulated number of deaths from HCV-related liver disease (170 per 100,000 
inhabitants). 
Finally, we aim to investigate the effect of baseline HCV resistance-associated substitutions 
(RASs) on treatment outcome in patients with HCV genotypes 1a and 3 in a prospective, real-
life, open label, non-randomized multi-center cohort study in Norway and Sweden (HCV 
Preexist). Baseline RASs appeared to be associated with lower cure rates. 
To conclude, our findings suggest a substantial rise in HCV-related morbidity and mortality in 
the coming years, despite a low prevalence of chronic HCV infection in the general 
population. Baseline RASs appear to impair the treatment response to DAAs in patients with 




Infeksjon med hepatitt C-virus (HCV) gir i de aller fleste tilfellene en asymptomatisk kronisk 
hepatitt med gradvis utvikling av progredierende leverfibrose. Sykdommen oppdages ofte 
ikke før det er etablert levercirrhose og/eller cirrhoserelaterte komplikasjoner. 
Sykdomsbyrden av kronisk infeksjon med HCV er antatt å øke i årene fremover. Nye 
direktevirkende antivirale medisiner (DAAs) har revolusjonert behandlingen av hepatitt C 
med svært høye kurasjonsrater i de fleste pasientgruppene, men viral resistens kan påvirke 
behandlingseffekten. 
Det er usikkerhet vedrørende prevalensen av HCV infeksjon i Norge ettersom det foreligger 
få populasjonsbaserte studier. I denne avhandlingen er det brukt data fra Tromsø 7 
undersøkelsen for å undersøke prevalensen av HCV infeksjon i den generelle voksne 
befolkningen. Vi fant en lav prevalens på 0.2 % av viremisk HCV infeksjon. Et betydelig 
antall (13/33) av disse visste ikke at de hadde smitteførende sykdom, noe som taler for at 
gjeldende nasjonale screeningsanbefalinger er suboptimale for å finne de som er smittet.  
Videre estimerte vi fremtidig insidens av komplikasjoner av kronisk HCV infeksjon frem mot 
2050 i vårt antatte lavprevalens område. Til dette brukte vi en Markov kohortmodell med data 
fra Hepatitt C Studien i Nord-Norge. Vi estimerte en stabil, lav insidens av HCV infeksjon 
frem mot 2050, men en nesten tredobbel økning i prevalensen av cirrhose (68 pr 100,000), av 
dekompensert cirrhose (21 pr 100,000) og av hepatocellulært karcinom (4 pr 100,000) frem 
mot 2050, i tillegg til en nesten seksdoblet økning i kumulert antall dødsfall forårsaket av 
HCV-relatert leversykdom (170 pr 100,000).  
Til sist undersøkte vi om resistensassosierte substitusjoner (RASs) i HCV påvirket 
behandlingseffekten av DAAs hos pasienter med HCV genotype 1a og 3. Data fra en 
prospektiv, multisenter, «real life» kohortstudie i Sverige og Norge (HCV Preexist) viste at 
tilstedeværelse av RASs syntes å ha innvirkning på behandlingsresultatet med høyere 
kurasjonsrater når behandlingen ble tilpasset funn ved resistensanalyse.  
For å konkludere indikerer våre funn en betydelig økning i HCV relatert morbiditet og 
mortalitet i årene fremover til tross for en lav prevalens av kronisk HCV infeksjon i den 
generelle befolkningen. Tilstedeværelse av RASs kan ha negativ innvirkning på 
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Hepatitis C virus (HCV) infection is increasingly being recognized as a serious health threat 
worldwide, but still remains relatively unknown in the general population in low endemic 
countries. Chronic HCV infection is a major cause of chronic liver disease, liver cirrhosis, 
hepatocellular carcinoma (HCC) and end-stage liver disease [1, 2]. The total number of HCV 
infections is expected to decline in the years to come, but HCV-related mortality and 
morbidity is projected to increase as the aging population infected during peak HCV 
epidemics decades earlier progresses to more advanced liver diseases [3-6]. The infection is 
often asymptomatic until late stage, hence the term “the silent epidemic”, where a substantial 
proportion of infected individuals are unaware of their diagnosis [7, 8]. Prevention of late 
complications requires treatment before patients reach advanced stages of the disease, which 
underlines the necessity of an early diagnosis.  
The development of direct-acting antiviral agents (DAAs) is one of the major breakthroughs 
in modern medicine and has changed the scenario and perspective of HCV treatment [9]. 
Compared to previous interferon (IFN)-based therapies, oral DAA regimens are well 
tolerated, have shorter treatment durations, cure rates above 95% in the majority of patient 
groups, and can be administered to potentially all HCV infected persons with all aspects of 
liver disease, and also in the presence of somatic- and psychiatric comorbidities.  
The improvement in HCV treatment has the potential to reverse the rising burden due to HCV 
infection, but undiagnosed infection is one major barrier to the health impact offered by 
DAAs. In 2016, the World Health Organization (WHO) released its first global strategy on 
viral hepatitis with aim on elimination of HCV as a major public health threat by 2030 [10]. 
This target includes a 90% reduction in new HCV infections and a 65% reduction in HCV 
liver-related mortality, requiring diagnosis of 90% and treatment of 80% of chronically 
infected patients. To achieve these goals for the care and management of HCV infection, 
countries need to develop national strategies based on reliable estimates of prevalence and 
disease burden. In Norway, the Ministry of Health and Care recently has launched a national 
strategy on viral hepatitis with aim on 90% reduction in new HCV infections by 2023 
compared to 2018, and which stated that no one should die or become seriously ill of HCV 
[11].  
Although DAAs offer exceptionally high cure rates in the majority of patient groups, a 
significant absolute number fail to achieve sustained virologic response (SVR), defined as 
undetectable HCV RNA 12 (SVR12) or 24 weeks after the end of treatment. The presence of 
12 
 
naturally occurring HCV viral variants which carry resistance-associated substitutions (RASs) 
is associated with impaired treatment effect of DAAs [12, 13] 
In this work, the epidemiology and future complications of chronic HCV infection in a low-
prevalence area have been explored. HCV viral resistance to DAAs has emerged as an 
important consideration in optimization of HCV-treatment, and the impact of baseline HCV 
RASs on treatment outcome has been investigated.  
 
1.1 Epidemiology of HCV infection 
1.1.1 Dissemination and transmission  
HCV infection has shown a pandemic spread through the twentieth century. As a blood-borne 
virus, transmission was initially driven by parenteral transmission routes like unsafe medical 
injections, surgical procedures, mass vaccination campaigns and blood transfusions [14, 15]. 
One of the most notorious examples of iatrogenic HCV transmission took place in Egypt, 
where a parenteral mass population antischistosomal treatment program from 1950s to 1980s 
led to widespread infection of HCV. Consequently, Egypt became the country with the 
highest HCV prevalence in the world [16]. Iatrogenic transmission is still a major 
transmission route in resource-limited countries [17], unlike developed countries where safety 
improvements in health-care related procedures and blood transfusions the last 40 years have 
eliminated or significantly reduced these transmission routes [18, 19]. However, iatrogenic 
transmission has been reported in western countries in recent years, e.g. a case report of 
transmission of HCV from patient-to-surgeon, and the subsequent transmission of HCV to 
surgical patients [20]. 
In the Western world, injecting drug use (IDU) is the most important route for HCV 
transmission [21-23]. Worldwide, 25 countries have reported that 60- 80% of people who 
inject drugs (PWID) have antibodies to HCV (anti-HCV), and in 12 countries the prevalence 
is over 80% [21]. In Europe, a systematic review showed that 53- 97% (median 72%) of 
PWID had chronic HCV infection [24]. Approximately 30% of PWID in Western Europe are 
younger than 25 years of age [25]. 
Of lesser importance are sexual transmission, mother-to-infant transmission and tattooing. 
The risk of perinatal transmission of HCV from a viraemic mother to child is approximately 
4-5% [22, 26]. While heterosexual transmission of HCV is not a significant contributor in the 
HCV epidemic [27], the incidence of HCV infection among men who have sex with men has 
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increased significantly in recent years, especially in individuals with human 
immunodeficiency virus (HIV) infection [22, 28]. HCV transmission has been associated with 
tattooing and piercing when performed under non-sterile conditions [29]. Finally, in about 
10% of infections, no potential risk factor can be identified [30].  
1.1.2 Global prevalence  
There is considerable geographic variation in HCV prevalence, as well as significant 
differences between regions and between age- and risk groups within regions. Currently, the 
estimated global prevalence of viraemic HCV infection is 1.0% (95% CI: 0.8-1.1%), 
corresponding to 71.1 million (62.5-79.4) chronically infected persons [31]. In three 
modelling studies involving several countries, the estimated viraemic prevalence’s ranged 
from 0.12% in the Netherlands to 7.3% in Egypt [4-6]. The highest HCV prevalence is found 
in Southeast Asia, North and Central Africa, and Russia [31]. In Europe, the highest 
prevalence is found in Italy and in countries in Eastern Europe, while in the Nordic countries 
the viraemic prevalence rates are 0.3-0.4% [31]. 
 1.1.3 Prevalence of HCV infection in Norway 
There is uncertainty regarding the prevalence of HCV infection in Norway as population-
based data is limited. A prevalence survey based on The Oslo Health Study in 2001, included 
11,456 individuals in the general population and revealed a prevalence of anti-HCV and 
HCV-RNA of 0.7% and 0.5%, respectively [32]. In a register study from Northern Norway in 
2002, the prevalence of RIBA positive HCV infection was 0.24% [33]. A study of pregnant 
women in Norway in 2000, showed an anti-HCV prevalence of 0.7% [34].  
1.1.4 Incidence of HCV infection 
There is scarcity of data describing HCV incidence due the asymptomatic nature of acute 
HCV infection. In Norway, HCV infection has been a notifiable disease to The Norwegian 
Surveillance System for Communicable Diseases (MSIS) since 1990 [35]. However, the 
notification criteria have changed several times and MSIS cannot distinguish between 
resolved and chronic HCV infection. Consequently, there is no reliable data on the HCV 
incidence in the general population in Norway. Hatzakis et.al. supposed, by using historical 
data and expert consensus, a peak in HCV incidence in Norway in 1980 due to an increase in 
IDU, followed by a slowly decrease thereafter to 14.9 cases per 100 000 persons per year in 
2013, corresponding to 750 new cases annually [4]. According to MSIS, there has been a 
decrease in the number of annual reported HCV cases since 2008. The number of reported 
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cases that are born outside Norway has been increasing and constitutes about 25% of reported 
cases [35].  
1.1.5 Prevalence of HCV genotypes 
HCV is classified into seven genotypes (GTs), with varying geographic distribution [36]. 
Globally, GT1 is the most common (46%), followed by GT3 (30%), GT2 (9%), GT4 (8%) 
and GT6 (5%) [37]. GT7 is only sporadically reported in Central Africa [37]. GT1 dominates 
in Europe, North- and South America, while GT3 is prevalent in many West European 
countries, South Asia, Russia and Australia [37, 38]. In Norway, GT3 accounts for 50% of 
HCV infections, GT1 36%, and GT2 9%, while in Sweden GT1 is most common (50%), 
followed by GT3 (30%) and GT2 (20%) [31].  
1.1.6 Health burden of HCV disease 
Chronic HCV infection is the leading cause of end stage liver disease, HCC, and liver-related 
death in the Western world and has a substantial effect on morbidity and mortality worldwide 
[1]. According to Pertz et al., 27% of cirrhosis and 25% of HCC worldwide are attributable to 
HCV infection [39]. In Western Europe, the attributable fractions of cirrhosis and HCC for 
HCV are 38% and 44%, respectively [39]. Individuals with chronic HCV infection has 
increased mortality from both hepatic and extrahepatic diseases [40]. Currently, complications 
of chronic HCV infection is the leading indication for liver transplantation in the Western 
world [1, 6, 41].  
Even with a decline in the total number of HCV infections, the number of patients with late-
stage liver disease and liver-related deaths is expected to increase until 2030 [4-6]. A 
modelling study from Sweden projects an increase in HCV-related decompensated cirrhosis, 
HCC, and liver-related deaths in the next two decades, unless an increased number of patients 
receive antiviral treatment [42]. In Norway, a modelling approach including active and former 
PWIDs, describes the estimated increase in people with cirrhosis, HCC, and liver 
transplantation until 2022 [43]. Findings from The Global Burden of Disease Study 2013 
revealed that viral hepatitis (hepatitis B (HBV) and HCV) was the seventh leading cause of 
death worldwide in 2013, a rise from tenth place in 1990 [3]. In addition, viral hepatitis is a 




1.1.7 Awareness of HCV infection 
A substantial proportion of individuals with chronic HCV infection has not been tested and 
are unaware of their diagnosis. A recent modelling study including 28 EU countries estimated 
that only 36.4% of those with viraemic HCV infection have been diagnosed [44]. In Norway, 
the diagnosis rate is estimated to be 57% [4]. Studies from the US have indicated that about 
half of those infected with HCV were aware of their infection [7, 8]. In a French cross-
sectional study, 40% of HCV RNA positive individuals were not aware of their infectious 
status [45].  
1.1.8 Screening strategies for HCV infection 
In 1968, Wilson and Jungner proposed ten criteria to guide the selection of diseases that 
would be suitable for screening [46]. Considering these criteria, and the revised version posed 
by WHO in in 2008 [47], screening for HCV infection meet the required conditions for a 
screening program:  
• HCV infection is a global health problem that can cause serious, life threatening 
complications in a substantial proportion of patients.  
• The infection is frequently asymptomatic, leaving many infected individuals unaware 
of the diagnosis until complications occur.  
• A suitable diagnostic test is available for the early stages of the disease.  
• The availability of potent antiviral therapies provides an opportunity to reverse the 
rising burden of HCV disease.  
Screening strategies vary in different areas, based on the local epidemiology of HCV 
infection. In Norway, as well as in other low-prevalence countries, a limited screening of 
high-risk individuals is recommended, such as individuals with current or previous IDU, 
recipients of blood products prior to 1992, patients infected with HIV, haemodialysis patients, 
incarcerated individuals, children born to HCV-infected mothers, individuals with elevated 
alanine aminotransferase (ALT), and migrants from endemic regions [48].  
In the new treatment landscape with highly effective and well tolerated DAA regimens, many 
countries are reconsidering their testing strategies to determine the optimal approaches for 
reaching persons who might not identify themselves as being at risk for HCV infection. In the 
US, it is recommended a one-time screening of persons in the 1945-1965 birth cohort, in 
addition to targeted risk-based testing [49]. In France, with a prevalence of viraemic HCV 
infection of 0.3%, a recent study showed that universal screening of all individuals aged 18-
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80 years is the most effective screening strategy, and also the most cost-effective, assuming 
rapid initiation of treatment after diagnosis [50]. In Spain, with an HCV RNA prevalence of 
0.35-0.41%, a recent modelling study concluded that screening of the general adult population 
would identify a larger number of additional individuals with chronic HCV infection than 
screening high-risk groups or screening the age-cohort with the highest anti-HCV prevalence 
plus high-risk groups [51].  
 
1.2 The HCV genome and its genetic heterogeneity 
1.2.1 The HCV genome 
HCV, discovered in 1989, is a positive sense, single stranded RNA virus belonging to the 
family Flaviviridae and genus Hepacivirus [52, 53]. The genome is 9,600 nucleotides in 
length and encodes a single polyprotein of about 3,000 amino acids that is co- and post-
translationally cleaved into ten polypeptides, including three structural (core (C), E1, E2) and 
seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) [53, 54]. The NS 
proteins include enzymes necessary for viral replication (RNA polymerase) and protein 
processing (protease). Figure 1 shows the HCV open reading frame (ORF) encoding the 
polyprotein and the predicted secondary structures.  
 
 
Figure 1. Hepatitis C virus genome organization. NTRs; non-translated regions, IRES; 
internal ribosome entry site. Polyprotein cleavage by cellular signal peptidases is indicated by 
scissors at the corresponding ORF position. Arrows refer to cleavage by the viral proteases. 
From: Bartenschlager et al 2013 [54]. Reprinted by permission from Springer Nature: Nature 




1.2.2 HCV genetic heterogeneity 
HCV displays a pronounced genetic heterogeneity at several different levels, resulting in 
seven different GTs, 67 confirmed subtypes and a large number of quasispecies [36, 53, 55, 
56]. First, over decades and centuries a substantial genetic diversity has evolved, resulting in 
seven distinct HCV GTs, with a 30 – 35% variability in their nucleotide sequences [53]. 
Second, rapid sequence drift of HCV increases the sequence variability within the different 
GTs, identifiably as separate strains or isolates [53]. Third, the lack of proofreading activity of 
the RNA dependent RNA polymerase (RdRp) combined with a high production of up to 1012 
virions per day, result in the production of quasispecies, which are different but closely 
related viral variants generated within an infected person over time [53, 56]. Quasispecies can 
differ by 1-5% in nucleotide sequences, and some variants bear polymorphisms in drug target 
genes. These polymorphisms, or baseline resistance associated substitutions (RASs), may 
confer reduced susceptibility to DAAs [12, 13, 57, 58]. Finally, inter- and intra-GT 
recombination can contribute to the tremendous genetic heterogeneity in HCV through the 
exchange of nucleotide sequences between different genomic RNA molecules [53, 55].  
 
1.3 The natural course of HCV infection  
HCV infection has some characteristics making it challenging to determine the accurate 
natural course of the infection [59]. Due to the asymptomatic course of the acute phase in the 
vast majority of cases, the onset of the disease is rarely identified. The phase of chronic 
infection may last several decades, and the progression of liver fibrosis, and ultimately 
development of liver cirrhosis, most often occurs without symptoms. Accompanying factors 
like comorbid conditions, co-infections with HBV and HIV, alcohol consumption, and 
antiviral treatment can modify the natural course of the disease.  
1.3.1 Acute HCV infection 
Clinical symptoms may develop in 15% to 30% of adults with acute infection, yet most acute 
HCV infections are asymptomatic [30, 60]. Reported rates of spontaneous clearance have 
varied widely (15-40%) due to the asymptomatic course of acute HCV infection [30, 61]. In a 
systematic review of 31 longitudinal studies, the estimated rate of spontaneous HCV 
clearance rate was 26% [62]. In a prospective study with pooled data from nine international 
cohorts of participants with well-defined HCV infection, spontaneous clearance of virus 
occurred in 25% and was associated with female sex, favorable IL28B genotype and GT 1 
infection [63].  
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1.3.2 Fibrosis progression in chronic HCV infection 
The majority of HCV infected individuals develop chronic HCV infection with subsequent 
progressive accumulation of fibrous tissue in the liver. The fibrosis progression is generally 
slow, leading to the development of cirrhosis in approximately 10-20% of patients after 20-30 
years of infection. However, the progression varies widely and may be affected by several 
external, viral and host factors [1, 61, 64].  
A systematic review of 111 studies revealed that fibrosis progression was non-linear, with an 
estimated risk of cirrhosis of 16% and 41% after 20 and 30 years of infection, respectively 
[65]. Others have also shown non-linear development, with major acceleration of fibrosis 
progression after 50 years of age [66]. A Norwegian autopsy study in injecting drug users, 
showed advanced fibrosis and cirrhosis in 35% of cases with disease duration of 25 years or 
longer [67].  
On the other hand, slower rates of progression to cirrhosis have also been shown. In a cohort 
study of young healthy women who had been infected with HCV GT 1b-contaminated anti-D 
immunoglobulin, the cirrhosis prevalence was 14.2% (treatment-naïve patients) and 15,3% 
(non-SVR group) 35 years after infection [68]. 
When advanced fibrosis, i.e. METAVIR stage F3, has developed, the risk of progression to 
cirrhosis is approximately 10 percent per year [69]. 
Several host, environmental and viral factors can affect the rate of fibrosis progression. Male 
gender, age at time of infection >40 years, alcohol consumption, co-infection with HIV or 
HBV, type 2 diabetes mellitus, and obesity are factors shown to be associated with faster 
fibrosis progression [30, 66, 70]. An association between viral GT 3 and accelerated fibrosis 
progression has also been suggested [71, 72]. Moreover, the variable rates of fibrosis 
progression shown in different studies can in part be explained by different study populations 
with variable risk factors for fibrosis progression, different study designs and settings, and 
different methods used to estimate fibrosis progression [64, 65]. Sweeting et.al. demonstrated 
considerable differences in disease progression rates in three cohorts of patients with the same 
demographics with estimated 20-year risk of cirrhosis of 12%, 6% and 23% in a hospital-
based cohort, a post-transfusion cohort, and in a cohort referred from a tertiary center, 
respectively [73].  
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1.3.3 Cirrhosis complications  
When compensated cirrhosis is established, patients are in risk of progression to 
hepatocellular carcinoma (HCC) and hepatic decompensation with complications including 
ascites, encephalopathy, hepatorenal syndrome and variceal bleeding [74]. The annual risk of 
HCC and hepatic decompensation is described to be in the range 1-5% and 3-6%, respectively 
[1, 69, 74, 75]. Further, the annual rate of death or liver transplantation in compensated 
cirrhosis is estimated to be approximately 4% [74, 76].  
When decompensation or HCC has been established, the prognosis is poor without a liver 
transplantation. The probability of survival at one and five years after decompensation is 
shown to be 81.8% and 50.8%, respectively [77]. Regarding HCC, the median overall 
survival time is a few months [78, 79]. 
Although a SVR to treatment has been shown to induce cirrhosis regression [80, 81] and 
reduce the risk of complications and mortality in cirrhotic patients [82-84], the risk of 
complications still remains significant. In one study, the annual risk of HCC after SVR ranged 
between 0.1% and 1.55% in various subgroups [85]. A recent study demonstrated that SVR 
was associated with a 76% reduced risk of HCC compared to non-SVR, however, the annual 
risk of HCC was 0.90% [86]. In individuals with decompensated cirrhosis, an SVR after 
antiviral therapy is associated with early improvement in liver function, however the long-
term clinical benefits remains to be ascertained [87, 88].  
1.3.4 Liver disease staging 
Liver biopsy with histologic staging of liver fibrosis using the Ishak and METAVIR semi-
quantitative scoring systems has historically been the gold standard for assessing liver 
fibrosis, and thus predicting the prognosis in chronic HCV infection [89-91]. The METAVIR 
fibrosis score is assessed on a five point scale; F0, no fibrosis; F1, portal fibrosis without 
septa; F2, portal fibrosis with few septa; F3, bridging fibrosis; and F4, cirrhosis [90], while 
the Ishak fibrosis score grades fibrosis into seven stages (0-6) [91]. However, liver biopsy has 
several limitations, including sampling error, significant interobserver variability and risk of 
complications [92-94]. During the last decade, non-invasive liver stiffness measurement 
(LSM) has replaced liver biopsy as the recommended method for the assessment of liver 
fibrosis in HCV infection [95]. The most widely used and validated method is transient 
elastography, which measures the velocity of a low-frequency elastic shear wave propagating 
through the liver [96, 97]. The velocity of the shear wave is directly related to the LSM value 
and is expressed in kilopascals (kPa), ranging from 2.5 to 75 kPa. LSMs can be used as a 
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prognostic tool for risk stratification, as values in the cirrhotic spectrum (12.5-75 kPa) 
correlate well with the degree of portal hypertension [98].  
Combination of serum markers of fibrosis, like the aspartate aminotransferase to platelet ratio 
index (APRI) and fibrosis-4 (FIB-4 test), and LSM improves the accuracy of non-invasive 
diagnosis of liver fibrosis [99, 100]. The Child Pugh Score and the model for end-stage liver 
disease (MELD) are commonly used score models to assess the severity of liver dysfunction 
[101].  
1.3.5 Extrahepatic manifestations  
In addition to its effect in the liver, chronic HCV infection can have serious consequences for 
other organ systems. A number of extrahepatic manifestations, independent of the severity of 
the liver disease, have been associated with chronic HCV infection, including hematologic 
diseases such as cryoglobulinemia and lymphoma, autoimmune disorders such as thyroiditis, 
renal disease such as membranoproliferative glomerulonephritis, and dermatologic conditions 
such as lichen planus and porphyria cutanea tarda [102, 103]. Extrahepatic manifestations are 
common, presenting in two thirds of patients with chronic HCV infection, and are associated 
with increased mortality [40, 104]. 
 
1.4 Diagnosis of HCV infection 
Diagnosis of HCV relies on serologic assays for detection of specific antibodies to HCV (anti-
HCV) and molecular assays for detection and quantification of virus-specific molecules [105]. 
1.4.1 Immunoassays 
Following the cloning of the HCV genome in 1989 [52], the first-generation enzyme 
immunoassay (EIA) for circulating anti-HCV immunoglobulin G was developed, reacting 
against an epitope from the NS4 region (C100-3) of the HCV genome [106]. The second 
generation EIA combined several antigens from the core, NS3, and NS4 regions, 
modifications which markedly improved the sensitivity and specificity of the test [107]. In the 
third-generation EIA, an additional antigen from the NS5 region was included [108], leading 
to a diagnostic specificity >99% [109]. However, in severely immunocompromised patients, 
patients on hemodialysis and transplant recipients, the third-generation EIAs can yield false-
negative results [110]. In a systematic review of the accuracy of third-generation EIA used to 
screen asymptomatic adults, the sensitivity compared with RNA detection varied between 61-
82% [111]. False-positive results are more likely to occur in populations with a low 
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prevalence of HCV-infection, i.e. low positive predictive values [110], and can be caused by 
increased gammaglobulins, liver diseases, nephritic syndrome, autoimmune diseases, or other 
viral or parasitic infections [112].  
1.4.2 Recombinant Immunoblot Assays (RIBA) 
RIBA is a more specific, supplemental test, in which antibody reactivity to four viral antigens 
is investigated. RIBA is used to confirm the result of the EIA, and is defined positive when 
antibodies to two or more antigens are detected, indeterminate when reaction to only one 
antigen occurs, and negative when there is no antibody reactivity detected [113]. RIBA can 
help distinguish between past infection (RIBA positive) and false-positive anti-HCV (RIBA 
negative) in individuals who have a reactive immunoassay and a negative HCV RNA test 
[114]. 
1.4.3 Detection of virus-specific molecules 
Nucleic acid testing (NAT) directly detect the presence of HCV RNA and is the gold standard 
for diagnosing active HCV infection [105, 110]. Several methods can be used to detect 
(qualitative assays) and quantify (quantitative assays) HCV RNA, including polymerase chain 
reaction (PCR), transcription mediated amplification, and branched DNA signal amplification 
[105]. Most of the currently available quantitative methods can detect as little as 5 IU/mL of 
HCV RNA, making qualitative tests redundant [105]. The specificity of all NATs is up to 
99% [105]. Immunoassays that detect the HCV core or nucleocapsid protein (HCVcAg) are 
alternatives to NAT to confirm viraemic infection, but is limited by a lower sensitivity than 
NAT [105].  
1.4.4 Point-of care assays  
Several rapid assays for detection of anti-HCV have been developed, based on recombinant 
antigens in an immunochromatographic format, and designed for point-of-care (PoC) testing 
to provide increased opportunities for HCV-testing outside of traditional clinical settings 
[105, 115, 116]. These assays can be run on serum, venous blood, plasma, finger stick blood, 
and oral fluid, and have a high specificity of >99% and sensitivity ranging from 86% to 99% 
[105]. The availability of a new PoC test with high sensitivity and specificity (close to 100%) 
for detection of HCV RNA might contribute to simplify HCV testing, i.e. to facilitate HCV 
RNA confirmation and diagnosis in a single visit [117]. 
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1.4.5 HCV genotyping 
HCV is classified into 7 GTs, which on average differ in their genetic sequences by 30-35% 
[53]. Determination of HCV GT has clinical implications regarding treatment regimen, 
duration of treatment, and predicting of treatment response. Assays for HCV genotyping use 
different approaches, like direct sequencing and reverse hybridization [105].  
 
1.5 Antiviral therapy in chronic HCV infection 
In recent years there has been a revolution in the treatment for chronic HCV infection. 
Troublesome regimens with pegylated (PEG)- IFN and ribavirin (RBV) for 12 to 48 weeks 
with limited success have been replaced with well-tolerated DAAs with cure rates exceeding 
95% in most patient groups [118]. Figure 2 shows the changes in the standard of care for 
HCV infection, and the subsequent tremendous improvement in treatment response.  
 
 
Figure 2. Changes in antiviral treatment for hepatitis C, and improvements in the number of 
SVR. PI= Protease inhibitor. From: Webster et al. 2015 [119]. Reprinted by permission from 





1.5.1 Direct-acting antiviral agents (DAAs) 
The development of a HCV RNA replicon model, and later other cell-based culture systems, 
gave tremendous new insight into the HCV molecular virology, and facilitated the 
development of drugs that directly inhibit key steps in the viral replication [54]. In principle, 
every step of the HCV replication cycle is a potential target for antiviral therapy. Currently, 
four classes of DAAs are available, classified on the basis on their molecular target and 
mechanism of action: NS3/4A protease inhibitors (PI), NS5A inhibitors, nucleoside-and non-
nucleoside inhibitors of the NS5B RdRp [54, 120]. Since 2014, an increasing number of new 
DAAs have been introduced, which differ with regard to efficacy, barrier to resistance and 
potential for drug interactions (Table 1). 
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Table 1. General characteristics of different classes of DAAs. Adapted from Asselah et al. 





1.5.2 Treatment response of DAAs 
Treatment with different combinations of DAAs with complementary mechanisms of action 
has made it possible to obtain SVR rates above 90-95% in most patient populations in 
randomized clinical trials [123-135]. High SVR rates are also shown in real-life clinical 
practice, e.g. a Spanish study of treatment with DAA regimens 
(ombitasvir/paritaprevir/ritonavir plus dasabuvir and ledipasvir (LDV)/sofosbuvir (SOF) in 
patients with GT1, which demonstrated SVR rates above 95% [136].  
However, treatment responses are still compromised in patients with cirrhosis, previous 
treatment failure and infection with HCV GT3 [118, 137]. A phase 3 trial (ALLY-3), 
demonstrated significantly lower SVR rates in GT3 patients with cirrhosis (63%) compared to 
those without cirrhosis (96%) after treatment with daclatasvir (DCV) and SOF in 12 weeks 
[128]. In the ALLY-3+ study, SVR was achieved in 86% of treatment-naïve and treatment-
experienced GT3 patients with cirrhosis who received DCV/SOF/RBV for 12 weeks, with no 
improvement by prolonging treatment to 16 weeks [132]. In a study assessing the treatment 
response of velpatasvir (VEL) and SOF (ASTRAL-3), the SVR was 98% in treatment-naïve, 
non-cirrhotic patients with GT3 infection, compared to 89% in cirrhotic patients with prior 
treatment failure [138]. In a large real-life study in individuals with GT3 infection, prior HCV 
treatment failure, cirrhosis and decompensated liver disease were significant predictors of 
reduced SVR rates, with reduced odds of SVR of 49%, 40%, and 32% respectively [139]. 
Lowest SVR rates were observed in treatment-experienced cirrhotic patients, where SVR 
rates ranged from 57 to 71% [139]. However, in a Scandinavian real-life SOF-based treatment 
study in GT3 patients, 89% of cirrhotic patients, including patients with decompensated 
cirrhosis, achieved SVR [140].  
The recent approved DAA combinations glecaprevir (GLE)/pibrentasvir (PIB) and 
SOF/VEL/voxilaprevir (VOX) have greatly improved the SVR rates also for “difficult-to 
cure” groups, with SVR rates exceeding 95% [133, 141-144]. 
The presence of pre-treatment resistance-associated substitutions (RASs) may impair the 
efficacy of DAAs, especially in individuals infected with GT 1a and GT 3, and in patients 




1.5.3 Goals of antiviral treatment and the impact of SVR 
The primary goal for treatment of chronic HCV infection is to eradicate HCV, and thus 
prevent disease progression and complications [95]. Other goals are to improve quality of life, 
remove stigma and prevent onward transmission of HCV [95]. SVR, defined as undetectable 
HCV RNA 12 or 24 weeks after completion of antiviral therapy [145], corresponds to a 
definite cure of HCV infection in more than 99% of cases [146]. SVR is associated with 
marked improvements in liver necro-inflammation, liver stiffness and fibrosis scores [80, 147, 
148]. Further, an SVR is associated with decrease in all-cause mortality, liver-related deaths, 
need for liver transplantation, HCC rates, and in liver-related complications, even among 
patients with advanced liver fibrosis [82, 84, 86, 149-152]. In addition, achievement of SVR 
can reduce extrahepatic manifestations related to chronic HCV infection [104].  
1.5.4 Treatment recommendations 
The impressive therapeutic improvement offered by potent and well-tolerated DAAs has 
changed the scenario and perspective of HCV treatment. DAAs can be administered to 
potentially all HCV infected persons with a wide spectrum of liver disease and somatic and 
psychiatric comorbidities, and provides an opportunity to reverse the rising burden of HCV-
disease. This new reality is reflected in changes in treatment guidelines, e.g. The European 
Association for the Study of the Liver (EASL) and WHO now recommend that treatment 
must be considered for all patients with HCV infection, including individuals with high risk 
of transmitting HCV, like PWIDs [95, 153]. Historically, PWIDs has been excluded from 
treatment guidelines due to concerns about adherence, side effects and reinfection [154].  
1.5.5 Treatment uptake  
In a recent Markov modelling study, is was estimated that 4.6% of the total viraemic HCV 
population or 12.7% of the diagnosed viraemic population in Europe received antiviral 
treatment in 2015 [44]. Annual treatment rates in the infected population varies widely 
between countries; for instance 5.2% in France, 4.7 % in Germany, 2.8% in Sweden, and 
0.5% in Denmark [6]. In 2013 in Norway, it was estimated, by modelling, that the annual 
treatment rate was 2.8% (610 of a total population of 21,900 HCV infections) [4]. In a 
Norwegian observational study of individuals who had received opioid substitution therapy 
(OST) between 2004 and 2013, 14% had received antiviral treatment, and the annual 
treatment rates varied between 1.3% and 2.6% [155]. In a Norwegian cohort of current or 
former PWIDs, approximately one-fourth of those alive at a median of 36 years of infection 
had received antiviral treatment [156].  
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In order to control the rising burden of HCV disease and achieve WHO elimination targets, 
treatment uptake has to be increased [4, 42, 157-159]. After the introduction of DAAs in 
2014, a major barrier to increased treatment uptake has been the initially very high list prices 
of DAAs, which has restricted treatment to individuals with significant liver fibrosis or 
serious extrahepatic manifestations [160]. Lately, access to treatment has increased in several 
countries [160]. In Norway, unrestricted treatment has been available since February 2018 
[161]. The annual number of treated patients in Norway has increased since the introduction 
of DAAs in 2014, from 799 in 2014 to 1955 in 2017 [162].  
 
1.6 HCV resistance to DAAs 
1.6.1 Resistance-associated substitutions (RASs)  
Due to the extremely fast replication rate and the lack of proofreading activity of the viral 
RdRp, HCV exist as populations of genetically distinct but closely related viral variants in the 
infected person [13, 56]. These HCV quasispecies differ by amino acid polymorphisms that 
emerge during replication, and variants with reasonable good replicative capacity (fitness) can 
subsequently be selected during the chronic HCV infection. The term “resistance-associated 
substitutions” (RASs) is used to describe HCV amino acid substitutions associated with 
treatment failure and/or reduced susceptibility to DAAs [57]. 
RASs may exist prior to treatment, i.e. baseline RAS, or can emerge under the selective 
pressure of treatment with DAAs, i.e. treatment- emergent RASs [57]. RASs can contribute to 
treatment failure, depending on several factors: viral factors (GT, viral fitness, frequency 
within the HCV quasispecies, level of resistance), host factors (cirrhosis, previous treatment 
failure), and treatment factors (the DAAs genetic barrier to resistance, duration of treatment, 
addition of RBV, and adherence) [58, 163]. The level of resistance of different RASs, i.e. the 
effect on DAA susceptibility expressed as fold change (FC) in resistance (often expressed in 
EC50 values, i.e. the effective DAA-concentration that inhibits 50% of viral replication 
compared to wild-type HCV), can be assessed in phenotypic resistance analysis for each HCV 
subtype in cell cultures [12, 13, 57]. The EC50 FC is the ratio between the EC50 against the 




1.6.2 Methods for sequencing HCV to detect RASs 
Methods used for detecting RASs are based on DNA sequencing technologies. No 
standardized tests for resistance analysis to approved DAAs are available in Europe, only in 
USA [164]). These methods mostly rely on in-house techniques and include population 
(Sanger) sequencing and next generation sequencing (NGS) based on deep sequencing 
methods [165]. In a study reviewing methods for sequencing RASs in clinical samples, 
Sanger population sequencing was the most commonly performed method, followed by NGS 
[166].  
In population sequencing, GT-specific or pan-genotypic PCR primers are used to amplify the 
target gene (NS3, NS5A or NS5B). This method has a sensitivity to detect the presence of 
RASs at an approximately 15-25% frequency within the HCV quasispecies [165, 167], 
compared to the NGS methods which provide detection of viral variants with a frequency 
down to 0.5 - 1% [12, 13]. However, as RASs present at low frequencies (1%-15%) do not 
impair the treatment response to DAAs with clinical relevance, the general consensus is to 
recommend a cut-off level of 15% for detecting RASs within the HCV quasispecies [13, 168, 
169]. Using a 15% cut-off level also allows for comparison of results achieved with different 
sequencing methods [13].  
1.6.3 Prevalence of baseline RASs and their level of resistance  
Several RASs in the non-structural proteins NS3 and NS5A have been associated with 
reduced susceptibility to DAAs. RASs in the NS5B seem to be of less clinical significance 
[167, 170].  
RASs in the HCV NS3 gene 
Q80K is the most common RAS in the NS3 protease domain and is associated with impaired 
treatment response to the NS3/4A PI simeprevir (SIM) [171]. Q80K, mainly present in 
individuals with HCV GT1a, shows a geographically varying prevalence within Europe, 
ranging from 4.8% in Norway [171], 5.7- 15.2% in Sweden [172], to 75% in Poland [171]. In 
North America the prevalence is estimated to be 48% [173]. Q80K confers a 7-11 FC in 
resistance to SIM in vitro [57, 167]. 
The NS3 RAS R155K is rarely observed at baseline (< 1%) in GT1a infections [12, 174]. It is, 
however, frequently observed in patients who have failed treatment with PIs (boceprevir, 
telaprevir or SIM) [58], and confers a 90 FC in resistance to SIM in vitro [57, 167]. 
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Combination of Q80K and R155K, results in an increased (1830) FC in resistance to SIM 
[57].  
RASs in the HCV NS5A gene 
In GT1a, the most clinically relevant NS5A RASs include variants at position Y93, M28, 
Q30, and L31 [57, 167]. The overall prevalence of baseline NS5A RASs as natural 
polymorphisms is 13-16%, using a 15% cut-off level [167, 169, 170]. However, clinically 
important NS5A RAS with high fold in vitro resistance are found at baseline in only 2-5% in 
GT1a [12, 58], e.g. RAS Y93H (prevalence <1.5%), which confers a very high FC in 
resistance to DCV (1600x), LDV (>1600x) and VEL (>600x) [12, 57].  
Regarding GT3, the NS5A RASs Y93H and A30K are clinically the most relevant [57, 167]. 
NS5A RASs have been found at baseline in 8-16% of GT3a patients [128, 138]. RAS Y93H, 
which is detected quite frequently at baseline in GT3a (5-9%) [128, 138, 175], possesses a 
high FC in resistance to DAC (>3000x) and VEL (>700x) [57]. The A30K RAS is observed 
baseline in about 5-6% [167, 175], and confers a lower FC to DCV (100x) and VEL (50x) 
[57]. Both Y93H and A30K confers ≤1 FC to pibrentasvir [57].  
1.6.4 Clinical relevance of RASs  
RASs are typically associated with a change in HCV nonstructural proteins, which affect the 
binding or interaction with DAAs [12]. Many RASs confer a high FC in resistance in in vitro 
replicon assays, however, the level of resistance is not necessarily directly associated with 
treatment failure. Baseline RASs with high-fold level of resistance seem to contribute to 
treatment failure in the presence of factors like cirrhosis, prior treatment failure, suboptimal 
treatment regimen, and in viral GT1a and GT3 infections [13, 122, 167]. The clinical effect of 
RASs may be overcome by extension of treatment duration and/or by adding RBV [13, 57, 
170]. Due to limited data, the clinical significance of RASs in less common GTs like GT5 and 
GT6 is less clear [57].  
In patients who fail to achieve SVR after treatment with DAAs, RASs are selected in more 
than 80% of patients, dependent on treatment duration, the DAA class and regimen [12].  
 
The impact of baseline NS3 RAS Q80K in treatment of patients with GT1a: 
The impact of RASs on treatment outcome was first documented in patients treated with the 
PI SIM in combination with PEG-IFN and RBV. Individuals with HCV GT1a having a Q80K 
substitution at baseline within the NS3 protein, had lower SVR12 rates than those without 
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Q80K (46.7% versus 78.5%, respectively) [176]. However, treatment duration and the 
presence of cirrhosis seem to modulate the effect of Q80K. In a study with non-cirrhotic 
patients treated with SIM plus SOF (OPTIMIST-1), Q80K had an negative impact on 
treatment outcome in patients receiving treatment in 8 weeks compared to 12 weeks (SVR 
73% and 96%, respectively), while there were no difference in SVR12 rates in those treated 
for 12 weeks [130]. In a study of patients with GT1a and cirrhosis (OPTIMIST-2), the SVR 
rate was 74% in individuals with baseline NS3 RAS Q80K, compared to 92% in individuals 
without Q80K [131].  
In two phase 3 trials in individuals with GT1a treated with the pan-genotypic NS3 PI VOX 
combined with SOF and VEL for eight weeks, the SVR12 rate was lower in patients with 
baseline Q80K (88%) compared to those without Q80K (94%) [133]. 
 
The impact of baseline NS5A RAS in treatment of patients with GT1a: 
In a study by Zeuzem and coworkers, the SVR12 rates in patients treated with LDV plus SOF 
were generally high regardless of the presence or absence of baseline NS5A RAS, however, 
lower SVR12 rates were observed in patients with previous treatment failure (SVR 76%) 
compared to treatment-naïve patients (SVR 97%) [169]. In treatment-naïve patients with 
cirrhosis, numerically lower SVR12 rates (86%) were observed, but the interpretability of this 
observation is limited due to a small number of patients [169].  
In treatment with DCV combined with SOF, pooled resistance data has shown that baseline 
NS5A RAS was associated with a 22% lower SVR12 rate [57].  
NS5A RASs at baseline did not affect treatment outcome of VEL plus SOF in patients 
without cirrhosis or with compensated cirrhosis (ASTRAL-1 trial) [135]. However, in patients 
with Child Pugh B cirrhosis, lower SVR12 rates were observed in patients with baseline 
NS5A RAS (ASTRAL-4 trial) [87].  
The impact of baseline NS5A RASs in treatment of patients with GT3a: 
In the phase 3 trial ALLY-3, which evaluated the treatment response of 12 weeks with DCV 
and SOF, the Y93H RAS was observed at baseline in 9% (13/147), of whom 67% (6/9) 
without cirrhosis and only 25% (1/4) with cirrhosis obtained SVR12 [128].  
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In the phase 3 study ASTRAL-3, which evaluated a 12-week treatment with the second 
generation NS5A inhibitor VEL combined with SOF, baseline NS5A RASs were observed in 
16% (43/274), of whom 88% (38/43) reached SVR12, compared to 97% of the 231 patients 
without baseline NS5A RAS [138]. The Y93H RAS was detected at baseline in 9% (25/274), 
of whom 84% (21/25) achieved SVR12 [138].  
In a recent pooled resistance analysis including eight studies, RAS A30K was identified in a 
few cases of treatment failure in regimen with the second generation NS5A inhibitor PIB. In 
treatment-naïve patients treated for 8 weeks, the SVR12 rates was 78% (14/18) in patients 
with baseline A30K, compared to 99% (161/163) in those without A30K [175]. Prolonging 
treatment to 12 weeks increased SVR to 93% (13/14) in patients with baseline A30K [175].  
1.6.5 HCV resistance testing in treatment guidelines 
Currently, baseline RASs do not appear to affect treatment response in GTs 1b, 2, 4, and 6, 
thus baseline RAS testing is not recommended in patients who are infected with these GTs 
[13]. The NS3 inhibitor SIM is no longer in use due to the advent of more effective DAAs. 
Since 2016, EASL guidelines recommend considering baseline resistance testing of clinically 
relevant NS5A RAS, using population sequencing or deep sequencing with a cut-off level of 
15% in patients with GTs 1a and 3 [177]. NS5A RASs may influence the choice of first-line 
treatment regimen in the following situations [177, 178]: 
• Elbasvir/grazoprevir in patients with GT 1a [129]. 
• Sofosbuvir/ledipasvir in treatment-experienced and cirrhotic patients with GT 
1a [169].  
• Sofosbuvir/velpatasvir in patients with GT 3 and cirrhosis [138]. 
 
1.7 Summary of Introduction: Key points 
Globally, an estimated 71 million people are living with viraemic HCV infection. Norway is a 
low-prevalence country in this respect, as are most other Western European countries. 
Chronic HCV infection can progress to cirrhosis, HCC and end-stage liver disease in a 
substantial proportion of patients and the burden of disease is increasing. The infection is 
frequently asymptomatic, leaving many infected individuals unaware of the diagnosis until 
complications occur. The availability of effective and well tolerated DAAs has provided new 
opportunities to reverse the rising burden of “the silent epidemic”. HCV viral resistance to 
DAAs has emerged as an important consideration in order to optimize the antiviral treatment 
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and minimize the risk of treatment failure. Since the advent of DAAs, data on optimal 
regimens has been rapidly emerging and treatment guidelines subsequently rapidly changing.  
There are many challenges and remaining knowledge gaps that represent barriers to the care 
and treatment of HCV infection. Undiagnosed infection is one important barrier to the health 
impact of DAAs, and effective screening programs are urgently needed to diagnose and 
provide treatment to individuals who are unaware of their infection. There is uncertainty 
regarding the prevalence of diagnosed and undiagnosed HCV infection in Norway due to 
limited population-based data. Projection of future complications of HCV, based on local 
data, is warranted to enable an estimate of the future disease burden. Although DAAs are 
effective with overall response rates above 95% in most patient groups, the presence of 
baseline RASs can significantly compromise the treatment response in the individual patient. 
Implementation of HCV resistance testing may enhance the likelihood of successful treatment 





2. AIMS AND HYPOTHESES  
The overall research aims of the thesis were to describe epidemiological aspects and viral 
resistance in chronic HCV infection among the general adult population in a low-prevalence 
area. The specific research aims and corresponding hypotheses were:  
• There is uncertainty regarding the prevalence of HCV infection in Norway and the 
proportion of undiagnosed HCV infection. It is assumed that 20-30,000 individuals 
live with chronic HCV infection, but population-based data are limited.  
Aim: To assess the prevalence HCV infection in the general adult population >40 
years of age in the municipality of Tromsø, Northern Norway, and to evaluate the 
effectiveness of such an approach (Paper 1).  
Hypothesis: The prevalence of diagnosed and undiagnosed HCV infection in the 
general population in the municipality of Tromsø is low.  
• Worldwide, the total number of HCV infections is expected to decline in the years to 
come, but HCV-related mortality and morbidity is projected to increase. 
Aim: To estimate the future prevalence and complications of chronic HCV infection 
towards 2050 in a low-risk area by using a Markov model (Paper 2) 
Hypothesis: The burden of HCV disease will increase in the coming years despite a 
low prevalence of chronic HCV infection in the region.  
• DAAs offer high cure rates in the majority of HCV infected patients, however, a 
significant absolute number of patients fail to achieve SVR. The presence of baseline 
RASs can impair the treatment outcome.  
Aim: To assess the prevalence of baseline NS3- and NS5A RASs, and to investigate 
the impact of these RASs on the treatment outcome in patients infected with HCV 
GTs 1a and 3a receiving personalized treatment regimens based on resistance testing 
in a real-life setting in Sweden and Norway (Papers III and IV). 
Hypothesis: The prevalence of baseline NS3 RASs (Q80K and R155K) and NS5A 
RASs (Y93H and A30K) are low. The presence of baseline RASs may impair 




3. STUDY POPULATIONS AND METHODS 
The individuals included in the studies referred to in this thesis were participants in the 
seventh survey of the Tromsø Study (Tromsø 7), the Hepatitis C Study in Northern Norway 
(Hep C North) and the HCV Preexist Study (Table 2).  
 Included Period Design 
Paper I 
Tromsø 7 




Hep C North 























3.1 The Tromsø 7 Study (Paper I) 
The Tromsø Study is a single-centre, population-based, prospective study with seven repeated 
health surveys since 1974 in the municipality of Tromsø in Northern Norway [179]. The study 
was initiated to explore the reasons for the high cardiovascular mortality in Northern Norway, 
but has gradually been expanded to include a broad spectrum of chronic diseases.  
The present population in the municipality of Tromsø (2nd quarter of 2018) is 76,062 
inhabitants [180]. The demographics of Tromsø is presented in Figure 3. 
 
Figure 3. The demographics of the municipality of Tromsø as of the 2nd quarter of 2018. 
Numbers of males (Menn) and females (Kvinner) in each 5-year age group. Reproduced with 
permission from Statistics Norway. År: years (age). 
 
We used data from Tromsø 7, which was performed in 2015-2016. Microbiological analyses 
were performed at the Department of Microbiology and Infection Control, University 
Hospital of North Norway, Tromsø.  
All 32,591 citizens aged 40 years and above were invited, and 21,083 (65%) attended. The 
participation rate was highest in the age group 60 to 69 years for both women and men, 
somewhat lower in younger age groups, and lowest among those older than 80 years.  
Sera from 20,946 participants (64.3%) were tested for anti-HCV (ARCHITECT Anti-HCV 
Assay, Abbott System, Wiesbaden, Germany), of whom 11,004 (52.5%) were women and 
9942 (47.5%) were men. A self-administered questionnaire (Appendix) was used to obtain 
35 
 
information concerning health, psychological problems, smoking habits, alcohol 
consumption, the use of drugs other than alcohol, level of education, marital status and main 
occupation/activity. There were two questions regarding hepatitis C (translated from 
Norwegian): “Have you been infected with the liver virus hepatitis C?”, and “If you have 
been infected with the liver virus hepatitis C: have you ever received treatment?” 
Individuals with a positive anti-HCV test received a letter with information and a request for a 
second blood test. Two reminders were sent to those who did not have the follow-up test. The 
follow-up samples were retested for anti-HCV and further tested for the presence of HCV 
RNA (ROCHE RT-PCR Cobas Amplicor Hepatitis C Viral Polymerase Chain Reaction, 
Roche Molecular System Inc., Branchburg NJ, USA), and the result of any previous 
laboratory HCV data were recorded. Samples positive for the anti-HCV test and negative to 
the HCV RNA test were analyzed with a recombinant immunoblot assay (RIBA HCV 3.0 SIA 
test, Chiron Cooperation, Emeryville, CA, USA). RIBA was not carried out in cases were 
existing laboratory results were consistent with either spontaneous recovery or obtained SVR 
after antiviral treatment. HCV genotyping was performed as a hybridization assay on products 
from the HCV RNA PCR according to the manufacturer’s instructions (INNO-LIPA HCV II 
kit, INNOGENETICS, Ghent, Belgium).  
All subjects with a positive HCV RNA test were offered a clinical evaluation, which included 
a thorough medical examination, blood tests, the recording of the medical history with 
questions concerning symptoms of chronic HCV and the assessment of risk factors for HCV 
infection. Liver fibrosis was assessed by LSM (expressed in kiloPascals, kPa), using transient 
elastography (FibroScan® 402, Echosens, Paris, France). Significant fibrosis and cirrhosis 
was defined as LSM values ≥7 kPa and 12,5 kPa respectively [97]. The Fibrosis-4 (FIB-4) 
index was calculated using ALT, aspartate aminotransferase, platelet count and age [181]. 
 
3.2 The Hep C North Study (Paper II) 
Data from the Hep C North Study constituted an incidence cohort, which was used to estimate 
the future prevalence and complications of chronic HCV infection in Northern Norway until 
2050.  
In 1992, a screening and medical follow-up program of patients with community-acquired 
HCV infection was established in the Health Region of Northern Norway, as previous 
reported [33, 182]. In short, patients with positive anti-HCV and RIBA were registered at the 
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two microbiological laboratories in the health region (Tromsø and Bodø). Referring general 
practitioners were encouraged to refer patients with HCV infection for follow-up at one of the 
11 medical centers in the region. An estimate of the year of transmission was made based on 
either the year of acute HCV infection or the first year of high-risk behavior. Liver biopsies 
were performed, and fibrosis was graded (0-6) according to Ishak et al. [91].  
We performed a registration study to estimate the annual number of newly diagnosed 
individuals with HCV infection in the years 1998-2012 at the two microbiological 
laboratories in Northern Norway. Previous registered patients in the years 1992-1997 were 
included [33]. The year of diagnosis was defined as the first year of a positive anti-HCV test 
(ARCHITECT Anti-HCV Reagens kit. Abbott System, Wiesbaden, Germany). Until 2004, a 
positive anti-HCV test was directly confirmed with RIBA (RIBA HCV 3.0 SIA test, Chiron 
Cooperation, Emeryville, CA, USA). Individuals with a positive or indeterminate RIBA were 
included, while individuals with a negative RIBA were excluded. The result of the HCV RNA 
test was recorded if available: An in-house reverse transcriptase polymerase chain reaction 
(RT-PCR) until 2004, where after the ROCHE RT-PCR (Cobas Amplicator Hepatitis C viral 
Polymerase Chain Reaction, Roche Molecular System Inc., Branchburg NJ, USA) was used. 
The ROCHE PCR test replaced the RIBA test for confirmation of HCV infection from 2005. 
HCV genotyping was performed as a hybridization assay on products from the HCV RNA 
PCR according to the manufacturers’ instructions (INNO-LIPA HCV II kit, 
INNOGENETICS, Ghent, Belgium). Individuals without a registered residence in Norway 
were excluded.  
Markov model 
Markov models are used to estimate the progression of a chronic disease through defined 
disease stages within a cohort [183]. We constructed a Markov model to simulate the natural 
course of HCV infection in our population over time. Patients were assumed to be in one of 
several defined disease stages (Markov states). All events were modelled as transitions from 
one stage to the next, based on probability estimates generated from different sources. The 
effect of medical treatment was modelled in three scenarios where 0%, 15%, and 50% of 
patients were assumed to receive medical treatment. The annual number of HCV-infected 
individuals entering the model and the fibrosis progression towards cirrhosis were based on 
local data. Individuals entered the Markov model at the time of contraction of HCV infection. 
Year of infection was known in a subgroup of the infected individuals, and had to be 
estimated for the remaining records.  
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The rate of fibrosis progression towards cirrhosis was estimated in an ordinal regression 
analysis, which included duration of infection and HCV GT as covariates of disease 
progression. A sub-cohort (n=237) with known duration of HCV infection and available liver 
biopsy were included. The distribution of gender and GTs in the sub-cohort was equal to the 
total cohort (n=2589). 
As we did not have exact local data for the transition probabilities from compensated cirrhosis 
(Ishak 6) to more severe states of liver disease, the remaining transition probabilities were 
based on data from a Scottish HCV population of PWID [184]. The effect of medical 
treatment were modelled in three scenarios where 0%, 15% and 50% of all patients were 
assumed to receive treatment. The model accounted for the improvement in treatment 
response offered by DAAs, and was corrected for standardized mortality rate according to 
Norwegian population characteristics.  
Handling of incomplete records 
The registration of HCV infection revealed that 18% of the records were incomplete regarding 
confirmation testing, i.e. records with only a positive anti-HCV test or an indeterminate 
RIBA. In the incomplete records, we estimated the likelihood of a true positive test based on 
samples with complete diagnostics, resulting in estimated probabilities for a true positive test 
given a positive anti-HCV and an indeterminate RIBA of 0.63 and 0.21, respectively. Thus, 
the starting cohort in the Markov model was based on individuals with confirmed HCV 
infection (each weighted 1.0) and individuals with incomplete diagnostics (each weighted 
0.63 or 0.21, respectively). 
 
3.3 The HCV Preexist Study (Paper III and IV) 
The HCV Preexist Study is a prospective, real-life, open label, non-randomized multi-center 
study in Sweden and Norway. The study was designed to investigate the effect of baseline 
RASs on treatment outcome in patients with HCV GT1a and HCV GT3 infection treated with 
DAAs. The Departments of Infectious Diseases in Uppsala and Gävle, Sweden, and of 
Gastroenterology in Tromsø, Norway, have performed routine NS3 resistance testing of HCV 
GT1a before treatment with DAAs since 2014, and NS5A resistance testing of HCV GT1a 
since 2015 and GT3 since 2014. At the initiation of the study there were no available 
guidelines regarding baseline resistance testing. 
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The inclusion criteria were ≥18 years of age, and HCV GT 1a (Paper III) or HCV GT 3 (Paper 
IV) and treatment according to Swedish and Norwegian consensus recommendations, as well 
as completed treatment course (per- protocol). Included patients were either treatment-naive 
or treatment-experienced to IFN-based therapy, including triple therapy containing the first 
generation NS3 protease-inhibitors boceprevir or telaprevir. Patients previously treated with 
other DAAs were excluded.  
Liver fibrosis was assessed by liver biopsy (graded 0-4 according to METAVIR [90]) or by 
transient elastography (FibroScan ® 502,Echosens, Paris, France in Swedish study sites, and 
FibroScan 402® Echosens, Paris, France in Norwegian study sites). Cirrhosis was defined as 
METAVIR score F4 [90] or LSM values > 12,5 kPa [97].  
In Paper III, the effect of baseline NS3 RASs (Q80K and R155K) and clinically relevant 
NS5A RASs on treatment outcome in patients with GT1a infection were investigated. Patients 
from Uppsala, Gävle and Tromsø (intervention group, n=92) were consecutively included. 
The control group consisted of patients from Örebro, Falun and Bodö (n=101). The inclusion 
period was from 1 April 2014 to 30 June 2015 (Sweden) and to 26 January 2016 (Norway).  
In Paper IV, the effect of baseline NS5A RAS Y93H on treatment outcome in patients with 
GT3 infection were investigated. Patients from Uppsala and Tromsø (intervention group, 
n=130) were consecutively included from 1 April 2014 to 31 December 2017. The control 
group consisted of patients from Bodø, Falun, Stockholm and Örebro (n=78).  
In both studies, a prospective intervention was performed. Treatment in the intervention group 
was tailored to baseline resistance findings. Recommended treatment, according to national 
guidelines, was given to patients without baseline RAS in the intervention group and to all 
patients in the control group. The primary endpoint was SVR 12 weeks after the end of 
treatment.  
HCV RNA titer quantification was performed at the Department of Clinical Microbiology, 
University Hospital, Uppsala, and at the Department of Microbiology and Infection Control, 
University Hospital of North Norway (Roche COBAS® AmpliPrep/TaqMan® HCV 
Quantitative Test, v2.0 with a LOQ of 15 IU/mL, Roche Molecular Systems Inc., Branchburg 
NJ, USA). The Clinical Microbiology laboratory at the University Hospital, Uppsala, 
performed the resistance analysis of RASs (baseline and emerging). A nested PCR method 
was adopted for NS3- and NS5A resistance analysis, followed by Sanger sequencing 
(population sequencing, cut-off 20%). The methods for RNA extraction, reverse transcription, 
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nested PCR and sequencing in NS3- and NS5A resistance analysis are described in detail 
elsewhere [172, 185]. Presence of baseline RASs was analyzed for all patients in the control 
group retrospectively. Resistance analysis for emerging RAS was performed in all non-
responders at the time of relapse. 
  
3.4 Statistical methods 
Statistical analysis were performed using Microsoft® Excel 2013 (Microsoft Office 
Professional Plus 2013, Microsoft Corporation) and the Statistical Package for Societal 
Science (SPSS), version 24 and 25 (IBM Corp., Armonk, N.Y., USA). Means, medians and 
proportions (%) were used to describe both baseline characteristics and outcomes, where 
appropriate. 
The Chi-Square and Mann-Whitney U tests were used for comparison between groups. The 
Fisher’s exact test was used to test the differences between groups in case of small sample 
numbers. In Paper 1, a multivariate logistic regression analysis were used to compare 
sociodemographic and behavioral characteristics between HCV exposed and anti-HCV 
negative. A two-tailed p-value <0.05 was considered statistically significant.  
In Paper II, an ordinal regression model was used to estimate transition points on an ordinal 
scale (like the Ishak fibrosis scale). Sex, duration of infection in years, and HCV GT were 
included as predictors of Ishak fibrosis grade. The individual effect of each covariate was 
assessed in a multivariate analysis, leaving duration of infection and HCV GT as significant 
predictors. GTs 1 and 4 were analyzed as a single group due to few observations of GT 4. The 
model predicted 70% of the observed fibrosis grades correctly within a margin of error of one 
Ishak grade, but overestimated the fibrosis grade in 13% and underestimated in 17%. From 
this model, a matrix of estimated probabilities of transition to a higher fibrosis grade versus 
staying in the present grade for each year of infection could be constructed. It was assumed 
that fibrosis development could only either stay the same or change to a higher stage each 






The Regional Committee for Medical and Health Research Ethics (REK) approved the 
Tromsø 7 study (ref: 2014/1406 and 2017/253) and the Hepatitis C Study in Northern Norway 
(ref: P-REK 55/2001), and all participants gave their written, informed consent to participate. 
The Data Protection Official at The University Hospital of North Norway approved 
processing of the microbiological data in the registration study in Paper II (Nr. 0552). The 
HCV Preexist study was a multicenter study carried out at the Uppsala University Hospital in 
Sweden. The regional committee of medical research ethics Committee in Uppsala (Dnr: 
2013/185 and Dnr: 2013/185/1) and the Data Protection Official at The University Hospital of 
North Norway (Nr. 0574) approved the study. All participants received written information 





4. SUMMARIES OF PAPERS AND MAIN RESULTS 
4.1 Paper I: Screening for hepatitis C in a general adult population in a low-prevalence 
area: The Tromsø Study 
 
Background/aim: Chronic HCV infection can progress to cirrhosis and end-stage liver 
disease in a substantial proportion of patients. The infection is frequently asymptomatic, 
leaving many infected individuals unaware of the diagnosis until complications occur. This 
advocates the screening of healthy individuals. The aim of this population-based survey was 
to estimate the prevalence of chronic HCV infection in a presumed low-prevalence area and 
evaluated the efficiency of such an approach.  
Methods: The study was part of the Tromsø 7 Study in 2015-2016. Sera from 20,946 
individuals aged 40 years and older were analysed for anti-HCV. A positive anti-HCV test 
was followed up with a new blood test for HCV RNA and the result of any previous 
laboratory HCV data were recorded. Samples positive for anti-HCV and negative for HCV 
RNA were tested with a recombinant immunoblot assay. All HCV RNA positive individuals 
were offered clinical evaluation.  
Results: Among 20,946 participants, HCV RNA was detected in 33 (0.2%; 95% CI: 0.1-0.3), 
of whom 13 (39.4%; 95% CI: 22.7-56.1) were unaware of their infection. The anti-HCV test 
was confirmed positive in 134 individuals (0.6%; 95% CI: 0.5-0.7) with the highest 
prevalence in the age group 50-59 years. Current or treatment-recovered chronic HCV-
infection was found in 85 individuals (0.4%; 95% CI: 0.3-0.5) and was associated with an 
unfavorable psychosocial profile.  
Conclusion: In this population-based study, the prevalence of viraemic HCV infection was 
0.2%. A substantial number (13/33) of persons with viraemic disease was not aware of their 
infectious status, which suggests that the current screening strategy of individuals with high 
risk of infection may be an inadequate approach to identify chronic HCV infection hidden in 





4.2 Paper II: Future complications of chronic hepatitis C in a low-risk area: projections 
from the hepatitis c study in Northern Norway 
 
Background/aim: Screening for HCV infection has confirmed a low prevalence in the 
general population in Northern Norway. Despite this, late complications are increasing. In this 
study we aimed to estimate future complications of chronic HCV infection in the period 2013-
2050 in our low-prevalence area.  
Methods: In order to predict HCV-related morbidity and mortality, an open Markov model 
was constructed. The estimated HCV cohort of 2589 individuals were entered into the model 
at the time of contraction of the disease. The rate of fibrosis progression was estimated in an 
ordinal regression analysis. Yearly transitions between disease categories were done 
according to probability estimates generated from different sources. The effect of medical 
treatment was modelled in three different scenarios. 
Results: It was estimated a stable low incidence of HCV infections in the projection period. 
The rate of fibrosis progression was relatively slow in the first 20-25 years of infection, 
followed by an accelerated fibrosis progression, especially in patients with GT 3. The model 
predicted an almost three-fold increase in the prevalence1 of cirrhosis (68 per 100,000), of 
decompensated cirrhosis (21 per 100,000) and of hepatocellular carcinoma (4 per 100,000) by 
2050, as well as a six-fold increase in the cumulated number of deaths from HCV-related liver 
disease (170 per 100,000 inhabitants). All estimates were made assuming an unchanged 
treatment coverage of 15%. The estimated numbers could be reduced by approximately 50% 
for cirrhosis, and by approximately one third for the other endpoints if treatment coverage was 
raised to 50%.  
Conclusion: These projections from a low-prevalence area indicate a substantial rise in HCV-
related morbidity and mortality in the coming years, despite a presumed stable incidence of 
HCV infection. Increased treatment coverage is necessary to reduce the burden of HCV 
disease.  
1 In the published journal article, the prevalence of complications is incorrectly referred to as 




4.3 Paper III: Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 
2014-2016: a study of treatment outcome in patients with or without resistance-based 
DAA-therapy 
 
Background/aim: RASs, either naturally occurring or selected, may impair treatment 
response to DAAs in HCV infection. We aimed to investigate the presence of baseline NS3-
RASs (Q80K and R155K) and clinical relevant NS5A-RASs together with treatment outcome 
in patients with GT 1a with and without resistance-based DAA-treatment.  
Methods: A prospective intervention was performed where treatment in the intervention 
group (n= 92) was tailored to baseline resistance (population sequencing method): i.e. 
detection of NS3 RAS led to a switch to an NS5A- inhibitor based regimen, and opposite 
switch with NS5A RAS. Patients without baseline RAS in the intervention group and all 
patients in the control group (n=101) received standard recommended DAA-treatment.  
Results: The overall prevalence of baseline NS3 RAS Q80K and R155K was 7.1% and 5.2%, 
respectively. The SVR12 rates in the intervention and control groups were 97.8% (90/92) and 
93.1% (94/101), respectively (p=0.174). A trend toward higher SVR rate in cirrhotic patients 
was noticed in the intervention group compared to the control group, 97.5% (39/40) and 
83.3% (35/42), respectively (p=0.058). All patients with baseline NS3 and NS5A RASs in the 
intervention group achieved SVR. In the control group, treatment failed in two of five patients 
with Q80K or R155K at baseline who were treated with the NS3/4A protease inhibitor SIM 
combined with SOF. Furthermore, one of three patients who failed treatment with the NS5A 
inhibitor LDV combined with SOF had NS5A RASs at baseline. 
Conclusion: In line with the findings of the OPTIMIST-2 trial for Q80K and the EASL 
guidelines 2016 for NS5A RASs, baseline RASs appear to have an impact on treatment 






4.4 Paper IV: Effect of the baseline Y93H resistance-associated substitution in HCV 
genotype 3 for direct-acting antiviral treatment: Real-life experience from a multicenter 
study in Sweden and Norway 
 
Background/aim: RAS may impair treatment response to DAAs in HCV infection. The 
NS5A RAS Y93H is found quite frequently (5 -10 %) at baseline in DAA treatment-naïve GT 
3a patients when studied by the population (Sanger) sequencing method with a cut-off of 
20%. This RAS possesses a high fold in vitro resistance to the NS5A inhibitors DCV and 
VEL in patients with HCV GT 3 infection.  
Methods: Treatment in the intervention group (n=130) was tailored to baseline resistance 
findings by population sequencing method. Detection of baseline Y93H prompted a 
prolonged treatment duration of NS5A inhibitor plus SOF and/or addition of RBV at the 
responsible medical doctor`s discretion. Patients without baseline Y93H in the intervention 
group and all patients in the control group (n=78) received recommended standard DAA-
treatment. 
Results: The overall prevalence of baseline Y93H RAS was 4.3% (9/208). A higher SVR rate 
in the intervention group was shown compared to the control group, 95.4% (124/130) and 
88.5% (69/78), respectively (p=0.06). All five patients with baseline Y93H in the intervention 
group achieved SVR with personalized treatment based on the results of baseline resistance 
testing; either with the addition of RBV or prolonged treatment duration (24w). In the control 
group, 2/4 patients with Y93H at baseline treated with LDV+SOF+RBV or DCV+SOF 
without RBV, failed treatment. Thereby, with baseline Y93H, a trend towards higher SVR 
rate was found in the intervention group compared to the control group (p=0.07).  
Conclusion: The results from this real-life study are in accordance with the findings of the 
randomized controlled trials in 2015 (ALLY-3 and ASTRAL-3) and the EASL-guidelines of 
2016, i.e. baseline Y93H impacts on DCV and VEL treatment outcome. However this could 





5. GENERAL DISCUSSION 
Collectively, the studies referred to in this thesis have highlighted important aspects of HCV 
infection. The assumed low prevalence of chronic HCV infection in a general population was 
confirmed (Paper 1). However, the study indicate that a substantial number of individuals 
with viraemic HCV infection are unaware of their diagnosis, rendering them in risk of 
developing serious complications. In addition, the high proportion of undiagnosed infection 
suggests that the current risk-based screening strategy may be an inadequate approach to 
identify individuals with chronic HCV infection hidden in the general population. Despite an 
estimated stable incidence of HCV infection in the years to come, a substantial increase in 
liver cirrhosis, liver cancer, hepatic decompensation, and liver-related deaths is projected by 
2050 (Paper II). The estimated numbers of complications can be reduced by approximately 
50% for cirrhosis, and by approximately one third for the other endpoints if treatment-
coverage is increased from the assumed base scenario of 15% to 50%. Effective and well-
tolerated DAAs have provided an opportunity to reverse the rising burden of HCV-related 
disease, however, viral resistance has added a layer of complexity to the treatment of HCV 
infection. The presence of baseline RASs may have an impact on the treatment outcome in 
patients infected with HCV GTs 1a and 3, however this could not be statistically determined 
(Paper III and IV). Baseline resistance testing may be an important tool for tailoring 
personalized treatment and enhance the likelihood of treatment success for the individual 
patient, as well as in a perspective of evidence-based healthcare delivery. 
 
5.1 Methodological considerations 
5.1.1 Study populations, recruitment and study designs 
An overview of the study populations and study designs in the respective papers has been 
presented in Table 2. In Paper 1, the HCV prevalence was determined in a population-based 
cross-sectional study of individuals aged 40 years and older. The main strength of this study is 
the large sample size in a general population, which reduces the risk of selection bias and 
enhances the probability that the study population is representative of the general population.  
In Paper II, future HCV-related morbidity and mortality was predicted by using a Markov 
cohort simulation model. The study population consisted of individuals with community-
acquired HCV infection registered at the two Departments of Microbiology in Northern 
Norway and referred from primary care to one of the medical centers in Northern Norway. 
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Fibrosis progression was modelled in an ordinal logistic regression analysis of 237 records 
with available liver biopsy and known duration of infection.  
Markov models are well suited and widely used to simulate the progression of a chronic 
disease through defined disease stages within a cohort, with transition from a given category 
to the next based on probability estimates [183]. However, precision of dynamic modelling in 
estimating future complications of a disease depends on the quality of the data entered and the 
assumptions made. The strength of our Markov model is the use of locally acquired data 
whenever available. The HCV cohort entered into the model and the progression of liver 
fibrosis to cirrhosis was based on local data. The further development from established 
cirrhosis to more severe states of disease and the rate of spontaneous recovery are not likely to 
be very different from that of other cohorts, and the use of estimated transition probabilities 
from other studies should not affect the projections measurably. The transition probabilities 
from compensated cirrhosis to decompensated cirrhosis, HCC, and liver-related death were 
based on pooled transition estimates, which increase the accuracy of the transition estimates 
[184]. Model limitations will be discussed further in Section 5.3.4. 
In Papers III and IV, the impact of baseline RASs on treatment outcome in patients with HCV 
GT 1a and GT 3 was investigated in two prospective, open label, non-randomized multi-
center cohort studies. The patients were consecutively included and managed in a real-life 
setting. The real-life design, where patients are more diverse and complex compared to 
patients included in clinical trials, enhances the probability that the study population reflects 
the real patient population encountered in clinical practice.                                               
Cohort studies are well suited for investigating risk factors and the natural history of a disease 
[186]. The temporal sequence of exposure/intervention (treatment tailored to baseline 
resistance analysis) and outcome (SVR) allows some indication of causality, however, an 
association between exposure and outcome in a prospective study is not enough to conclude 
with causality. The high number of participants required when studying rare conditions makes 
cohort studies less appropriate. In Papers III and IV, the prevalence of baseline RASs turned 
out to be lower than expected. As a consequence, statistically significant results could not be 
obtained when investigating the impact of baseline RASs on treatment outcome. Lastly, the 





The aim of epidemiological studies is to obtain correct and precise results that can be 
generalized to other populations. The validity of a study refers the extent to which this aim is 
achieved [186]. External validity refers to the results’ generalizability, whereas internal 
validity denotes to which extent it is possible to draw conclusions concerning the study 
population [186]. Most threats to internal validity can be classified as: selection bias, 
information bias, and confounding [186]. Internal validity is regarded as a prerequisite for 
external validity. 
5.1.3 Bias 
Bias is the result of a systematic error in the design or conduct of a study, which can influence 
both the internal and the external validity of a study [187]. 
Selection bias may occur when there are systematic errors in the recruitment and retention of 
study participants in a way that affects the conclusions of the study [187, 188]. This bias may 
arise as a result of participant selection procedures or from factors that influence participation 
in the study. In The Tromsø 7 Study (Paper 1), all inhabitants of the municipality of Tromsø 
aged 40 years and older were invited to participate. This age restriction was inherent to the 
overreaching study design of Tromsø 7, but clearly introduces a selection bias. IDU is the 
main mode of transmission of HCV [21] and it is estimated that approximately 30% of PWID 
in Western Europe are younger than 25 years of age [25]. There is no clear data available on 
the age distribution of PWIDs in the Tromsø population, but it is reasonable to assume that 
the proportion of young PWID in Tromsø is comparable to other countries in Western Europe. 
In addition, self-selection bias may be an important issue that may threaten the external 
validity. The attenders in health surveys tend to be more educated and have a healthier life 
style than non-attenders [189], and various psychiatric disorders and alcohol abuse have been 
shown to be significant predictors of nonattendance in health surveys [190]. It is therefore 
reasonable to assume that PWID are less likely to participate in health surveys. Due to these 
biases, the true prevalence of HCV infection probably is underestimated.  
In Paper II, the study participants included in the simulated fibrosis progression were referred 
from primary care to one of the medical centers in Northern Norway between 1992 and 2011. 
In this period, only IFN-based treatment was available, thus many HCV infected persons were 
not considered eligible for treatment due to concerns of side effects, compliance and 
reinfection. It is likely that persons with ongoing IDU, psychiatric comorbidities and heavy 
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alcohol consumption were referred from primary care to a lesser extent than the rest of the 
HCV population. Thus, the recruitment procedure was inherently subject to selection bias. 
In Paper I, a self-administered questionnaire was used to obtain information regarding health, 
psychological problems, use of alcohol, and use of drugs other than alcohol. Self-administered 
questionnaires are prone to response bias that may promote more socially acceptable 
responses, e.g. response to alcohol use and current or past drug injection [191]. In the self-
administered questionnaire used in the Tromsø 7 Study, only six of the 13 individuals with 
previous unknown HCV infection reported current (n=2) or past (n=4) IDU. In the follow-up 
examination, an additional three persons reported past IDU.  
The non-randomised design in Papers III and IV makes them prone to selection bias. Cirrhosis 
and previous treatment failure to IFN-based therapy are well known negative predictors of 
non-SVR. In Paper III, the distribution of patients with cirrhosis was similar in the 
intervention and the control groups, however, in Paper IV, the distribution of cirrhosis was 
significantly higher in the control group compared to the intervention group, 61.5% (48/78) 
and 37.7% (49/130), respectively. Further in Paper IV, the proportion of treatment-
experienced patients was significantly higher in the control group compared to the 
intervention group, 39.7% (31/78) and 21.5% (28/130), respectively. Thus in Paper IV, the 
observed trend of a lower SVR rate in the control group compared to the intervention group 
could be explained by the presence of more advanced liver disease and a higher proportion of 
previous treatment failure in the control group.  
5.1.4 Confounding 
Confounding refers to a situation where the association between an exposure variable and the 
outcome may be attributed to the influence of a third variable, which is independently related 
to both the exposure variable and the outcome [187]. Confounding represents a threat to the 
assessment of causal relationships in cohort studies, and may lead to underestimation, 
overestimation or even change in the direction of the observed association [187]. Age and 
gender are often confounding variables in population-based studies. 
Confounding can be minimized by proper adjustment and by using multivariable statistical 
analysis, where potential confounding variables are included as covariates in multivariable 
regression models. In Paper 1, sociodemographic and behavioural characteristics between 
HCV exposed and anti-HCV negative individuals were compared. To control for confounders, 
we used multivariate logistic regression analysis, adjusted for age and gender. Significant 
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independent predictors of being exposed to HCV were thus: being disabled or unemployed, 
smoking, and current or previous use of drugs other than alcohol.  
5.1.5 Sample size and study power  
Statistical power is the probability that a given study will reject the null hypothesis when the 
alternative hypothesis is true [186]. This depends on the strength of the true association 
between risk and exposure, the number of participants in the study, and the distribution of the 
exposure in the population being studied. A type II error is the failure to reject a null 
hypothesis when it is false, i.e. to disregard an effect that is in fact present [186]. Type II 
errors are usually related to small sample sizes, which limits the possibility to stratify the 
population into subgroups for analysis.  
In Papers III and IV, an important limitation is the relatively small sample sizes. In addition, 
the prevalence of observed baseline RASs was lower than expected based on previous reports. 
The failure of detecting statistically significant associations between baseline RASs and 
treatment outcome may therefore be attributable to a lack of statistical power.  
5.1.6 Methods for HCV diagnosis 
Diagnosis and monitoring of HCV infection in the four papers referred to in this thesis are 
based on two different kinds of tests; determination of specific antibodies against HCV and 
detection of HCV RNA.  
Anti-HCV test (EIA) 
The specificity of EIAs has improved from the start of the study in Paper II, from about 80% 
diagnostic specificity of first-generation EIAs to >99% specificity in third- generation EIAs 
[105]. As a result, some records might have been missed in the registration of early anti-HCV 
positive cases in Paper II. The sensitivity of third-generation EIAs is variable (61-82%), 
yielding low positive predictive values in low-prevalence populations [111]. In Paper I, the 
proportion of false-positive results was 38%. False-positive results can cause harm by way of 
anxiety and stigmatization [192]. According to the criteria for screening proposed by Wilson 
and Jungner, the screening test should be “suitable (simple, sensitive, specific)” [46]. The 
current HCV testing algorithm requires first the detection of anti-HCV. In people with 
positive anti-HCV, a new blood sample for HCV RNA is required to confirm viraemic 
infection. The consequence of this two-step algorithm is that a significant proportion of 
individuals with positive anti-HCV test never receive the confirmatory HCV RNA rest, as we 
observed in the registration study in Paper II, and also described by others [116]. The 
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availability of point-of-care diagnostics has the potential to simplify testing, thus obtaining 
HCV diagnosis in a single visit [116].  
RIBA 
RIBA can help distinguish between past infection (RIBA positive) and false-positive anti-
HCV (RIBA negative) in individuals who have a reactive EIA and a negative HCV RNA test 
[114]. The interpretation and significance of RIBA-indeterminate reactions is unclear. In one 
study, 4.9% of cases with indeterminate RIBA were HCV RNA positive [114]. Still, in most 
RIBA-indeterminate cases the HCV RNA test is negative, which may indicate both 
spontaneously resolved HCV infection and unspecific antibody reactions [113]. Studies in 
blood donors have indicated that approximately half of RIBA indeterminate results could be 
explained in previous resolved HCV infections [193, 194]. The number of cases with 
indeterminate RIBA reactions in both Papers I and II were low, making the contribution of 
these records less significant. 
HCV RNA 
Testing for HCV RNA is the gold standard for diagnosing active HCV infection [105, 110]. In 
Papers I, III and IV, HCV RNA was detected with PCR methods with high specificity (up to 
99%) and high sensitivity [105]. In Paper II, an in-house reverse transcriptase PCR with lower 
sensitivity was used until 2004, thus false negative HCV RNA results might have been 
obtained in early records.  
Incomplete records 
In Paper II, registration of HCV infection at the two microbiological departments in the study 
region revealed that 18% of the records were incomplete regarding confirmation testing, i.e. 
records with only a positive anti-HCV test or an indeterminate RIBA. Studies have revealed 
that only 46-73% of individuals with positive anti-HCV received a confirmatory HCV RNA 
test [116]. We estimated the likelihood of a true positive test, as described in Section 3.2 and 
in Paper II. Thus, the incidence cohort in the Markov model was based on individuals with 
confirmed HCV infection (each weighted 1.0) and individuals with incomplete diagnosis 
(weighted 0.63 when only positive anti-HCV and 0.21 when indeterminate RIBA, 
respectively). This estimation may have resulted in uncertainty regarding the number of 
individuals entering the Markov model. However, our estimate of 63% true positive among 
those who only had a positive anti-HCV test is in accordance with a reported value of 68% 
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true positive in a population with low prevalence of HCV infection [114]. The estimate is also 
in accordance with the findings in Paper I, where 62% of those with positive anti-HCV test 
were confirmed to be true positive.  
5.1.7 Resistance testing 
RASs can be detected by Sanger (population) sequencing and NGS method. In Papers III and 
IV, the Sanger method was used in the resistance analyses. The Sanger method has a 15-25% 
sensitivity for detecting RAS in the viral population, compared to the more sensitive NGS 
method with a cut-off of 1% [13, 167]. However, in order to be of clinical relevance in 
predicting treatment failure, the general consensus is to recommend a cut-off level of 15% for 
detecting RASs in all clinical trials, real-life studies and in clinical practice [13, 167, 177]. 
The viral load must be > 1000-2000 IU/mL in order to increase the likelihood of a successful 
test [167].  
5.1.8 Liver fibrosis staging 
Liver fibrosis was assessed by LSM in Paper I, by liver biopsy in Paper II, and by LSM or 
liver biopsy in Papers III and IV. The cut-off value for significant liver fibrosis and cirrhosis 
was defined as LSM values >7 kPa and ≥12.5 kPa, respectively, equivalent to METAVIR 
fibrosis stage F2 and F4, respectively. 
Liver biopsy and histologic staging of liver fibrosis using the Ishak and METAVIR semi- 
quantitative scoring systems has been the traditional gold standard for assessing liver fibrosis. 
However, liver biopsy has several limitations, including sampling error and significant intra- 
and interobserver variability that may cause over- or understaging of fibrosis [90, 92, 93].  
Non-invasive LSM has replaced liver biopsy as the recommended method for assessing the 
severity of the liver disease in HCV infection [95]. LSM correlates with METAVIR fibrosis 
stages, however, there is a substantial overlap of LSM output between adjacent fibrosis 
stages, particularly in the lower range [97]. LSM overestimate fibrosis in cases with acute 
liver inflammation (as reflected with ALT >3x upper limit of normal value) and 
postprandially [195, 196]. LSM can be difficult to perform in obese patients, and limited 
operator experience can give unreliable results [195]. In the studies referred to in this thesis, 
LSM was performed by experienced nurses and doctors. Furthermore, the positive predictive 
value for cirrhosis with a cut-off value of ≥12.5 kPa is 77%, compared to 90% when a cut-off 
value of 18.3kPa is used [197]. Thus, the risk of a false positive diagnosis of liver cirrhosis 
can not be ruled out, especially in patients with LSM values between 12.5-18.3 kPa. However, 
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the diagnosis of liver cirrhosis was not merely based on the LSM, but also on a clinical 
evaluation including serum markers of fibrosis and ultrasound. 
5.2 Summarized study strengths and limitations  
The main strengths of the study in Paper I is its population based approach and the high 
participation rate, providing a large sample in the general population. The main limitation is 
the age-restriction of 40 years and a possible self-selection, which likely led to an 
underestimation of the true HCV prevalence. 
The main strengths of the study in Paper II are the use of locally acquired data regarding the 
HCV-infected subjects in the region and the use of local data in the simulated fibrosis 
progression. However, as with all modelling studies, our findings are only as valid as the 
quality of the data used and the assumptions made.  
The main strength of the studies in Paper III and IV is the real-life design, which enhances the 
probability that the study populations reflect the real patient population encountered in 
clinical practice. The non-randomized design and the small sample sizes are important 
limitations. The failure of detecting statistically significant associations between baseline 
RASs and treatment outcome may be attributable to a lack of statistical power.  
 
5.3 Discussion of main results 
Detailed discussion of the main results can be found in the respective Papers I-IV. The 
following sections are focused on aspects which are relevant in view of the WHOs global 
strategy on eliminating HCV as a public health threat by 2030, i.e. a 90% reduction in new 
HCV infections and a 65% reduction in HCV liver-related mortality. This requires the 
diagnosis of 90% and treatment of 80% of chronically infected patients. The Norwegian 
Ministry of Health and Care has recently launched a national strategy on viral hepatitis, which 
defines challenges and aims in order to eliminate HCV in Norway [11]. In this context, local 
estimates on HCV epidemiology, disease dynamics, and barriers to screening and treatment 
are relevant.  
5.3.1 Prevalence of HCV infection in the general population 
There are uncertainties regarding the prevalence of HCV infection in Norway as population-
based data is limited. We found a prevalence of anti-HCV and chronic (viraemic) HCV 
infection of 0.6% and 0.2%, respectively. The highest prevalence of anti-HCV (1.2%) and 
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chronic HCV infection (0.4%) was found in people born between 1956 and 1965, which may 
be explained by the epidemic of IDU in Norway, with a gradual increase in the number of 
PWID from the beginning of the 1970s until a peak was reached in 2000 [43]. We found that 
being exposed to HCV was associated with an unfavorable psychosocial profile, which is 
generally well established [32, 198]. The last population-based study in Norway was in 2001 
and revealed a prevalence of chronic HCV infection of 0.5%, an estimate which also included 
treatment-recovered cases [32]. In our study, the prevalence of current and treatment-
recovered HCV infection was 0.4%. In a register study from Northern Norway in 2002, the 
prevalence of RIBA positive HCV infection was 0.24% [33], and a study of pregnant women 
in Norway in 2000, showed an anti-HCV prevalence of 0.7% [34]. The last two studies did 
not report the viraemic prevalence. A modelling study in 2013 estimated the viraemic 
prevalence in Norway to be 0.43% [4]. The discrepancy of this estimate compared to our 
findings can be explained by different study designs, where the modelling study was based on 
historical data and expert opinions rather than measured values. Register studies in Sweden 
and Denmark have shown prevalence of chronic HCV infection of 0.36% and 0.38%, 
respectively [199, 200].  
To summarize, the population-based study in a general population (Paper I) confirms the 
assumed low prevalence of HCV infection. Due to probable biases discussed in Section 5.1.3 
above, the true prevalence is likely higher.  
5.3.2 Undiagnosed HCV infection in the general population 
In Paper I, we reported that 39.4% (13/33) of individuals with viraemic HCV infection were 
previous undiagnosed. In a modelling study from 2013 including several countries and based 
on historical data and expert opinion, the diagnosis rate in Norway was estimated to be 57% 
[4]. A recent modelling study including 28 EU countries estimated that only 36.4% of those 
with viraemic HCV infection were diagnosed in 2015 [44]. A population-based study in a 
small health area in Spain revealed a prevalence of viraemic HCV infection of 0.5%, of whom 
38.5% were previously undiagnosed with HCV [201]. In a French cross-sectional study, 40% 
of HCV RNA positive individuals were not aware of their infectious status [45]. A large 
population-based study in the US (NHANES) indicated that fewer than half of those infected 
with HCV were aware of their infection [7]. An observational cohort study among adults with 




Based on LSM values, more than half of those with undiagnosed HCV infection in our study 
had developed significant liver fibrosis (LSM value >7 kPa), and two patients had advanced 
liver fibrosis or cirrhosis (LSM value >12.5 kPa). In an observational study, 17% of HCV 
infected patients had advanced liver disease at the time of diagnosis [202]. In a Danish study, 
32% of patients had advanced liver fibrosis (LSM >9.5 kPa) at first evaluation in specialized 
care [203]. Another finding in our study was that a majority (69%) of those with undiagnosed 
infection reported previous or current IDU, thus should theoretically have been captured by a 
risk-based screening strategy.  
Summarized, a high proportion of HCV infected individuals are unaware of their disease, 
which suggests that the current recommendation of screening of individuals with high risk of 
infection is an inadequate approach to identify all chronically infected persons. Undiagnosed 
HCV infection is an important barrier in the control of the HCV epidemic. 
5.3.3 Screening in the general population 
We estimated a prevalence of chronic HCV infection of 0.2% in a general population (Paper 
1), yet due to the described biases, the true prevalence is likely higher, reducing the efficiency 
of such an approach. To be effective, people with the highest risk of infection must also attend 
the screening. With the availability of effective HCV-treatment, whom and how to screen has 
become a prioritized health policy issue.  
In low-prevalence countries, routine screening of the entire population has not been 
considered cost-effective, however, recent studies indicate that universal screening of the 
general population may be an effective strategy. In a Spanish cross-sectional pilot study for an 
eventual population-based screening strategy, the participation rate was 46.2% (2637/5706) 
and the prevalence of viraemic HCV infection was 0.5% [201]. The study revealed that 5 of 
13 viraemic individuals were unaware of their diagnosis, leading the authors to conclude that 
screening in the general population are “good means” to allow diagnosis and treatment of 
individuals who are unaware of their status. However, the same study points out that the high 
costs of a universal screening strategy makes it less feasible, [201], which is in 
correspondence with the cost estimations in Paper I. In France (HCV RNA prevalence 0.3%), 
a modelling study indicated that universal screening of all individuals aged 18-80 years was 
the most effective screening strategy [50]. A modelling approach in Spain (HCV RNA 
prevalence 0.35-0.41%) concluded that screening of the general adult population would 
identify a larger number of additional individuals with chronic HCV infection compared to 
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screening of high-risk groups or screening the age-cohort with the highest anti-HCV 
prevalence plus high-risk groups [51].  
In population surveys, the attenders tend to be more educated and have a healthier life style 
than non-attenders [189]. Further, psychiatric disorders and alcohol use are significant 
predictors of nonattendance in health surveys [190], and non-response bias is a problem in 
alcohol and drug population surveys [204]. Thus, it is reasonable to assume that current and 
former PWIDs are less likely to participate in health surveys. Based on this, strategies to 
improve targeted screening of people in high-risk groups in various settings, like primary 
care, outpatient clinics, OST programs, jails, and psychiatric clinics may still be the most 
effective approach in low-prevalence regions [205-210]. 
5.3.4 Fibrosis progression  
The critical aspect in HCV pathophysiology is the progressive development of hepatic 
fibrosis. In Paper II, the fibrosis progression model predicted a relatively slow development in 
the first 20-25 years of infection, followed by an accelerated fibrosis progression, especially 
in patients with GT 3. Most studies show that fibrosis generally is progressing slowly, leading 
to the development of cirrhosis in approximately 10-20% of patients 20-35 years after 
infection, however, the progression varies widely and may be affected by several external, 
viral and host factors [1, 61, 64, 68]. The non-linear fibrosis progression and the association 
between viral GT 3 and accelerated fibrosis progression are in line with other reports [65, 66, 
71, 72].  
The cohort, which was the basis for the simulated fibrosis progression, was relatively young 
with a mean age at liver biopsy of 40 years and median duration of infection of 13 years, 
resulting in few observations with long duration of infection and a limited number of 
observations with advanced liver fibrosis or cirrhosis (Ishak grade 4-6). This bias may have 
caused less precise estimates regarding progression through high fibrosis stages. In addition to 
duration of infection, age at infection may affect the fibrosis progression. Acquisition of HCV 
infection after the age of 50 years is associated with a more rapid progression of liver fibrosis 
[66, 70]. However, omitting this covariate from the model should not have a major impact on 
the estimated fibrosis progression as the cohort was relatively young.  
Another limitation is the questionable accuracy in the duration of infection. Due to the 
asymptomatic course of acute HCV infection, the exact time of infection is often uncertain 
and estimates must rely on patient history. We used the first year of high-risk behavior as the 
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presumed year of transmission, e.g. the year of onset of IDU, like others have done [66, 211]. 
HCV infection is rapidly acquired after onset of IDU, however, it has been reported that time 
to HCV infection in developed countries has lengthened in recent years [212]. This may 
indicate that the duration of infection could be shorter than estimated in the model, resulting 
in a spurious slow fibrosis progression rate. If so, our estimates of fibrosis progression are 
relatively conservative. 
Finally, several host and environmental factors which may affect the fibrosis progression were 
not included in the fibrosis model due to incomplete data. Moderate and excessive alcohol 
use, high body mass index, diabetes mellitus, and co-infection with HBV or HIV are 
important risk factor for accelerated fibrosis progression [68, 213-215]. The prevalence of co-
infection with HBV or HIV were low in our HCV cohort, however, lack of data regarding the 
remaining cofactors may have reduced the accuracy of the simulated fibrosis progression.  
5.3.5 Future complications of chronic hepatitis C 
In Paper II, a Markov model was used to predict HCV-related morbidity and mortality until 
2050, given various scenarios of HCV treatment coverage. Assuming a treatment coverage of 
15%, an almost threefold increase in the prevalence of cirrhosis (68 per 100,000 inhabitants), 
of decompensated cirrhosis (21 per 100,000), and of HCC (4 per 100,000) by 2050 were 
estimated. Complications were expected to reach a peak around 2040. Further, we estimated a 
six-fold increase in the cumulated number of deaths due to HCV-related disease (170 per 
100,000). By scaling up treatment coverage to 50%, the estimated numbers could be reduced 
by approximately 50% for cirrhosis, and by approximately one third for the other endpoints.  
These projections from a low-prevalence area indicate a substantial rise in HCV-related 
morbidity and mortality in the coming years, in line with other reports. A modelling approach, 
including Norway and several other countries, estimated that the total number of viraemic 
infections in Norway will decline slightly from 22,000 cases in 2018 to 21,300 cases in 2030, 
based on treatment levels in 2013 [4]. However, complications were projected to rise 
considerably from 2013 until 2030, with an estimated increase in cases with cirrhosis, 
decompensated cirrhosis, and HCC of 90%, 20%, and 115%, respectively [4]. Further, liver-
related mortality was expected to increase with 80% in the same period. Estimates from The 
Global Burden of Disease Study have demonstrated a continued upward trend in viral 
hepatitis (HBV and HCV) burden of disease and attributable mortality [3].  
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The focus of the study in Paper II was descriptive, showing the impact on disease burden 
given locally generated data and certain assumptions. The precision of the estimates depends 
of the quality of the data entered and the assumptions made. The remarkable advances in 
HCV treatment in recent years will likely change clinical practice in the future, however there 
are several uncertainties regarding how these new therapies will affect the care and 
management of HCV infection, which in turn may impact future complications and disease 
burden. Several aspects which can have an impact on our modelled projections will be 
discussed in the following. 
Incidence 
We estimated a constant incidence of 90 new HCV infections in Northern Norway per year 
from 2013 towards 2050 (Paper II). Currently, there is no reliable data on the HCV incidence 
in the general population in Norway. By using expert consensus, it is proposed an incidence 
of 14.9 HCV cases per 100 000 persons per year in Norway in 2013 [4]. Extrapolating this 
estimate to the population in Northern Norway (460,000 inhabitants) would imply 70 new 
HCV cases annually, which indicate that the incidence used in the Markov model is 
overestimated. However, IDU is an ongoing problem and accounts for 90% of all HCV 
infections in Norway [4], indicating a stable HCV incidence in the coming years. The model 
did not take into consideration the impact of treatment as prevention; i.e. scaling up treatment 
in individuals with high risk of transmitting HCV, like PWID, which can reduce the HCV 
incidence and have an impact on HCV prevalence and future disease burden [157, 216-218]. 
The possibility of reinfection after successful treatment and the impact of immigration were 
not considered in the model. In a Norwegian study among PWID, reinfection was observed in 
27% of people who had relapsed to IDU after achieving SVR and in 11% of people with a 
history of IDU [219]. Harm reduction programmes may have a considerable impact on the 
incidence, e.g. in the Netherlands, where IDU as a risk factor for HCV infection is almost 
absent due to effective prevention programmes [4].  
Undiagnosed HCV infection 
The number of undiagnosed HCV infected persons was not included in the Markov model. In 
the Tromsø 7 Study, almost 40% (13/33) of those with viraemic HCV infection were unaware 
of their diagnosis (Paper I). This corresponds to a population prevalence of 0.06% (13/20946), 
which, when extrapolated to the population in Northern Norway, would imply 276 persons 
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with undiagnosed chronic HCV infection in the region. This may indicate that the projections 
in Paper II are underestimated.  
The proportion of people with undiagnosed infection contrasts the WHO goal of diagnosing 
90% of chronically infected. In the new therapeutic scenario with effective DAAs, many 
countries, including Norway [220], are reconsidering their screening and testing strategies. 
Implementation of effective screening strategies may contribute to reverse the increasing 
burden of HCV disease, making the modelling forecasts overestimated.  
Treatment uptake 
The estimated future complications can be reduced if treatment uptake is increased. Our 
estimates were based on a treatment coverage of 15%. By scaling up treatment coverage to 
50% the estimated numbers of future complications could be reduced by approximately 50% 
for cirrhosis, and by approximately one third for the other endpoints.  
In order to reach the WHOs aim on eliminating HCV as public health threat by 2013, 80% of 
chronically infected persons need to be treated [10]. By modelling, it has been estimated that 
the annual treatment rate in Norway was 2.8% in 2013 [4]. Estimates from Norway indicated 
that 14% of HCV-infected patients in OST had received HCV treatment between 2004-2013, 
with annual treatment rates varying between 1.3% and 2.6% [155]. 
Strategies to manage the burden of HCV disease were evaluated in a modelling study of 
several countries including Norway [221]. The analysis showed that a combined aggressive 
treatment and diagnosis strategy, requiring a 3- to-5-fold increase in diagnosis and/or 
treatment, were critical for achieving substantial reductions in future disease burden [221]. A 
significant barrier to increased treatment uptake has been the initially extremely high costs of 
DAAs. However, due to tender negotiations, unrestricted treatment has been available in 
Norway since February 2018 [161]. The annual number of treated individuals in Norway has 
increased in recent years, from 610 treatments in 2013 [4] to an average of approximately 
1000 annual treatments since the introduction of DAAs in 2014 [11]. A continued substantial 
increase in treatment-uptake is likely to improve the projections presented in Paper II.  
Altogether, the uncertainties regarding the future HCV incidence, treatment uptake, and the 
effect of more extensive prevention and screening strategies can have impact on the 
projections in Paper II. A recent modelling study including data from 190 countries evaluated 
what is required to achieve the WHO targets for 2030, and concluded that “a comprehensive 
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package of prevention, screening, and treatment interventions” has to be implemented [222]. 
The authors emphasize that the potentials of DAAs to reverse the burden of HCV disease only 
can be fulfilled with a considerably increase in the diagnosis rate. HCV testing must be 
implemented in a variety of settings and new technology such as PoC HCV RNA testing 
should be implemented. Further, the study emphasizes that strategies to control the HCV 
epidemic among PWID are of crucial importance to reach the incidence target of 90% 
reduction in new HCV infections.  
5.3.6 Clinical relevance of RASs  
The studies presented in Papers III and IV were performed when data on optimal treatment 
regimens were emerging and treatment guidelines were rapidly changing. At the initiation of 
the studies, there were no available guidelines regarding baseline resistance testing and the 
knowledge of the impact of baseline RASs in treatment with DAAs was very limited. The 
costs of DAAs were very high, rendering it important to find the most cost-efficient treatment 
approach.  
In Paper III, baseline NS3 RASs Q80K and R155K and clinically relevant NS5A RASs 
appeared to have an impact on treatment outcome in patients with HCV GT 1a, although 
statistically significant results could not be obtained. The SVR12 rates in the intervention and 
control groups were 97.8% and 93.1%, respectively. In patients with cirrhosis, the difference 
in SVR12 rates were more pronounced, with SVR12 rates 97.5% and 83.3% in the 
intervention and control groups, respectively. Our findings appear to agree with prior studies. 
The COSMOS study in 2014 indicated lower SVR12 rates in patients with GT 1a and 
baseline Q80K RAS compared to patients without this RAS at baseline [123]. The 
OPTIMIST-1 study in 2016 showed that the presence of baseline Q80K RAS adversely 
affected SVR12 rates in patients treated with 8 weeks of SIM + SOF, but not in patients 
treated for 12 weeks [130]. In the OPTIMIST-2 study, the SVR12 rates in cirrhotic patients 
with baseline Q80K was 74%, compared to 92% in cirrhotic patients without baseline Q80K 
[131].  
In Paper IV, the SVR12 rates in patients with GT 3 infection who received treatment tailored 
to the result of baseline resistance analysis was 95.4%, compared to 88.5% in the control 
group. All five patients with baseline Y93H in the intervention group achieved SVR with 
personalized treatment, compared to 2/4 patients with baseline Y93H in the control group. 
Although we could not obtain statistically significant results, our findings are in line with 
60 
 
previous randomised controlled trials (ALLY-3 and ASTRAL-3) and the EASL-guidelines of 
2016 [128, 138, 177].  
Since the introduction of DAAs, the treatment has improved steadily with SVR rates >95% in 
the majority of patients groups [9]. Pan-genotypic DAA combinations with high genetic 
barriers to resistance are available [133-135, 138, 142]. The study in Paper IV was conducted 
prior to the recent approved DAA combinations GLE/PIB and SOF/VEL/VOX. These 
regimens have greatly improved the SVR rates, even for patients with GT 3 infection, 
cirrhosis, previous treatment failure, and baseline NS5A RASs [133, 141, 144, 223]. In 
clinical practice, the impact of RASs will probably become less important with the 
availability of these effective DAA combinations. However, it could be noted that RAS Q80K 
was the most commonly observed baseline NS3 RAS in the few GT 1a patients experiencing 
treatment failure in a trial evaluating the efficacy of SOF/VEL/VOX (POLARIS-2 trial) 
[133]. Further, a pooled resistance analysis in patients treated with GLE/PIB suggested a 
negative effect of baseline Y93H and A30K in patients with GT 3 infection. In treatment-
experienced, non-cirrhotic patients who received 12 weeks of GLE/PIB, lower SVR rates of 
25% (1/4) and 50% (2/4) were observed for patients with baseline A30K and Y93H, 
respectively, compared to 96% (43/45) and 93% (42/45), respectively, in patients without 
these RASs [175]. The small number of patients limits the generalizability of these results, but 
they suggests that viral resistance may have a negative impact also in recently approved DAA 
therapies with high antiviral potency and high genetic barrier to resistance.  
The proportion of patients who fail to achieve SVR after treatment with DAAs is small. 
However, given the size of the infected population, the absolute number of treatment failures 
is substantial and will probably increase as more patients receive treatment [224]. Effective 
and well-tolerated DAAs have improved the feasibility of HCV treatment among patients 
with ongoing IDU, psychiatric comorbidities, and alcohol abuse. However, reduced 
compliance to treatment may be likely in some of these patients, rendering non-adherence to 
treatment as the most important risk factor for non-SVR. In patients who fail DAA treatment, 
RASs are selected in more than 80% of patients and long-term persistence of NS5A RASs (>2 
years) is likely [12, 167]. Onward transmission of resistant HCV variants [225] and new 





In the current “changeable and dynamic” treatment landscape, our understanding of resistance 
testing as a diagnostic tool is far from settled [122, 167]. The recently approved effective, 
pan-genotypic DAAs with high genetic barrier to resistance are more expensive than prior 
approved regimens and are currently not extensively available. Retreatment options are still 
limited for some patient groups, and resistance testing is an important tool for tailoring 
personalized treatment [122]. Also, in order to reach the WHO elimination goals, surveillance 
of HCV resistance must be addressed [163, 224].  
 
6. CONCLUSIONS 
• The prevalence of chronic HCV infection in Northern Norway is low. Still, a 
substantial number of persons with viraemic disease are not aware of their infection, 
suggesting that the current strategy of screening individuals with high risk of infection 
is an inadequate approach to identify all patients with chronic HCV infection. 
Screening of the general population may unmask asymptomatic infected individuals 
that do not define themselves as belonging to known risk groups, and may be a 
sensible approach in addition to screening of high risk groups.  
• Despite a low prevalence of HCV infection, projections indicate a substantial rise in 
HCV-related morbidity (cirrhosis, decompensated cirrhosis and hepatocellular 
carcinoma) and mortality in the coming years.  
• Baseline RASs appear to have a negative impact on treatment outcome in patients with 
HCV infection GTs 1a and 3. Some RASs do to some extent predict lower SVR rates, 
but the results are limited due to small sample sizes and a low prevalence of RASs. 
Personalized treatment tailored to baseline resistance analysis may be of importance to 
guide the selection of cost-effective treatment combinations and treatment durations, 
both in a perspective of evidence-based healthcare delivery and to avoid treatment 





7. FINAL REMARKS AND FUTURE PERSPECTIVES 
Despite a low prevalence of HCV infection, the morbidity and mortality attributable to 
chronic HCV infection are projected to increase and clearly represent a challenge to the health 
care system. The availability of effective DAA therapies has provided an opportunity to 
reverse the rising burden of HCV disease, however, prevention of late complications requires 
early diagnosis and treatment. Effective screening strategies are urgently needed in order to 
achieve the WHO targets for elimination of HCV infection as a public health threat by 2030. 
Screening for HCV infection should identify asymptomatic, infected persons also outside of 
known risk groups. Screening in the general population in low prevalence areas may be a 
sensible approach in addition to strategies to improve targeted screening of people in high-risk 
groups. Implementation of PoC HCV RNA testing might contribute to simplify HCV testing, 
and thus enable decentralization of HCV care and treatment. Improvements in the entire HCV 
cascade of care from infection to cure are required in order to reach the WHOs elimination 
goals. 
The availability of highly effective and well-tolerated DAAs play a major role in the 
elimination effort. DAAs will improve the feasibility of HCV treatment in a wide range of 
patient groups, including marginalized populations of PWIDs, persons with psychiatric 
comorbidities and alcohol abuse. This changing patient population presents some challenges, 
e.g. non-adherence to treatment as a risk factor for treatment failure. Although DAAs provide 
high SVR rates, selection of RASs in persons who fail treatment is almost certain. Given the 
approximately 5% failure rates of the currently approved DAA regimens, a significant number 
of patients in the global HCV-infected population will have resistant variants of HCV. 
Prevention of onward transmission of resistant HCV variants and effective rescue treatment 
strategies for patients who fail first line therapies are needed. The long-term effects of HCV 
resistance remain unclear, hence surveillance of RASs is necessary to provide data in order to 
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Abstract
Background: Chronic hepatitis C virus (HCV) infection can progress to cirrhosis and end-stage liver disease in a
substantial proportion of patients. The infection is frequently asymptomatic, leaving many infected individuals
unaware of the diagnosis until complications occur. This advocates the screening of healthy individuals. The aim of
this study was to estimate the prevalence of HCV infection in the general adult population of the municipality of
Tromsø, Norway, and to evaluate the efficiency of such an approach in a presumed low-prevalence area.
Methods: The study was part of the seventh survey of the Tromsø Study (Tromsø 7) in 2015–2016. Sera from
20,946 individuals aged 40 years and older were analysed for antibodies to HCV (anti-HCV). A positive anti-HCV test
was followed up with a new blood test for HCV RNA, and the result of any previous laboratory HCV data were
recorded. Samples positive for anti-HCV and negative for HCV RNA were tested with a recombinant immunoblot
assay. All HCV RNA positive individuals were offered clinical evaluation.
Results: Among 20,946 participants, HCV RNA was detected in 33 (0.2%; 95% CI: 0.1–0.3), of whom 13 (39.4%; 95%
CI: 22.7–56.1) were unaware of their infection. The anti-HCV test was confirmed positive in 134 individuals (0.6%;
95% CI: 0.5–0.7) with the highest prevalence in the age group 50–59 years. Current or treatment-recovered chronic
HCV-infection was found in 85 individuals (0.4%; 95% CI: 0.3–0.5) and was associated with an unfavorable
psychosocial profile.
Conclusion: In this population-based study, the prevalence of viraemic HCV infection was 0.2%. A substantial
proportion (39%) of persons with viraemic disease was not aware of their infectious status, which suggests that the
current screening strategy of individuals with high risk of infection may be an inadequate approach to identify
chronic HCV infection hidden in the general population.
Keywords: Epidemiology, Hepatitis C, Norway, Population surveys, Prevalence
Background
Chronic infection with hepatitis C virus (HCV) is a leading
cause of liver cirrhosis, resulting in increased risk of liver fail-
ure, hepatocellular carcinoma (HCC) and premature death
[1]. Globally, an estimated 71 million people are living with
viraemic HCV infection (HCV RNA positive) [2]. Norway is
a low-prevalence country in this respect, as are most other
Western European countries. There are uncertainties
regarding the prevalence of HCV infection in Norway, as
population-based data is limited. A cross-sectional study
based on the Oslo Health Study in 2001 included 11,456 in-
dividuals and reported a prevalence of anti-HCV and HCV
RNA of 0.7 and 0.5%, respectively [3]. In Sweden and
Denmark, the estimated prevalence of chronic HCV infec-
tion is 0.36 and 0.38%, respectively [4, 5].
The incidence of HCV infection is projected to decline,
but the burden of the disease is increasing [6]. According to
a recent modelling approach from Norway, the HCV inci-
dence among people who inject drugs (PWID) peaked in
2000, and has thereafter decreased. However, the occur-
rence of HCV-related cirrhosis and HCC in active and
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former PWID is expected to increase in the coming years
[7]. Prevention of late complications requires treatment in
the early stages of the disease, and the availability of potent
direct-acting antiviral therapies (DAAs) has provided an
opportunity to reverse the rising burden of HCV-related
complications [8].
Surveillance of HCV is challenging for several reasons.
Individuals infected with HCV are often asymptomatic
until a late stage, and it is presumed that up to half of
infected individuals are unaware of their status [5, 9, 10].
A recent modelling study including 28 EU countries, es-
timated that only 36% of those with viraemic HCV infec-
tion have been diagnosed [11].
HCV infection in Norway has by law been a notifiable
disease to The Norwegian Surveillance System for Com-
municable Diseases (MSIS) since 1990. The surveillance
system did not distinguish between resolved and chronic
HCV infection prior to 2016, when it started to include
only HCV RNA positive cases [12]. Yet it still does not
adequately discriminate chronic HCV infection from
acute infection with subsequent spontaneous clearance.
Another limitation of the MSIS registration is the low
notification rate. In a study of HCV treatment uptake
among people who had received opioid substitution
therapy (OST), only 57% of OST patients treated for
HCV infection were notified to MSIS [13]. Notifications
of HCV infection may reflect testing practices rather
than real occurrence of the disease, thus rendering offi-
cial surveillance in Norway incomplete.
In 2016, the World Health Organization (WHO) released
its first global strategy on viral hepatitis aiming to eliminate
HCV as a public health threat by 2030, including an 80%
reduction in new HCV infections and a 65% reduction in
HCV liver-related mortality, requiring diagnosis of 90% and
treatment of 80% of chronically infected patients [14]. Sev-
eral measures are necessary to achieve these goals. Ideally,
screening for HCV infection should identify asymptomatic,
infected persons before they develop cirrhosis and
cirrhosis-related complications. The subsequent early treat-
ment would improve clinical outcomes, reduce transmis-
sion risk and thus save health costs.
Screening strategies vary in different areas, based on the
local epidemiology of HCV infection. In low-prevalence
countries, routine screening of the entire population has not
been considered cost-effective [15–18] and the approach to
prevention and control of HCV infection has focused on
testing persons with risk factors. Recent studies have, how-
ever, indicated that screening of the general population may
be cost-effective compared to risk-based screening [19, 20].
In Norway, a limited screening of high-risk individuals is rec-
ommended, such as current or previous PWID, recipients of
blood products prior to 1992, patients infected with human
immunodeficiency virus (HIV), haemodialysis patients, incar-
cerated individuals, children born to HCV-infected mothers,
individuals with elevated alanine aminotransferase (ALT),
and refugees from endemic regions [21].
In the new treatment landscape with highly effective
and well tolerated DAAs, many countries are reconsider-
ing their testing strategies. Whom and how to screen
has become a prioritized health policy issue.
The Norwegian Ministry of Health and Care recently
launched a national strategy on viral hepatitis with aim of
90% reduction in new HCV infections by 2023 compared
to 2018 [22]. Prevalence studies in the general population
may be an important tool for assessing the number of in-
fected with HCV and thus to enable an estimate of the fu-
ture disease burden. The Tromsø Study is an established
population survey in the municipality of Tromsø in North-
ern Norway, making such a prevalence study feasible.
The primary aim of the present study was to estimate
the prevalence of diagnosed and undiagnosed HCV in-
fection in the general adult population of Tromsø,
Northern Norway, and second, to evaluate the efficiency
of a screening approach to find individuals with undiag-
nosed hepatitis C infection.
Methods
Study population
The study was part of the seventh survey of the Tromsø
Study (Tromsø 7) in 2015–2016. The Tromsø Study is a
longitudinal population-based, prospective study with
repeated health surveys since 1974 in the municipality of
Tromsø in Northern Norway [23]. Tromsø is the largest
city in Northern Norway, harbouring the world’s north-
ernmost university, thus having a high proportion of
young people. The present population (per 2nd quarter
of 2018) is 76,062 inhabitants, predominantly of Norwe-
gian origin (14% immigrants) [24].
Tromsø 7 included more than 50 research projects, cov-
ering various health issues, symptoms and chronic diseases.
HCV detection was included for the first time. Based on
the official population registry, residents of the municipality
of Tromsø aged 40 years and older were invited to partici-
pate. A personal invitation was sent about 2 weeks before a
suggested time of appointment at one permanent study site.
The subjects were free to attend whenever suitable within
the opening hours of the study site and within the one year
duration of the study. The invitation leaflet included all ne-
cessary information, and a questionnaire was enclosed, as
well as username and password for an optional online re-
sponse. Non-attenders were given one reminder. Informa-
tion about the survey and invitation to participate were
repeatedly provided in the local newspapers.
All 32,591 citizens aged 40 years and above were invited,
and 21,083 (65%) attended. Sera from 20,946 participants
(64.3% of invited citizens) were tested for anti-HCV, of
whom 11,004 (52.5%) were women and 9942 (47.5%) were
men. The participation rate was highest in the age group 60
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to 69 years for both women and men, somewhat lower in
younger age groups, and lowest among those older than 80
years (Table 1).
Questionnaire
The participants responded to a self-administered ques-
tionnaire with questions about health, psychological prob-
lems triggering contact to professional health care, anxiety
or depression, smoking habits, alcohol consumption, the
use of drugs other than alcohol, level of education, marital
status and main occupation/activity. There were two ques-
tions regarding hepatitis C (translated from Norwegian):
“Have you been infected with the liver virus hepatitis C?”,
and “If you have been infected with the liver virus hepa-
titis C: have you ever received treatment?”
Data collection and laboratory methods
Sera from 20,946 participants were stored frozen at − 20 °C
and tested for anti-HCV (ARCHITECT Anti-HCV Assay,
Abbott System, Wiesbaden, Germany) at the Department
of Microbiology and Infection Control, University Hospital
of North Norway, Tromsø, Norway. Individuals with a posi-
tive anti-HCV test received an information letter with their
test results, describing the requirement for a second blood
test to discriminate between current infection and previous
exposure to HCV. The second blood test was performed at
the University Hospital in Tromsø, where the result was
followed up by the responsible medical doctor at the De-
partment of Gastroenterology, and compared to any exist-
ing HCV test results. Two reminders were sent to those
who did not have the follow-up test. The follow-up samples
were retested for anti-HCV and further tested for the pres-
ence of HCV RNA (ROCHE RT-PCR Cobas Amplicor
Hepatitis C Viral Polymerase Chain Reaction, Roche Mo-
lecular System Inc., Branchburg NJ, USA). Samples positive
for the anti-HCV test and negative to the HCV RNA test
were analyzed with a recombinant immunoblot assay
(RIBA HCV 3.0 SIA test, Chiron Cooperation, Emeryville,
CA, USA) as a secondary confirmation test of the first line
anti-HCV test to rule out unspecific positive tests. Samples
were considered anti-HCV positive with reactivity to two
or more antigens in the RIBA test, indeterminate when re-
activity to only one antigen was present, which may repre-
sent previous resolved HCV-infection or unspecific
antibody reactions [25], and negative when no
antigen-specific reactivity was observed. The RIBA test was
not carried out in cases were existing laboratory results
were consistent with either spontaneous clearance (previ-
ous positive RIBA test or positive HCV RNA test followed
by at least two consecutive negative HCV RNA tests with
at least three months interval) or obtained sustained viro-
logic response (SVR) after antiviral treatment. HCV geno-
typing was performed as a hybridization assay on products
from the HCV RNA PCR according to the manufacturer’s
instructions (INNO-LIPA HCV II kit, INNOGENETICS,
Ghent, Belgium).
Definitions
The term HCV exposure is used in Tables 2 and 3 to in-
clude individuals with the following characteristics: (1)
persons with chronic (viraemic) HCV infection; i.e. with
positive HCV RNA: (2) persons with treatment-recovered
HCV infection: (3) persons with spontaneously resolved
HCV infection; i.e. with positive RIBA test or positive
HCV RNA test followed by at least two consecutive nega-
tive HCV RNA tests with at least three months interval:
(4) persons with positive anti-HCV test, negative HCV
RNA and indeterminate RIBA test.
Estimated prevalence numbers of HCV exposure and
chronic HCV infection
Estimated prevalence numbers of HCV exposure and
chronic (viraemic) HCV infection in the Tromsø popula-
tion were calculated based on the observed prevalence
in each age group and corrected for different attendance
rates between the groups. An equal prevalence between
attenders and non-attenders was presumed for the cal-
culation of expected numbers of infected individuals.
Clinical follow-up
All subjects with a positive HCV RNA test were offered a
clinical evaluation, which included a thorough medical
Table 1 HCV testing in the Tromsø 7 Study (n = 20,946)
Women Men Total
Age (years) Invited Tested (%) Invited Tested (%) Invited Tested (%)
40–49 5195 3360 (64.7%) 5562 3033 (54.5%) 10,757 6393 (59.4%)
50–59 4534 3230 (71.2%) 4327 2767 (63.9%) 8861 5997 (67.7%)
60–69 3586 2652 (74.0%) 3543 2487 (70.2%) 7129 5139 (72.1%)
70–79 2001 1352 (67.6%) 1897 1310 (69.1%) 3898 2662 (68.3%)
80–89 981 386 (39.3%) 639 322 (50.4%) 1620 708 (43.7%)
90–104 242 24 (9.9%) 84 23 (27.4%) 326 47 (14.4%)
Total 16,539 11,004 (66.5%) 16,052 9942 (61.9%) 32,591 20,946 (64.3%)
Actual numbers for invitation to the Tromsø 7 Study, and rates (n (%)) of testing for anti-HCV according to sex and 10-year age groups
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examination, the recording of the medical history and the
assessment of risk factors for HCV infection. An estimate
of the time-point of transmission was made based on infor-
mation on the first year of high-risk behaviour, such as
injecting drug use (IDU), tattoos or transfusion of blood
products prior to 1992 [26]. At this stage, an additional
blood sample was analysed for platelet count, alanine ami-
notransferase (ALT), and aspartate aminotransferase (AST)
in order to calculate the Fibrosis-4 (FIB-4) index [27]. The
blood sample was also analysed for hepatitis B surface anti-
gen (HBsAg), hepatitis B core antibody (HBcAb) and anti-
gens/antibodies to human immunodeficiency virus (HIV
Ag/Ab combo). Liver stiffness (kPa) was measured with
transient elastography (FibroScan® 402, Echosens, Paris,
France). Significant fibrosis and cirrhosis was defined as
liver stiffness values ≥7 kPa and ≥ 12,5 kPa, respectively,
equivalent to METAVIR fibrosis stage ≥F2 and F4, respect-
ively [28]. Ultrasound was performed at the responsible
medical doctor’s discretion. Treatment was offered to all
HCV RNA positive patients who met for clinical follow-up.
Statistical analysis
Data summaries were performed using SPSS 24.0 software
and Microsoft Excel 2013. The Chi-Square test and
Mann-Whitney U test, as well as multivariate logistic re-
gression analysis, were used to compare sociodemographic
and behavioral characteristics between HCV exposed and
anti-HCV negative. The Fisher’s exact test was used to test
the differences between groups in case of small sample
numbers. A two-tailed p-value < 0.05 was considered sta-
tistically significant.
Results
Prevalence of hepatitis C
Figure 1 shows a flowchart of the study with associated
results. The anti-HCV screening test was positive in 217
(1.0%) of 20,946 individuals. The follow-up test was nega-
tive for anti-HCV and/or RIBA in 83 samples. Thus, the
prevalence of confirmed anti-HCV was 0.6% (95% CI:
0.5–0.7%) (n = 134), with a sex distribution of 71 (53%)
men and 63 (47%) women. HCV RNA was detected in 33
(0.2%; 95% CI: 0.1–0.3) of 20,946 participants, 18 male
(54.5%). Of these viraemic cases, 13 (39.4%; 95% CI: 22.7–
56.1) were not aware of their infection. Two of the 33 per-
sons with current positive HCV RNA reported that they
had received antiviral treatment earlier, one of whom had
interrupted the treatment before scheduled treatment-end
and was considered to be a treatment failure. The second
person did not meet for clinical follow up, rendering it un-
clear whether the vireaemia represents reinfection or
treatment failure. Overall, current or treatment-recovered
HCV infection was found in 85 (0.4%; 95% CI: 0.3–0.5) of
20,946 individuals, 48 (56.5%) men and 37 (43.5%)
women. Of those, 52 (61.2%) had previously received anti-
viral treatment with achieved SVR.
Spontaneous clearance of HCV was demonstrated in 33
(24.6, 95% CI: 17.3–31.9) of 134 anti-HCV positive individ-
uals. The RIBA test was indeterminate in 16 of the cases
that were anti- HCV positive and HCV RNA negative.
Table 2 shows the observed prevalence of HCV expos-
ure and chronic (viraemic) HCV infection according to
sex and 10-year age groups, as well as the estimated
over-all prevalence. The highest prevalence of HCV ex-
posure (1.2%) and chronic HCV infection (0.4%) was
seen in the age group 50–59 years.
HCV genotype
Data on HCV genotype (GT) was available in 75 of the 85
persons with current or recovered chronic HCV infection.
HCV GT 1a was detected in 19 (25.3%) individuals, GT 1b in
10 (13.3%), GT 2b in 10 (13.3%), GT 3a in 33 (44%), GT 4 in
one (1.3%) and GT 1 not available for subtyping in 2 (2.7%).
Unawareness of HCV infection
Thirteen of the 33 (39.4%) individuals with viraemic
HCV infection were not aware of their infectious status,
Table 2 Observed and estimated prevalence of HCV exposure and chronic HCV infection
















40–49 10,757 6393 32 0.5% (0.4–0.7) 54 5 0.08% (0.0–0.2) 8
50–59 8861 5997 69 1.2% (0.9–1.5) 102 24 0.4% (0.2–0.6) 35
60–69 7129 5139 28 0.5% (0.4–0.8) 39 4 0.08% (0.0–0.2) 6
70–79 3898 2662 3 0.1% (0.0–0.3) 4 0 0% (0.0–0.1) 0
80–89 1620 708 2 0.3% (0.1–1.0) 5 0 0% (0.0–0.5) 0
90–104 326 47 0 0% (0.0–7.6) 0 0 0% (0.0–7.6) 0
Total 32,591 20,946 134 0.6% (0.5–0.7) 209 33 0.2% (0.1–0.3) 51
Observed prevalence of HCV exposure and chronic HCV infection in the Tromsø 7 Study according to 10-year age groups. Total prevalence is corrected for
different attendance rate in the different age-groups
aEstimated numbers of individuals in the Tromsø population is based on an equal prevalence between attenders and non-attenders. All numbers are n or
proportions (%) with 95% confidence intervals (95% CI)
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P value ORc (95% CI)
Age (yrs), median (range) 20,946 54 (40–84) 56 (40–99) p = 0.004
Gender (%) 20,946 p = 0.199
Male 71 (53%) 9871 (47%) N.s.
Female 63 (47%) 10,941 (53%)
Live with a spouse/partner (%) 19,767 p < 0.0005
No 50 (43.5%) 4530 (23.1%) N.s.
Yes 65 (56.5%) 15,122 (76.9%)
Level of education (%) 20,573 p = 0.001
< 12 years 85 (64.4%) 10,394 (50.8%) N.s.
> 12 years 47 (35.6%) 10,047 (49.2%)
Disability benefit recipient or unemployed
(%). Retired excluded
15,870 p < 0.0005 2.5 (1.7–3.7)
Yes 46 (36.8%) 1973 (12.5%)
No 79 (63.2%) 13,772 (87.5%)
Self-reported health (%) 20,768 p < 0.0005
Very bad 1 (0.8%) 73 (0.4%) N.s.
Bad 18 (13.6%) 1065 (5.2%)
Neither good nor bad 46 (34.8%) 5353 (25.9%)
Good 61 (46.2%) 11,104 (53.8%)
Excellent 6 (4.5%) 3041 (14.7%)
Psychological problems (%)a 20,251 p < 0.0005
Current 16 (12.9%) 879 (4.4%) N.s.
Previous 12 (9.7%) 1801 (8.9%)
No 96 (77.4%) 17,447 (86.7%)
Daily smoking (%) 20,753 p < 0.0005
Current 54 (40.3%) 2827 (13.7%) 4.4 (2.2–8.6)
Previous 65 (48.5%) 9129 (44.3%) 2.7 (1.4–5.1)
Never 15 (11.2%) 8663 (42.0%)
Alcohol consumption (%) 20,816 p = 0.419
4 or more times a week 5 (3.8%) 1235 (6.0%) N.s.
2–3 times a week 30 (22.6%) 4920 (23.8%)
2–4 times a month 48 (36.1%) 7795 (37.7%)
Monthly or less frequently 34 (25.6%) 5067 (24.5%)
Never 16 (12%) 1666 (8.1%)
Use of drugs other than alcohol (%)b 20,498 p < 0.0005
Yes, now 15 (11.5%) 65 (0.3%) 35.4 (17.4–71.9)
Yes, previously 53 (40.8%) 824 (4.0%) 15.7 (10.2–24.2)
No 62 (47.7%) 19,479 (95.6%)
All numbers are n (%) or median (range). Chi Square, Fisher’s exact or Mann-Whitney U test were used where appropriate
aPsychological problems triggering contact to professional health care
bE.g. cannabis, amphetamines, cocaine, heroin, hallucinogens, solvents, gamma hydroxybutyrate (GHB)
cResults from multivariate logistic regression analysis, adjusted for age and gender, shown as odds ratios (OR) with 95% confidence intervals (CI). N.s.:
Not significant
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corresponding to a population prevalence of 0.06% (95%
CI: 0.03–0.09). Nine of the 13 were women and the me-
dian age was 55 years. The distribution of genotypes 1
through 3 was six GT 1a, two GT 2 and five GT 3a. The
median ALT value was 48 U/L (range 21–276 U/L), with
eight of thirteen persons demonstrating a normal ALT
value. The median liver stiffness value was 6.7 kPa (range
4.1–17.6). Liver stiffness values were < 7 kPa in five per-
sons and between 7 and 12 kPa in six persons. Two per-
sons had liver stiffness > 12.5 kPa, one of whom was
considered to have established liver cirrhosis based on
liver stiffness of 17.6 kPa and signs of cirrhosis on ultra-
sound. The second person had probable liver cirrhosis
based on liver stiffness of 12.6 kPa and a FIB-4 index of
3.86. HBsAg was negative in all, and HBcAb was detected
in three of the 13 persons. In the self-administered ques-
tionnaire, six of the 13 individuals reported current (n = 2)
or past (n = 4) drug injection. In the follow-up examin-
ation, an additional three persons reported past drug in-
jection, thus 69.2% reported a history of IDU. The median
estimated time from infection to diagnosis was 30 years
(range 10–40 years). Extrapolating the observed propor-
tion of individuals who were unaware of their HCV
infection to the whole population of Northern Norway
(484,001 inhabitants) implies that 290 persons above 40
years of age in this region could be unaware of ongoing
HCV infection.
All 13 persons with previously undiagnosed chronic
HCV infection have been successfully treated with
achieved SVR 12 or 24 weeks after completed treatment.
Factors associated with HCV exposure
Frequencies of socio-demographic characteristics in the
HCV-exposed cohort compared to the background
population are shown in Table 3. In univariate analysis,
there was a positive association between HCV exposure
and self-reported bad health, daily smoking, the use of
drugs other than alcohol, lower level of education, living
without a spouse/partner, being disabled or unemployed,
and having psychological problems triggering contact to
professional health care. In a separate question about
anxiety or depression, the HCV-exposed cohort scored
higher than the background population (data not
shown). We found no association between alcohol con-
sumption and HCV infection. In a multivariate logistic
regression analysis including significant variables from
Fig. 1 Flow chart of study design and results
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the univariate analysis and adjusting for age and gender,
significant independent predictors of being exposed to
HCV were: Being disabled or unemployed (OR 2.5; 95%
CI 1.7–3.7), current daily smoking (OR 4.4; 95% CI 2.2–
8.6), previous daily smoking (OR 2.7; 95% CI 1.4–5.1),
current use of drugs other than alcohol (OR 35,4; 95%
CI 17.4–71.9), and previous use of drugs other than al-
cohol (OR 15.7; 95% CI 10.2–24.2).
Estimated cost of screening
Table 4 shows the estimated costs for the screening pro-
ject. The total cost for screening of 20,946 individuals
was NOK 1177705 (€ 125,175), and the cost per newly
detected chronic HCV infection (n = 13) was NOK
90593 (€ 9629).
Discussion
We have carried out a population-based screening for
HCV infection in a presumed low-prevalence area. In clin-
ical practice, the identification of individuals with viraemic
HCV infection is most important. For surveillance pur-
poses, however, reliable data for both current infection
and recovered disease, either spontaneously or through
treatment, is of interest. In this survey of individuals aged
40 years and older, the prevalence of chronic (viraemic)
HCV infection was 0.2%. In comparison, the last popula-
tion survey in Norway in 2001, including people aged 30
years and older, revealed a prevalence of chronic HCV in-
fection of 0.5%, an estimate which also included
treatment-recovered cases [3]. In our study, the prevalence
of current and treatment- recovered chronic HCV infec-
tion was 0.4%, of which a high proportion (61.2%) had
already received treatment with achieved SVR. A model-
ling study in 2013 estimated the viraemic prevalence in
Norway to be 0.43% [29]. The slightly higher estimate in
this study compared to ours might partly be explained by
different study designs, where the modelling study was
based on historical data and expert opinions.
The present study revealed that a substantial proportion
(39.4%) of individuals with chronic HCV infection were un-
aware of their infectious status, a finding which is in line
with the results of others [5, 9–11, 29]. Of the 13 previously
undiagnosed individuals, 69% had a history of IDU, thus
should theoretically have been detected by a risk-based
screening strategy. This suggest that the current recom-
mendation of risk-based screening is suboptimal in identify-
ing all chronically infected persons hidden in the general
population. One reason for this is that infected persons
may not consider themselves as being at risk for HCV in-
fection, i.e. persons with occasional drug use, especially in
the remote past, and individuals who received blood trans-
fusion before 1992 [9, 17]. Others have pointed out that the
stigma associated with IDU; and the socio-demographic
characteristics of PWIDs, create barriers that impede test-
ing and linkage to care in this population [30].
Strengths and weaknesses
The strength of this study is the large sample size in a gen-
eral population, which enhances the probability that the
study population is representative of the general popula-
tion. However, there are important limitations. First, The
Tromsø 7 study only included individuals aged 40 years
and older. This age restriction was inherent to the over-
reaching study design of Tromsø 7, but clearly introduces
a selection bias. IDU is the main mode of transmission of
HCV [31], and it is estimated that 29.8% (range 25.0–34.8)
of PWIDs in Western Europe are younger than 25 years
[32]. In the municipality of Tromsø, it is estimated that
the number of PWIDs is approximately 300 (personal
communication, Inger Hilde Trandem, MD, Social Med-
ical Center, Tromsø, May 28, 2018). There is no clear data
on their age distribution, but it is reasonable to assume
that the proportion of young PWID in Tromsø is compar-
able to the findings in the above mentioned study. Due to
the age restriction, the prevalence of HCV infection in our
study is most likely underestimated.
Table 4 Cost of screening for HCV in the Tromsø 7 Study
Cost per analysis Analyses (n) Total cost Cost per newly detected chronic
HCV infection (n = 13)
Reagentsa 20,946 NOK 922705
(GBP 86,987, € 98,071)
NOK 70977
(GBP 6691, € 7544)
Labour costsb NOK 180000
(GBP 16,969, € 19,132)
NOK 13846
(GBP 1305, € 1472)
Otherc NOK 75000
(GBP 7071, € 7972)
NOK 5769
(GBP 544, € 613)
Total NOK 56.23
(GBP 5.30, € 5.98)
20,946 NOK 1177705
(GBP 111,028, € 125,175)
NOK 90593
(GBP 8541, € 9629)
Estimated costs for the HCV screening project in Norwegian Kroner (NOK), Pounds (GBP) and Euros (€). 1 GBP and 1 € approximated 10.69 and 9.48 NOK,
respectively, as of 2. October 2018. 1 € = 1.15 US Dollars
aReagents (anti-HCV test kits) for this study were provided by Abbvie AS, Norway. Cost is based on prices for test kits used for daily routine HCV testing
bLabour costs in this study were covered by the Northern Norway Regional Health Authorities with the sum mentioned, which was based on estimated time used
for testing the samples in the study
cParticipation fee for the Tromsø 7 Study
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Second, even if participation rates were generally high
across all age groups, self-selection is still an important
issue that may affect the representativeness of the study
sample. The attenders in population surveys tend to be
more educated and have a healthier life style than
non-attenders [33]. The second survey of the Tromsø
study (Tromsø 2) showed that various psychiatric disor-
ders and alcohol abuse were significant predictors of non-
attendance in health surveys [34], and a Canadian study
demonstrated that non-response bias is a problem in alco-
hol and drug use surveys [35]. It is therefore reasonable to
assume that current and former PWIDs are less likely to
participate in health surveys, also resulting in underesti-
mation of the true HCV prevalence and reducing the effi-
ciency of screening in the general population.
The interpretation and significance of indeterminate
RIBA reactions are unclear. In one study, 4.9% of RIBA
indeterminate cases were found to be HCV RNA posi-
tive [36]. Still, most individuals with indeterminate RIBA
have a negative HCV RNA test, which may represent
previous resolved HCV-infection as well as unspecific
antibody reactions [25]. Reports have shown that ap-
proximately half of those with indeterminate RIBA have
a resolved HCV infection [37, 38]. In this study, we have
chosen to include persons with RIBA indeterminate re-
sult in the HCV-exposed cohort, which could have led
to overestimation of anti-HCV positive. However, the
number of RIBA-indeterminate records was low, making
the contribution of these less important.
Screening strategies in a low-prevalence area: Whom and
how to screen
Our study was integrated in an established
population-based survey with repeated health surveys
since 1974. The attendance rate was 64.3% and the esti-
mated cost per newly detected chronic HCV infection was
approximately NOK 90000 (€ 9629). HCV-screening of
the general population outside such an established popu-
lation survey would have been more laborious and at an
expected considerably higher costs, thus making it less
feasible. As discussed above, it is likely that persons be-
longing to risk groups for HCV infection attended the
study to a lesser degree than the general population, redu-
cing the efficiency of such an approach. On the other
hand, the study has unmasked several individuals with
chronic HCV infection that did not define themselves as
belonging to known risk groups. A recent Spanish pilot
study for an eventual population-based screening program
included the adult population (20–75 years) in a small
health area with a participation rate of 46.2% (2637/5706)
[39]. HCV RNA was detected in 13 persons (0.5%), of
whom five were unaware of the disease.
In low-prevalence countries, routine screening of the en-
tire population has not been considered to be cost-effective
[15–18], and screening are limited to high-risk populations.
However, the high proportion of undiagnosed HCV infec-
tion clearly underscores the limitations of the risk-based
screening approach and the need to reconsider screening
strategies in order to achieve the diagnosis rate of 90% pro-
moted by the WHO.
In the US, it is recommended a one-time screening of
persons in the high-prevalence 1945–1965 birth cohort, in
addition to targeted risk-based testing [40]. In the present
study, the highest prevalence of anti-HCV and viraemic
HCV infection was found in the age group 50–59 years,
i.e. in people born between 1956 and 1965, which may be
explained by a later onset of the epidemic of IDU in
Norway, with a gradual increase in the number of PWID
from the onset of IDU in 1973 until a peak was reached in
2000 [7]. In a birth-cohort analysis, 73% of the
HCV-infected population in Norway was born between
1955 and 1980 [41]. A systematic review including several
countries concluded that screening of birth cohorts, drug
users, and high-risk populations was cost-effective [18].
However, recent studies indicate that universal screening
of the general population may be an effective strategy. In
France, where the prevalence of chronic HCV infection is
0.3% [2], a modelling study showed that universal screen-
ing of all individuals aged 18–80 years was the most effect-
ive screening strategy, and also the most cost-effective,
assuming rapid initiation of treatment after diagnosis [19].
Likewise, in Spain with an HCV RNA prevalence 0.35–
0.41%, a recent modelling study concluded that screening
of the general adult population would identify a larger
number of additional individuals with chronic HCV infec-
tion than screening high-risk groups or screening the
age-cohort with the highest anti-HCV prevalence plus
high-risk groups [20].
Others suggest strategies to improve targeted screening
of people in high-risk groups in various settings. Primary
care practitioners can play an important role in targeted
screening, especially in former PWID, whereas screening
of current PWID is more appropriate in settings like out-
patient clinics, opioid substitution programs, jails, and
psychiatric clinics [17, 42–46]. In a screening and medical
follow-up programme in Northern Norway, primary care
practitioners were encouraged to screen patients with
former or present risk factors for HCV infection, which
led to an increase in the number of newly diagnosed HCV
infections in the subsequent years [47]. Technical bottle-
necks in HCV testing can lead to missed opportunities in
the HCV cascade of care, e.g., when a high proportion of
anti-HCV positive individuals are not followed up with a
confirmatory test for HCV RNA [48]. The availability of a
new point-of-care (PoC) test with high sensitivity and spe-
cificity (close to 100%) for detection of HCV RNA might
contribute to simplification of HCV testing and thus en-
able decentralisation of HCV care and treatment [49].
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New technology, such as the use of dried blood spot and
saliva sampling could increase access to HCV testing, e.g.
in people with difficult venous access [50, 51].
There are potential negative effects associated with
screening large numbers of persons in a population with
low prevalence of HCV infection. In our study, the pro-
portion of false positive anti-HCV tests was 38.2% (83/
217). False-positive results can cause harm by way of
anxiety and stigmatization, although such effects are dif-
ficult to quantify [52].
Implications
Modelling studies have indicated that screening in the
general adult population may be an effective screening
strategy [19, 20]. Universal screening may allow diagnosis
and treatment of asymptomatic infected persons, avoiding
the development of complications and onward transmis-
sion, thus saving health costs. To be effective, people with
the highest risk of infection must also attend the screening
project. Based on this, strategies to improve targeted
screening of people in high-risk groups in various settings,
including primary care-based interventions, may still be
the most effective approach in low-prevalence regions. To
overcome the high costs associated with screening in the
general population, the use of a birth-cohort screening
strategy could be considered, which in our case would be
based on the finding of the highest prevalence of
anti-HCV and chronic HCV infection in people born be-
tween 1956 and 1965. Finally, implementation of simpli-
fied testing methods may increase access to HCV testing
in both risk groups and birth cohorts.
Conclusion
In this population-based survey the prevalence of chronic
HCV infection in the general population in Tromsø was
0.2%, but due to biases the true prevalence is likely higher.
A substantial proportion (39.4%) of individuals with vir-
aemic infection was not aware of their diagnosis, suggest-
ing that the current recommendation of screening of
individuals with high risk of infection is an inadequate
approach to identify all chronically infected persons.
Strategies to improve HCV awareness and case-finding
are needed, and for some communities, testing the general
population may be a sensible approach.
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Future complications of chronic hepatitis C
in a low-risk area: projections from the
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Abstract
Background: Hepatitis C (HCV) infection causes an asymptomatic chronic hepatitis in most affected individuals,
which often remains undetected until cirrhosis and cirrhosis-related complications occur. Screening of high-risk
subjects in Northern Norway has revealed a relatively low prevalence in the general population (0.24%). Despite
this, late complications of HCV infection are increasing. Our object was to estimate the future prevalence and
complications of chronic HCV infection in the period 2013–2050 in a low-risk area.
Methods: We have entered available data into a prognostic Markov model to project future complications to
HCV infection.
Results: The model extrapolates the prevalence in the present cohort of HCV-infected individuals, and assumes a
stable low incidence in the projection period. We predict an almost three-fold increase in the incidence of cirrhosis
(68 per 100,000), of decompensated cirrhosis (21 per 100,000) and of hepatocellular carcinoma (4 per 100,000) by
2050, as well as a six-fold increase in the cumulated number of deaths from HCV-related liver disease (170 per
100,000 inhabitants). All estimates are made assuming an unchanged treatment coverage of approximately 15%.
The estimated numbers can be reduced by approximately 50% for cirrhosis, and by approximately one third for
the other endpoints if treatment coverage is raised to 50%.
Conclusion: These projections from a low-prevalence area indicate a substantial rise in HCV-related morbidity and
mortality in the coming years. The global HCV epidemic is of great concern and increased treatment coverage is
necessary to reduce the burden of the disease.
Keywords: Disease burden, Fibrosis development, Hepatitis C, Markov modelling, Natural course
Background
Chronic hepatitis C virus (HCV) infection is a major
cause of chronic liver disease and the burden of the dis-
ease is expected to increase [1–3]. Worldwide, 64–103
million people are persistently infected with HCV [4].
After acute HCV infection, between 75% and 85% of the
patients establish a chronic infection [5]. In industrial
countries, most of the patients infected with HCV will
have contracted the disease in the 1970s and 1980s.
Thus, at the beginning of the twenty-first century, a
large pool of infected patients exists, and in many coun-
tries, the cohorts of patients with chronic HCV infection
have come of age. Most infected individuals are asymp-
tomatic, but the number of patients with liver cirrhosis
and hepatocellular carcinoma (HCC) is increasing [6, 7].
Thus, 30–40 years after the start of the epidemic, the
disease is a growing burden on the health care system in
many countries.
The natural course of late-stage HCV infection is so
far unsettled. The disease increases the risk of develop-
ing liver cirrhosis and its complications such as liver
cancer and liver failure. The prognosis is highly
dependent on the rate of progression of liver fibrosis
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towards cirrhosis. Most studies have shown that the rate
of fibrosis is slow the first two decades. However, the
estimated risk of cirrhosis varies as much as 3–30% in
different populations [5, 8–10], suggesting that the
progression of the disease may not be universal but
rather depend on additional risk factors [11]. Beyond the
two first decades, the rate of fibrosis progression is
sparsely documented. One study reported that fibrosis
progression is non-linear with an estimated a risk of cir-
rhosis of 41% after 30 years [8], whereas an autopsy
study reported septal fibrosis or cirrhosis in 35% of cases
with disease duration of 25 years or longer [12].
Among patients with liver cirrhosis the annual rate of
progression to hepatic decompensation and HCC has
been described to be in the range 4–8% and 2.4–3.4%, re-
spectively [13–15]. In the absence of retrospective as well
as prospective data for the long-term progression of the
disease (>20 years), various mathematical models have
been used to reconstruct the natural course and estimate
future complications of HCV infection [1, 13, 16–18].
Even with a decline in the incidence rate after 1990, an in-
crease in the number of patients with complicated disease
and deaths from chronic HCV is expected in the coming
decades [1–3, 19, 20].
Norway is a country with a low prevalence of HCV
[21, 22]. Drug abuse is the primary transmission route,
and low age at transmission indicates a low risk for rapid
disease progression. Despite this, late complications of
HCV infection is a growing problem [23] and health
costs are expected to increase. Markov models are well
suited for simulation of chronic diseases [24], and we
have used a Markov model to estimate the future preva-
lence and complications of chronic HCV infection in the
period 2013–2050 in a low-risk area.
Methods
The study population consists of individuals included in
the Hepatitis C study in Northern Norway between 1992
and 2011 [21, 23]. In addition, we performed a registra-
tion study to assess the number of newly diagnosed indi-
viduals with HCV each year between 1998 and 2012 at
the two microbiological departments in our region.
The Hepatitis C study in Northern Norway
In 1992, a screening and medical follow-up programme
of patients with HCV infection was established in the
Health Region of Northern Norway (460.000 inhabi-
tants). In brief, general practitioners were encouraged to
screen patients with former or present risk behavior for
HCV infection. If chronic HCV infection was detected,
the general practitioners were encouraged to refer the
patient for follow-up at one of the 11 medical centers in
the region. An estimate of the year of transmission was
made for all referred patients based on either the year of
acute HCV infection or the first year of high-risk behav-
iour [23]. Liver biopsies were performed, and fibrosis
was graded (0–6) according to Ishak et al. [25]. Presence
of concomitant alcoholic liver disease was assessed by
clinical judgment.
The registry study
Individuals with a positive anti-HCV test registered at
the two microbiological departments in Northern
Norway between 1998 and 2012 were included. The year
of diagnosis was defined as the first year of a positive
anti-HCV test (ARCHITECT Anti-HCV Reagens kit.
Abbott System, Wiesbaden, Germany). Until 2004, a
positive anti-HCV test was directly confirmed with a re-
combinant immunoblot assay (RIBA HCV 3.0 SIA test,
Chiron Cooperation, Emeryville, CA, USA). Individuals
with a positive RIBA (two or more positive bands) or
indeterminate RIBA (one band) were included, while
individuals with a negative RIBA (no bands) were
excluded. The result of the HCV RNA test was recorded
if available: an in-house reverse transcriptase polymerase
chain reaction (RT-PCR) until 2004, where after the
ROCHE RT-PCR (Cobas Amplicor Hepatitis C Viral
Polymerase Chain Reaction, Roche Molecular System
Inc., Branchburg NJ, USA) was used. The ROCHE PCR
test replaced the RIBA test for confirmation of HCV in-
fection from 2005. HCV genotyping was performed as a
hybridization assay on products from the HCV RNA
PCR according to the manufacturers’ instructions
(INNO-LIPA HCV II kit, INNOGENETICS, Ghent,
Belgium). Individuals without a registered residence in
Norway were excluded. The results of HBsAg (hepatitis
B surface antigen) and anti-HIV (human immunodefi-
ciency virus) were recorded if available.
Markov model
In order to predict HCV-related morbidity and mortality
an open Markov model was constructed (Fig. 1). Of in-
fected patients, 20% were assumed to recover spontan-
eously during the first year of infection [26]. Yearly
transitions between categories were done according to
probability estimates generated from different sources.
The effect of medical treatment was modelled in three
scenarios where 0%, 15% and 50% of all patients were
assumed to receive medical treatment. Before the intro-
duction of direct acting antivirals (DAAs), treatment was
offered to eligible patients irrespective of fibrosis stage,
i.e. patients with Metavir fibrosis score F0/F1 were also
treated. The treatment coverage at this time was
approximately 15%. When the highly expensive DAAs
became available, the Norwegian national guidelines
restricted treatment to patients with fibrosis score ≥ F2.
However, since DAAs offer a simple, tolerable, short-
term and highly effective therapy, we consider an
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increased treatment coverage to 50% as possible. Recently
(March 2017), updated national guidelines recommend
treatment for all patients with genotype 1, irrespective of
fibrosis grade. Treatment of genotype 2 and 3 is still
restricted to patients with fibrosis score ≥ F2.
To estimate the rate of fibrosis progression in the
cohort, 237 records with a positive HCV RNA test, known
duration of infection, and available liver biopsy results
were entered into an ordinal regression analysis, which
can be described as a multilayer logistic regression. This
method estimates points of transition on an ordinal scale
(like the Ishak fibrosis scale). Sex, time after contraction of
the disease and HCV genotype were included as predic-
tors of Ishak fibrosis grade. Non-significant terms were re-
moved from the model leaving time after contraction and
genotype as significant predictors. Genotype 1 and 4 were
analyzed as a single group due to few observations of
genotype 4. The model predicted 70% of the observed fi-
brosis grades correctly within a margin of error of one
Ishak grade, but overestimated fibrosis grade in 13% and
underestimated in 17%. From this model, a matrix of esti-
mated probabilities of transition to a higher fibrosis grade
versus staying in the present grade for each year of infec-
tion could be constructed. It was assumed that fibrosis
development during ongoing HCV infection could only
either stay the same or change to a higher stage each year
of infection. Additional file 1 shows the regression model
in more detail. The Markov model was adjusted for geno-
types in the estimation of fibrosis progression, according
to the prevalence of the different genotypes in our popula-
tion. For transitions from Ishak 6 (compensated cirrhosis)
to more severe states, fixed probabilities were used. We
did not have exact data from Northern Norway for the
various transitions, and have thus used data from a Scot-
tish HCV population of drug-injecting abusers (as in our
study), as described by Hutchinson et al. [13], with
transition probabilities similar to that reported by others
[14, 27], as shown in Table 1. The model was corrected
for standardized mortality rate according to Norwegian
population characteristics. Non-cirrhotic subjects success-
fully treated for HCV with achieved sustained virological
response (SVR) were removed from the model. Subjects
with cirrhosis remain in risk of liver complications in spite
of SVR, and of those, 50% were retained in the model
[28]. All successfully treated subjects with decompensated
cirrhosis and HCC were kept in the model.
The overall SVR rate until 2015 was 71.3%, based on
the response of interferon-based treatment in our own
Fig. 1 The natural course of hepatitis C. The Markov model is based on simulation of transition from a given category to the next based on probability
estimates. The progression of fibrosis towards cirrhosis is based on local data, whereas most of the remaining estimated probabilities are previously
published from other cohorts. In all states of HCV, there is also an annual risk of dying from natural courses, which is implicitly included in the model
Table 1 Transition rates between different states of hepatitis C
Transition rates
From state To state Yearly transition rate Reference
Infection time Spontaneous remission 0.200 Thomas Clin Liver Dis 2005 [26]
Compensated cirrhosis Decompensated cirrhosis 0.065 Hutchinson Hepatol 2005 [13]
Decompensated cirrhosis Liver-related death 0.186 Hutchinson Hepatol 2005 [13]
Cirrhosis Hepatocellular carcinoma 0.035 Hutchinson Hepatol 2005 [13]
Hepatocellular carcinoma Death 0.605 Hutchinson Hepatol 2005 [13]
The table shows the estimated rates of transition between different states of development of hepatitis C and its complications, as used in the Markov model
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clinical practice. For individuals treated from 2015 on-
wards, the overall SVR rate was set to 90% to reflect the
improved treatment response provided by DAAs.
Entering of data into the Markov model
Figure 2 shows the actual incidence of newly diagnosed
HCV infection per year in the period from 1992 to 2012
(dark bars). After 2004, the incidence decreased to a
stable level of approximately 90 newly diagnosed cases
each year. In view of this stable number, we have pro-
jected a stable occurrence of 90 newly diagnosed cases
each year from 2013 and forwards (light bars).
HCV-positive individuals were entered into the model
at time of contraction. Since only a subgroup had a
known time of transmission, this had to be estimated for
the remaining records. First, we investigated the 402 re-
cords with known times of transmission. In 2004, all
general practitioners in the area were subject to a HCV
campaign encouraging screening of their patients with
known risk behaviour. We found an increased amount
of early diagnoses (within the first year of transmission)
in the years after this campaign compared to before
(35.5% vs. 21.3%). From these data, probability distribu-
tions could be derived in order to estimate time of con-
traction for records diagnosed before and after 2004,
respectively. Records without known time of transmis-
sion were then entered into the model using these distri-
butions as weights. From 2013 forward, the estimated
number of 90 newly diagnosed cases each year were
allocated due to the late probability distribution in order
to estimate their time of contraction.
The registration of HCV infection revealed incomplete
records regarding confirmation testing. A positive anti-
HCV test normally should be followed up with a new
blood sample for the confirmation with RIBA and/or
HCV RNA. Not all the persons with positive anti-HCV
tests had a recorded confirmation test. The starting co-
hort in the model thus consists of patients with con-
firmed HCV infection (either a positive RIBA or a
positive HCV RNA test), as well as individuals with un-
confirmed HCV (either only a positive anti-HCV or an
indeterminate RIBA). We therefore estimated the likeli-
hood of a true positive test in incomplete records in the
following way: In a sample of 326 records with a positive
anti-HCV-test where RIBA had been measured, 207 sub-
jects (63%) had a positive RIBA test, and the probability
of a true positive anti-HCV test was estimated to 0.63.
Similarly, in a sample of 14 records with an inconclusive
RIBA and a HCV RNA test, we found three individuals
with a positive HCV RNA test, and the probability of a
true positive record in case of inconclusive RIBA was es-
timated to 0.21. Summarized, individuals with either a
positive HCV RNA or RIBA were weighted 1.0, and in-
dividuals with only a positive anti-HCV test or an incon-
clusive RIBA were weighted 0.63 and 0.21, respectively.
Results
Based on the registration and subsequent weighting de-
scribed above, the estimated HCV cohort consists of
Fig. 2 Newly diagnosed hepatitis C in Northern Norway. The figure shows numbers per year of newly diagnosed individuals with hepatitis C in
Northern Norway, from the first registration in 1992 to the end of 2012 (dark bars). The estimated yearly occurrence of newly diagnosed from
2013 and forward are also shown (light bars)
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2589 individuals (positive HCV RNA or positive RIBA)
with a sex distribution of 64% men and 36% women.
Additional file 2 shows the estimation of the HCV co-
hort in more detail. The distribution between genotypes
1 through 4 was 45%, 8%, 46% and 1%, respectively. The
prevalence of HBsAg and anti-HIV was 2.3% and 1%,
respectively.
Modeled fibrosis progression
In the subgroup that was the basis for estimation of fi-
brosis progression (n = 237), the sex distribution was
the same as in the total cohort and the distribution be-
tween HCV genotypes 1 through 4 were approximately
equal to the total cohort, 45%, 10%, 44%, and 1%,
respectively. The median duration of infection was
13 years (range 0–42 years) and the mean age at liver
biopsy was 40 years. The rate of fibrosis progression was
relatively slow in the first 20–25 years of infection,
followed by an accelerated fibrosis progression, especially
in patients with genotype 3 (Fig. 3).
Markov modelling
The Markov model projects the number of patients
(per 100,000 inhabitants) in the different states of com-
pensated cirrhosis, decompensated cirrhosis and HCC
for the years 2013 to 2050, given various scenarios of
HCV treatment coverage. It estimates an almost three-
fold increase in the incidence of cirrhosis (68 per
100,000), of decompensated cirrhosis (21 per 100,000)
and of hepatocellular carcinoma (4 per 100,000) by
2050, as shown in Fig. 4a-c. Complications are expected
to reach a peak around 2040. The model predicts a six-
fold increase in the cumulated number of deaths from
HCV-related liver disease (170 per 100,000 inhabitants),
as shown in Fig. 4d. All estimates are made assuming
an unchanged treatment coverage of approximately
15%. The estimated numbers can be reduced by ap-
proximately 50% for cirrhosis, and by approximately
one third for the other endpoints if treatment coverage
were scaled up to 50%.
Discussion
In our low-risk area of HCV infection, we have esti-
mated the fibrosis progression in untreated hepatitis C.
Fibrosis develops slowly the first 20–25 years of infec-
tion, where after an accelerated fibrosis progression,
especially in genotype 3, is predicted.
Using a Markov model, we have estimated the future
complications of HCV based on the actual number of
infected individuals until the year 2012, followed by an
estimated low and stable incidence rate. The model pre-
dicts a gradual increase in HCV-related liver cirrhosis,
decompensated cirrhosis and HCC with an apparent
peak around 2040, accompanied by a gradual increase in
liver-related deaths.
Modelling
Precision of dynamic modelling for prognosis of preva-
lence, morbidity and mortality depends on the quality of
the data entered and the assumptions made. We have
used locally acquired data whenever possible. The critical
aspect in HCV pathophysiology is the progressive devel-
opment of fibrosis towards cirrhosis, and in this aspect,
our model also made use of local data. The further
Fig. 3 Development of fibrosis in hepatitis C. The figure shows the time course of distribution of estimated median fibrosis grade according to
genotype and duration of HCV disease. Estimates were derived by ordinal regression analysis of Ishak scores in 237 patients with duration of
infection and genotype as independent variables
Kileng et al. BMC Infectious Diseases  (2017) 17:624 Page 5 of 9
development from established cirrhosis is not likely to be
very different from that of other cohorts, and the use of
estimated transition rates from other studies [13] should
not affect the prognosis measurably.
Our Markov model is based on an assumed low and
stable incidence until 2050, whereas other reports esti-
mate a declining or stable incidence [2]. The observed
incidence peak in 2002–2004 in our data is probably a
result of increased focus on HCV infection among
general practitioners due to our encouragement of
diagnosis in that period.
Our cohort is relatively young, and the liver biopsy
data has a limited number of observations of severe
fibrosis (Ishak grade 4–6). Hence, the estimates
generated from these data are less precise regarding
progression through high fibrosis stages.
Published data show variable rates of liver fibrosis
progression, with 10%–40% developing cirrhosis after
20–35 years of infection [5, 8, 29]. A large systematic
review supports nonlinear fibrosis progression [8] and
other studies have shown that HCV genotype 3 is
associated with a faster fibrosis progression [30–33].
Male sex is a reported risk factor for disease
progression [5, 31]. However, we found no effect of sex
in the progression of fibrosis, which is also observed in
other studies [34].
Strengths and weaknesses
The strengths of this study are; first, we have reliable
data on the HCV-infected subjects in our health re-
gion; second, the simulated fibrosis progression in the
cohort is based on local data. However, there are ap-
parent weaknesses. First, the number of undiagnosed
HCV-infected individuals in the population is un-
known. In Sweden, a comparable country regarding
HCV epidemiology, it has been suggested that the rate
of undiagnosed HCV infection is approximately 20%
[35]. Second, incomplete records regarding confirm-
ation testing has made it necessary to estimate the
number of true positive cases, resulting in uncertainty
regarding the true prevalence. However, our estimate
of 63% true positives among those who only tested
positive for anti-HCV is not controversial compared to
another reported value of 68% true positive [36].
Moreover, the significance of RIBA-indeterminate re-
actions is unclear. Most individuals with indeterminate
RIBA have a negative HCV RNA test, which may rep-
resent previous exposure to, but spontaneous recovery
ba
c d
Fig. 4 Prediction of hepatitis C-related complications. The figure shows the predicted number of patients with cirrhosis, decompensated cirrhosis
and hepatocellular carcinoma (panels a-c), and predicted cumulated number of deaths from liver disease (panel d) in the period 2013 to 2050
according to different treatment coverage. Numbers are given per 100,000 inhabitants
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from HCV [37]. Authors have shown that approxi-
mately half of those with indeterminate RIBA have a
resolved HCV infection [38, 39]. The proportion of
RIBA-indeterminate records in our HCV population
was low, making the contribution of these records less
significant.
Third, the future incidence may be underestimated.
Most likely, transmission of HCV will still be mainly
by drug abuse, which is an ongoing problem in our re-
gion as is the case in the rest of Europe [40]. On the
other hand, the introduction of highly effective, simple,
short-term and tolerable therapies has the potential to
increase treatment coverage among people who inject
drugs. Thus, scaling up treatment in people with a
transmission risk could reduce the future incidence
and have a major impact on the HCV prevalence [41].
Fourth, it is documented that both moderate and ex-
cessive alcohol intake increase fibrosis progression in
patients with HCV [42, 43]. Presence of concomitant
excessive alcohol use was in our study assessed by clin-
ical judgment, and not by a validated questionnaire of
drinking habits. We have therefore chosen to omit al-
cohol use from the model over concerns on the quality
of the data. Several other factors have been shown to
accelerate the fibrosis progression, like co-infection
with hepatitis B virus or HIV, diabetes and obesity [9].
The prevalence of HBV or HIV co-infections in our
HCV population were low, 2.3% and 1% respectively,
and therefore not included in the model. Data regard-
ing diabetes and obesity were incomplete and neither
included in the model.
Fifth, the exact time of infection is often not known.
In individuals with unknown time of infection, we have
used the first year of high-risk behavior as the presumed
year of transmission, as others have done [30, 44, 45].
However, it has been reported that the interval between
onset of drug injection and HCV infection has length-
ened in recent years [46], which may indicate that the
duration of infection could be shorter than estimated in
our model of fibrosis progression. If so, our fibrosis
model produces a spuriously slow rate of fibrosis pro-
gression, making the prognosis relatively conservative.
Sixth, the Markov model assumes that HCC only oc-
curs when liver cirrhosis is established (Ishak 6). How-
ever, HCC can develop in lower fibrosis stages in
chronic HCV infection [47, 48]. Finally, regression of
fibrosis, cirrhosis and cirrhosis complications is pos-
sible after achieving SVR [49–51]. We do not have data
to assess the effect of SVR on fibrosis regression, i.e.
available pretreatment and post-treatment liver
biopsies, and this is another limitation of the model.
However, removing subjects achieving SVR from the
model can mimic fibrosis regression in non-cirrhotic
cases. In patients with cirrhosis, about 60% can regress
after SVR [49, 50], and much less likely in decompen-
sated cirrhosis. In patients with HCV-induced cirrhosis
who attain SVR, the risk of HCC declines, but persists
[52, 53]. To reflect that model cases with cirrhosis and
SVR still are in risk of cirrhosis complications, we have
retained 50% of these in the model.
Implications
HCV is the leading cause of chronic liver disease and
cirrhosis and is the main cause of liver transplantation
in the Western world [10]. Although the total number of
HCV-infected individuals is estimated to be stable or de-
cline in the future, an increase in liver cirrhosis, liver
cancer, hepatic decompensation and liver-related deaths
is expected in the coming years.
This assessment is underlined by the World Health
Organization (WHO) statement that the burden of
HCV disease has been largely ignored as a health pri-
ority, and the organization has developed the first-ever
global health sector strategy for addressing the viral
hepatitis pandemic [54].
To reduce the future burden of hepatitis C it is ne-
cessary to meet the challenge at three levels. First,
prophylaxis measures must focus on reducing the
transmission rate among active injection drug users. In
addition, recent guidelines suggest that treatment
should be offered to this group of individuals at high
risk of transmitting HCV due to a potential prevention
benefit [55]. Second, HCV infection among apparently
healthy subjects must be diagnosed by screening of
high-risk groups. Strategies to expand screening be-
yond high-risk groups should be considered since a
substantial proportion of infected are unaware of their
status [56]. Third, antiviral treatment has been offered
only to a small percentage of patients, as treatment is
hampered by the high cost of the new direct-acting
antiviral drugs (DAAs). Based on the unpredictable
course of liver fibrosis at the individual level, delaying
treatment of patients with early fibrosis stages will in-
crease the risk of liver complications [11]. DAAs has
the potential to reduce the future burden of disease of
HCV, but this is restricted by the current treatment levels
[19]. In spite of the high costs of DAAs, several studies
show that interferon-free regimens are cost-effective
compared to interferon-based regimens [57–61].
Conclusion
Based on the registration of patients with HCV in a
low risk area, we estimate a relatively slow fibrosis pro-
gression within the first 20–25 years of infection,
followed by an accelerated fibrosis progression, espe-
cially in subjects with HCV genotype 3. This may have
important implications in the clinical management of
patients infected with genotype 3.
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Furthermore, we estimate a gradual increase in fu-
ture complications with an estimated peak around
2040. The projected scenario implies a substantial in-
crease in HCV-related morbidity and mortality in the
coming years. An increased number of patients need
to be treated to have an impact on the future burden
of HCV disease.
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ABSTRACT
Objectives: Resistance-associated substitutions (RASs) may impair treatment response to direct-acting
antivirals (DAA) in hepatitis C virus (HCV) treatment. We investigated the effects of baseline NS3-RASs
(Q80K and R155K) and clinically relevant NS5A-RASs in patients with HCV genotype (GT) 1a infection
on treatment outcome, with or without resistance-based DAA-treatment. This multi-center study was
carried out between 2014 and 2016.
Patients/methods: Treatment in the intervention group (n¼ 92) was tailored to baseline resistance.
Detection of NS3-RAS led to an NS5A-inhibitor-based regimen and detection of NS5A-RAS to a prote-
ase-inhibitor regimen. Patients without baseline RAS in the intervention group and all patients in the
control group (n¼ 101) received recommended standard DAA-treatment.
Results: The sustained virologic response rates (SVR) in the intervention and control groups were
97.8% (90/92) and 93.1% (94/101), respectively (p¼ .174). A trend toward higher SVR-rate in cirrhotic
patients (p¼ .058) was noticed in the intervention group compared to the control group with SVR-
rates 97.5% (39/40) and 83.3% (35/42), respectively. All patients with baseline NS3 (Q80K/R155K) or
NS5A-RASs in the intervention group achieved SVR with personalized resistance-based treatment. In
the control group, five patients with Q80K or R155K at baseline were treated with simepre-
virþ sofosbuvir and treatment failed in two of them. Furthermore, one of three patients who failed
ledipasvirþ sofosbuvir treatment had NS5A-RASs at baseline.
Conclusions: In line with the findings of the OPTIMIST-2 trial for Q80K and the EASL-guidelines 2016
for NS5A-RASs, baseline RASs appeared to have an impact on treatment outcome albeit a statistical
significance was not observed in this low-prevalence population.
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Hepatitis C virus (HCV) infection is a major cause of chronic
liver disease, liver cirrhosis, hepatocellular carcinoma (HCC)
and liver failure [1]. Globally, the prevalence of viremic HCV
infection is estimated to be around 1.1%, corresponding to
64–103 million actively infected individuals [2]. In Sweden and
Norway, about 0.4–0.5% of the population is infected with
HCV, i.e., approximately 45,000 and 20,000 individuals, respect-
ively [3–5]. HCV is classified into seven genotypes (GT) and
several subtypes [6]. In Sweden, the most common GT is 1a,
followed by 3a [7], while in Norway GT 3a is the most com-
mon, followed by 1a (personal communication Gutteberg T).
The development of direct-acting antiviral agents (DAAs) has
led to major advances in the treatment of HCV infection, with
substantially higher sustained virologic response (SVR) rates,
shorter treatment duration and fewer side effects than previous
interferon-based treatment. Currently, four classes of DAAs are
available targeting three nonstructural proteins in HCV; NS3/4A
protease inhibitors (PI), NS5A inhibitors and nucleoside and non-
nucleoside inhibitors of the NS5B RNA-dependent RNA
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polymerase (RdRP) [8]. Treatment with different combinations of
these potent DAAs with or without ribavirin has made it
possible to obtain SVR rates of above 95% in the majority of
patients with chronic hepatitis C (CHC).
HCV displays a pronounced genetic heterogeneity due to
the lack of proofreading activity of the RdRP and the rapid
turnover rate in HCV replication [9]. In the resulting HCV qua-
sispecies, resistance-associated substitutions (RASs) can
emerge under the selective pressure of treatment with DAAs
[10], but may also occur prior to treatment, i.e., baseline resist-
ance [9]. Depending on their frequency within the HCV qua-
sispecies and the level of resistance conferred, baseline RAS
can contribute to treatment failure in the presence of other
negative predictive factors such as advanced stages of liver
fibrosis, previous treatment and suboptimal treatment [8].
These methods available for detecting RASs are the
Sanger sequencing and the next-generation sequencing
(NGS) methods. The Sanger sequencing method carries a
20% cutoff level for detecting RASs in the viral population
compared to 1% with the NGS method. However, the gen-
eral consensus is to recommend a cutoff level of 10–20%, for
detecting RASs within the HCV quasispecies, in order to be
of clinical relevance in predicting treatment failures [11].
The polymorphism Q80K, a naturally occurring amino acid
substitution in the viral NS3 region, is mainly present in HCV
GT 1a and is associated with reduced susceptibility to the
NS3/4A protease inhibitor simeprevir, as indicated by the
COSMOS and the first OPTIMIST studies [12,13]. The preva-
lence of baseline Q80K varies geographically and is reported
to be 48% in the USA [14], compared to 5.7–15.2% in
Sweden [7,15], and 4.8% in Norway [15].
The NS3 amino acid substitution R155K confers resistance
to PI and is frequently observed in GT 1a-infected patients
who failed to achieve SVR after treatment with boceprevir,
telaprevir or simeprevir [10]. R155K can also be present in
<1% of GT 1a PI treatment-naïve patients [16].
In current clinical practice, it is more important to con-
sider baseline RASs in NS5A than NS3 for GT 1a. Many RASs
confer a very high fold resistance, e.g., Y93H/N (>1000 fold),
with GT 1a in in vitro replicon assays [8]. It should be noted
that NS5A RASs at positions 30 and 31 confer a medium to
high resistance, but these in vitro resistance profile might
not be high enough to be of clinical importance for current
approved NS5A inhibitors (with exception of elbasvir and
ledipasvir). Nevertheless, these NS5A RASs are rarely found
as baseline polymorphisms in GT 1a patients, i.e., in 2–5% of
DAA treatment-naïve patients when using the population-
sequencing method. However, EASL and AASLD guidelines
recently recommended NS5A baseline testing for GT 1a prior
to treatment with elbasvir and that testing should also be
considered in treatment-experienced patients before treat-
ment with ledipasvir regimens [17,18].
At the start of the study, there were no available guide-
lines regarding baseline resistance testing. The aim of this
real-life study was initially to investigate the impact of Q80K,
subsequently also including R155K and NS5A RASs, on treat-
ment outcome in GT 1a infected patients treated with DAAs,
and to evaluate the resultant economic consequences.
Known factors influencing treatment outcome were eval-
uated. The study was conducted during 2014–2016 when
simeprevir plus sofosbuvir combination was a recommended
alternative to NS5A inhibitor based regimes.
Patients and methods
Patients diagnosed with chronic HCV GT 1a infection from
Uppsala, G€avle and Tromsø received resistance-based treat-
ment (intervention group) and from €Orebro, Falun and Bod€o
received treatment according to the national guidelines
[19,20] without previous resistance testing (control group).
They were consecutively included in this real-life, open-label,
non-randomized Nordic multi-center study from 1 April 2014
to 30 June 2015 (Sweden) and 26 January 2016 (Norway).
During this period, baseline NS3 resistance testing (Q80K and
R155K) of HCV GT 1a was performed routinely for the inter-
vention group. In January 2015, when the fixed combination
ledipasvir plus sofosbuvir was approved in Sweden and
Norway, analysis of NS5A RAS was introduced and was per-
formed in the intervention group, approximately 40% of 92
patients in the intervention group. The NS5A RASs consid-
ered important by us at that time were Q30E/H/R, L31M and
Y93C/H/N. All these RASs were indicated by the HCV drug
development advisory group to be clinically relevant with
a> 100 fold increase in resistance toward ledipasvir [10].
Recommended treatment, according to the National
Boards [19,20], was, therefore, given to patients without
baseline RASs in the intervention group and to all patients in
the control group. For patients in the intervention group
with Q80K or R155K mutation, the treatment was amended
to a NS5A inhibitor-based regimen. In case of baseline NS5A
RAS, treatment with a protease inhibitor-based regimen i.e.,
simeprevir plus sofosbuvir was considered. Presence of base-
line NS3 RASs were analyzed for all patients in the control
group retrospectively, whereas baseline NS5A analysis in the
control group was only done (also retrospectively) for those
that had failed ledipasvir plus sofosbuvir treatment.
Resistance analyses for emerging RASs were performed in
all non-responders at the time of relapse; NS3A analysis in
simeprevir failures and NS5A analysis in patients with failure
after the treatment with NS5A inhibitor-based regimen.
Ribavirin was added at the responsible medical doctors
(MD) discretion, mainly due to the presence of cirrhosis.
The inclusion criteria were: infection with HCV GT 1a; 18
years of age; informed consent; and treatment according to
Swedish and Norwegian consensus recommendations as well as
completed treatment course (per-protocol). Patients included
were either treatment-naive or treatment-experienced to inter-
feron-based therapy, including triple therapy containing the first
generation NS3 protease-inhibitors boceprevir or telaprevir.
Patients previously treated with other DAAs were excluded.
Liver elasticity (kPa) was measured with FibroScanVR 502
(Echosens, Paris, France) (Swedish study sites) and
FibroScanVR 402 (Norwegian study sites) by experienced
nurses or doctors. For patients who had undergone a liver
biopsy, the Metavir score was recorded [21]. Presence of cir-
rhosis was determined by FibroScan >12.5 kPa or Metavir
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score 4 in liver biopsy. Child-Pugh score was estimated from
available information on the level of liver elasticity [22], bio-
chemical results and ultrasound. Patient data were extracted
from the medical records by the responsible MD at each
study site, anonymized and transferred to a joint database.
SVR was defined as undetectable HCV RNA 12 weeks after
the end of treatment. Non-SVR was regarded as a viral break-
through (a negative viral load nadir followed by a positive
HCV RNA level during therapy), or viral relapse (non-detect-
able viral load at the end of treatment followed by an
increase in HCV RNA level after therapy).
Laboratory methods
The Clinical Microbiology laboratory at the University
Hospital, Uppsala, performed the resistance analysis of RASs
(baseline and emerging). A nested PCR method, followed by
Sanger sequencing (population sequencing, cutoff 20%)
method was adopted for the NS3 resistance analysis. The
pan-genotypic NS3 resistance method has been described
elsewhere [7]. In brief, RNA extraction from the samples was
done using the BioMerieux NucliSENSVR easyMAGTM system
(bioMerieux, Marcy-l’Etoile, France). cDNA was synthesized
from RNA template with the SuperScriptTM III Reverse
Transcriptase (InvitrogenTM, Thermo Fisher, Waltham, MA,
USA) using random hexamers. First round PCR and nested
PCR were performed with in-house primers targeting parts of
the NS3 region using the Taq PCR Master Mix (Qiagen,
Hilden, Germany). The integrity of the nested PCR products
was verified by agarose-gel electrophoresis. PCR-positive
samples were purified using QIAquickVR PCR Purification Kit
(QIAgen, Hilden, Germany). All protocols used were per-
formed according to the manufacturer’s instructions. The
purified products were sequenced by the Sanger sequencing
method using the same primers used in the nested PCR. The
HCV NS3 sequences were analyzed using SeqScapeVR
Software version 2.6 (Applied Biosystems, Foster City, CA).
The NS3 sequence of GT 1a H77 strain was used as a refer-
ence template. The mutations were interpreted as relevant
NS3 RASs by comparing with RASs reported in the literature
[10,23]. The NS5A resistance analysis was performed with the
same method and is described elsewhere [24].
HCV RNA titer quantification was performed at the
Department of Clinical Microbiology, University Hospital,
Uppsala, Sweden and at the Department of Microbiology
and Infection Control, University Hospital of North Norway,
Tromsø, Norway using Roche COBASVR AmpliPrep/TaqManVR
HCV Quantitative Test version 2.0 with a LOQ of 15 IU/mL
(Roche Molecular Systems Inc., Branchburg, NJ).
Outcomes
The primary objective was to study the treatment efficacy in
the intervention group compared to the control group, with
respect to the proportion of patients achieving SVR.
Secondary objectives included to determine (1) the propor-
tion of patients with baseline NS3 (Q80K and R155K) RASs,
(2) the proportion of patients with baseline NS3 and NS5A
RASs experiencing viral breakthrough or relapse, (3) the pro-
portion of patients with baseline NS3 RASs not experiencing
viral breakthrough or relapse and (4) to compare total
expenditures (treatment and baseline analysis costs) per cap-
ita in the two study groups.
Statistics
The null hypothesis of this study was that the SVR rate is equal
in the intervention and control groups. The basic statistical
computing was done in MicrosoftVR ExcelVR 2013 (Microsoft
Office professional plus 2013, Microsoft Corporation) and in
Statistical Package for Societal Sciences (SPSS version 24, SPSS
Inc., Chicago, IL). The Fishers exact test was used to test the dif-
ferences between groups (small expected cell count). A two-
tailed p value <.05 was considered significant.
Ethics
The regional committee of medical research ethics
Committee in Uppsala (Dnr: 2013/185 and Dnr: 2013/185/1)
and the Data Protection Official at The University Hospital of
Northern Norway (Nr. 0574) approved the study. All partici-
pants received written information and the opportunity to
withdraw from the study.
Results
Patient baseline characteristics
In total, 200 patients were assessed to be eligible for the
study. Samples from 196 patients were available for baseline
resistance analyses (95 in the intervention group and 101
analyzed retrospectively in the control group). In the inter-
vention group, three patients were omitted from further
analyses; two of them died before the time of evaluation
for SVR and one patient started treatment before the result
of the baseline resistance analysis was available. Thus, week
12 follow-up data were obtained from 193 patients; 92 in
the intervention group and 101 in the control group
(Figure 1).
Demographic and baseline clinical characteristics are
provided in Table 1. The majority of patients were treat-
ment-naïve and male. The median age was 56 years. The
distribution of patients with cirrhosis and baseline NS3
RASs (Q80K and R155K) in the intervention and the control
groups were similar. The majority of cirrhotic patients were
Child-Pugh A.
Table 2 shows treatment characteristics. The proportion of
patients treated with simeprevir was higher in the interven-
tion group compared to the control group. Most of the
patients received treatment for 12 weeks and ribavirin was
added to a minority.
Efficacy and baseline RASs
The overall prevalence of baseline Q80K and R155K polymor-
phisms was 7.1% (14/196) and 5.2% (10/196), respectively.
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The prevalence of Q80K in Sweden and Norway was 7.0%
(11/158) and 10.5% (4/38), respectively. The prevalence of
R155K in Sweden and Norway was 4.4% (7/158) and 7.9% (3/
38), respectively. Prevalence data of NS5A RASs could not be
specified since the mandatory screening of baseline NS5A
RASs was not started until January 2015, and done only for a
part of the intervention group. However, three patients with
baseline NS5A RASs were found: two in the intervention
group (M28T and Y93H), and one in the control group that
harbored both M28A and Q30R.
The SVR rate in the intervention group and the control
group was 97.8% (90/92) and 93.1% (94/101), respectively
(p¼ .174). A trend toward higher SVR rates in cirrhotic
patients (p¼ .058) was noticed in the intervention group
compared to the control group, 97.5% (39/40) and 83.3%
(35/42), respectively (Figure 2). Overall, liver cirrhosis was
associated with a lower SVR12 rate compared to non-cirrho-
sis, 90 (74/82) and 99% (110/111), respectively (p¼ .005).
NS3 RASs
In the intervention group, all patients with baseline Q80K
(n¼ 5) and R155K (n¼ 6) were successfully treated with a
regimen containing a NS5A inhibitor. In the control group,
the SVR rates in patients with baseline Q80K and R155K were
89% (8/9) and 75% (3/4), respectively. Only five of 13
patients with such RASs at baseline were treated with sime-
previr plus sofosbuvir in the control group. Notable, of this
one in four (1/4) patients with Q80K RAS and one in one
(1/1) with R155K RAS failed treatment (Figure 2).
Table 1. Patient demographics and baseline characteristics.
Intervention group (N¼ 92 ) Control group (N¼ 101) p
Median age, year (range) 56 (27–74) 56 (28–74) .9
Sex, male, n (%) 61 (66) 70 (69) .8
Cirrhosis, n (%) 40 (43) 42 (42) .9
Child A, n (%) 35 (87.5) 40 (95.2) –
Child B, n (%) 5 (12.5) 2 (4.8) –
Child C, n (%) 0 0 –
Median HCV RNA, log10 IU/ml (range) 6.1 (3.3–7.5) 6.1 (4.4–7.2) .7
Baseline Q80K and R155K RAS, n (%) 11 (12.0%) 13 (12.9) .6
HCV antiviral treatment history, n (%) .07
Treatment-naïve 45 (48.9) 67 (66.3) –
Non-responder 21 (22.8) 14 (13.9) –
Relapse/ breakthrough 19 (20.7) 12 (11.9) –
Othera 7 (7.6) 8 (7.9) –
Previous therapy with PIb, n (%) 11 (12.0) 6 (5.9) .2
aReinfection, discontinuation.
bPI: protease inhibitor (boceprevir or telaprevir).
Figure 1. Flowchart of patients included in the study. Baseline resistance testing in the control group was performed retrospectively.
Table 2. Treatment characteristics.
Intervention
group (N¼ 92 )
Control
group (N¼ 101) p
Treatment regime, n (%) .023
Simeprevirþ Sofosbuvir 46 (50.0) 30 (29.7) –
Ledipasvirþ Sofosbuvir 34 (37.0) 58 (57.4) –
Daclatasvirþ Sofosbuvir 11 (12.0) 11 (10.9) –
OBV/PTV/rþDSVa 1 (1.0) 2 (2.0) –
Addition of ribavirin, n (%) 14 (15.0) 9 (8.9) .2
Treatment duration, week (%) .4
8 5 (5.4) 3 (3.0) –
12 73 (79.3)b 88 (87.1) –
16 3 (3.3) 1 (1.0) –
24 11 (12.0) 9 (8.9) –
aOmbitasvir/paritaprevir/ritonavirþ dasabuvir.
bOne patient scheduled for 12 weeks of treatment discontinued after 4 weeks
because of an accident, but achieved SVR.
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NS5A RASs
In the intervention group, all patients with baseline
NS5A RASs (n¼ 2) were successfully treated. The patient
with Y93H was treated with simeprevir plus sofosbuvir,
whereas the patient with M28T was treated with ledi-
pasvir plus sofosbuvir since the M28T was not consid-
ered a clinically relevant NS5A RAS. In the control
group, three patients failed ledipasvir plus sofosbuvir
treatment and one of these patients harbored a relevant
NS5A RAS at baseline Q30R (together with M28A)
(Supplementary Table S1).
In total, nine patients failed to achieve SVR, the reason for
non-SVR was a viral relapse. In three of these nine patients,
Q80K, R155K and Q30R one each, were detected at baseline
(all in control group). Majority of the 10 observed baseline
R155K was connected with prior boceprevir or telaprevir
treatment failure, but in one patient, it was found as a nat-
ural polymorphism. Overall, patients with treatment failure
were all male, had a median age of 56 years, 89% (8/9) of
them had liver cirrhosis and most were treatment naïve (6/9)
(Table 3).
Supplementary Table S1 gives an overview of the patients
with detected baseline NS3 RASs (Q80K and R155K) and
NS5A RASs.
Economic implications
In 2014/2015, the cost of simeprevir plus sofosbuvir treatment
for 12 weeks was 750,000 NOK/650,000 SEK. In 2015, the price
for 12 weeks of ledipasvir plus sofosbuvir treatment was
500,000 NOK/400,000 SEK. Baseline NS3 RAS was detected
retrospectively in two patients who experienced virological
relapse after treatment with simeprevir plus sofosbuvir.
Switching these two patients to a NS5A inhibitor-based regi-
men could possibly have reduced treatment costs and in add-
ition, contributed to a best practice approach. The same trend
occurred with the use of simeprevir plus sofosbuvir treatment
for the patient with NS5A Q30R RAS at baseline. Thus, in the
control group, there was an economic loss of 2.0 million NOK/
1.7 million SEK compared to the intervention group where no
patients with Q80K/R155K or clinically important NS5A RAS at
baseline experienced non-SVR. In comparison, the baseline
analysis costs (2000 NOK/SEK per analysis) for the 95 patients
in the intervention group were less than 0.2 million NOK/SEK.
Discussion
In this real-life study conducted in Q2 2014 to Q1 2016, we
found a low prevalence of baseline Q80K RAS in HCV GT 1a
Figure 2. Sustained virologic response rates (SVR) in the intervention and control groups. SVR rates in the intervention group (dark grey bars) and the control
group (light grey bars). The two bars to the right show SVR rates by simeprevir treatment in patients with baseline Q80K and R155K RAS in the control group.





















60 I 4 (B) 42.8 Sþ S N 5.2 0 R155K Yes 12
54 I 3 10.4 Sþ S NR 5.7 0 0 No 12
56 C 4 (A) – Sþ S N 6.1 0 0 Yes 12
46 C 4 (A) – Sþ S N 6.2 R155K R155K No 12
66 C 4 (A) – Lþ S N 6.9 0 Q30Rþ L31M No 12
59 C 4 (A) – Lþ S NR 6.0 0 L31I No 12
52 C 4 (A) 75 Sþ S NR 5.8 0 D168A No 12
52 C 4 (B) 75 Sþ S N 4.8 Q80K Q80K No 12
65 C 4 (A) 47.2 Lþ S N 6.4 M28A, Q30R M28A, Q30R Yes 12
I: intervention group; C: control group; Lþ S: ledipasvir plus sofosbuvir; N: naïve; NR: null responder to pegylated interferon plus ribavirin; Sþ S: simeprevir
plus sofosbuvir
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in Sweden and Norway (7.1%), which is in line with previous
studies [7,15]. Liver cirrhosis was significantly associated with
treatment failure. There were not enough GT 1a patients
with Q80K RAS to detect a significant effect of baseline
resistance-guided treatment on the SVR rate. However, our
findings appear to agree with earlier studies. The COSMOS
study in 2014 indicated lower SVR rates in GT 1a patients
with baseline Q80K RAS compared to patients without Q80K
at baseline [13]. The OPTIMIST-2 study revealed lower SVR
rates for GT 1a patients with cirrhosis and baseline Q80K
(SVR 74%) compared to those without Q80K (SVR 92%) [25].
In the control group, only 30% of the patients were
treated with simeprevirþ sofosbuvir combination compared
to 50% in the intervention group, possibly due to new treat-
ment guidelines introduced in February (Sweden) and March
(Norway) 2015, which recommended treatment with the
fixed combination of ledipasvir plus sofosbuvir. Thus, these
guidelines recommended NS5A inhibitor-based regimens for
previous treatment failures of boceprevir/telaprevir, without
regard to baseline resistance analysis. Of note, the only
patient in the control group with Q80K at baseline that failed
treatment was one out of four patients with such RAS that
were treated with simeprevir plus sofosbuvir (i.e., SVR 75%).
Furthermore, the single patient with baseline R155K that
underwent simeprevir plus sofosbuvir treatment in the con-
trol group also failed to attain SVR.
Our study also indicated that baseline resistance analysis
may have an impact on treatment outcome in patients with
liver cirrhosis, but the difference was not statistically signifi-
cant, possibly due to the low prevalence of baseline NS3 and
NS5A RASs.
Currently, the NS3 inhibitor simeprevir is no longer in use
due to the development of more effective DAA treatment
regimens. As a result, the focus has switched to study base-
line NS5A RASs in predicting the most effective DAA combin-
ation and treatment duration [11]. Since 2016, NS5A baseline
resistance analysis is mainly recommended before treatment
of GT 1a with the NS5A inhibitor elbasvir, co-formulated with
the NS3 inhibitor grazoprevir. However, it is also recom-
mended to consider baseline analysis of the NS5A RASs for
treatment-experienced GT 1a patients prior to treatment
with ledipasvir plus sofosbuvir [17,18]. Therefore, it was rele-
vant for this study, when conducted in 2015, to include also
baseline NS5A analysis.
Although we cannot report any significant effect on base-
line Q80K/R155K and NS5A resistance analyses on the treat-
ment outcome, baseline resistance testing could have
economic implications. However, today’s considerably lower
drug expenditures per patient combined with recommended
regimens that are less dependent on the preexisting RASs
addressed in this study, made our economic calculations
somewhat obsolete.
In clinical practice, the impact of HCV RASs will probably
become less important with the availability of new effective
DAAs. However, drug resistance can be a problem in the
context of other negative predictors for treatment response
like the presence of cirrhosis, suboptimal treatment duration
and prior treatment [8,11], and new emerging mutations in
the highly variable HCV genome may affect the current high
SVR rates. It could be noted that the Q80K RAS was the
most commonly observed baseline NS3 variant in the few
failures in the POLARIS-2 trial [26]. In patients with GT 1a
treated with the pan-genotypic NS3 protease inhibitor voxi-
laprevir combined with sofosbuvir plus velpatasvir for eight
weeks, the SVR rate was lower in patients with baseline
Q80K compared to patients without (88 and 94%, respect-
ively) [26].
Conclusion
We found a low prevalence of NS3 Q80K RAS in HCV GT 1a
in Norway and Sweden. In this real-life study, baseline resist-
ance analyses for NS3 RAS (Q80K and R155K) and clinically
relevant NS5A RASs could not statistically determine the
treatment outcome, probably due to small sample sizes.
Liver cirrhosis was the most important predictor of treatment
failure. However, the results indicate an adverse effect of RAS
Q80K preexistence on the treatment outcome with simepre-
vir plus sofosbuvir, findings that were published in the
OPTIMIST-2 trial in 2016. Furthermore, the results are in line
with the recommendations by EASL in 2016 that NS5A RASs
at baseline appeared to have an impact on ledipasvir plus
sofosbuvir treatment outcome. Personalized treatment with
regard to baseline resistance analyses could thereby be
important to find the most cost-effective treatment combina-
tions/duration, both in a perspective of evidence-based
healthcare delivery and in the case of the individual patient
to avoid relapse and reducing the retreatment options.
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Information brochure and questionnaires Tromsø 7 
Vil du være med i 
Tromsøundersøkelsen?
Hva er Tromsøundersøkelsen?
Tromsøundersøkelsen er en folkehelseundersøkelse. 
Formålet er å samle inn opplysninger til forskning som 
gir økt kunnskap om helse og sykdom, og hvordan folke-
helsen kan forbedres gjennom forebygging og behandling. 
Tromsøundersøkelsen startet i 1974 med bakgrunn i den 
høye forekomsten av hjerte -og karsykdom i Nord-Norge. 
Siden den gang er undersøkelsen gjennomført med  
6-7 års mellomrom og dette er den sjuende runden. 
Ved å delta bidrar du til viktig forskning om forekomst, 
forebygging og behandling av sykdom, hva som fremmer 
god helse, og hva som er årsak til helseproblemer.
Ditt bidrag teller!
Forespørsel  
om deltakelse i 
Tromsøundersøkelsen
Hvorfor spør vi deg? 
Alle innbyggere i Tromsø kommune fra 40 år og oppover 
spørres om å delta. I tillegg inviterer vi ca.1000 personer i 
alderen 21-25 år. Hver deltaker er like viktig, enten du er 
ung eller gammel, frisk eller syk. 
Sammen med denne informasjonsbrosjyren finner du en 
invitasjon med praktiske opplysninger om undersøkelsen.
 
Det er gratis å delta i Tromsøundersøkelsen. Trenger du 
videre undersøkelse eller oppfølging av fastlegen eller  
spesialisthelsetjenesten, betaler du vanlig egenandel.
 
Slik foregår undersøkelsen
Alle deltakere inviteres til en hovedundersøkelse som 
omfatter spørreskjema, intervju, blodprøver og under- 
søkelser. Et helt tilfeldig utvalg av deltakere inviteres  
tilbake til en spesialundersøkelse som omfatter flere  
prøver og mer omfattende undersøkelser. Alle under- 
søkelsene gjennomføres av helsepersonell.
Tilbakemelding
Noen uker etter undersøkelsen får du et brev med noen 
resultater, det vil si høyde, vekt, BMI, hemoglobin, blod-
trykk, kolesterolnivå og om du har diabetes. Det gis ikke 
rutinemessig tilbakemelding om resultater av andre blod-
prøver eller målinger. Dersom prøveresultatet viser at det 
er nødvendig med oppfølging av lege eller henvisning til 
spesialist, vil du få råd om det. Ved behov for henvisning 
til spesialist, sørger vi for å sende henvisning. 
 
Du kan reservere deg mot å få vite resultatene av prøvene 
dine. Men hvis et prøveresultat krever rask legebehandling, 
vil du likevel bli kontaktet.
Du vil også få informasjon om undersøkelsen underveis 
gjennom aviser, sosiale medier (Facebook, Twitter m.m) 
samt på arrangementer som “Lørdagsuniversitetet” og 
“Forskningsdagene”.
Frivillig deltakelse
Det er frivillig å delta i Tromsøundersøkelsen.  
Om du sier ja til å delta, kan du når som helst trekke 
tilbake samtykket.
Hva er Tromsøundersøkelsen?
Tromsøundersøkelsen er en folkehelseundersøkelse. 
Formålet er å samle inn opplysninger til forskning som 
gir økt kunnskap om helse og sykdom, og hvordan folke-
helsen kan forbedres gjennom forebygging og behandling. 
Tromsøundersøkelsen startet i 1974 med bakgrunn i den 
høye forekomsten av hjerte -og karsykdom i Nord-Norge. 
Siden den gang er undersøkelsen gjennomført med  
6-7 års mellomrom og dette er den sjuende runden. 
Ved å delta bidrar du til viktig forskning om forekomst, 
forebygging og behandling av sykdom, hva som fremmer 
god helse, og hva som er årsak til helseproblemer.
Ditt bidrag teller!
Forespørsel  
om deltakelse i 
Tromsøundersøkelsen
Hvorfor spør vi deg? 
Alle innbyggere i Tromsø kommune fra 40 år og oppover 
spørres om å delta. I tillegg inviterer vi ca.1000 personer i 
alderen 21-25 år. Hver deltaker er like viktig, enten du er 
ung eller gammel, frisk eller syk. 
Sammen med denne informasjonsbrosjyren finner du en 
invitasjon med praktiske opplysninger om undersøkelsen.
 
Det er gratis å delta i Tromsøundersøkelsen. Trenger du 
videre undersøkelse eller oppfølging av fastlegen eller  
spesialisthelsetjenesten, betaler du vanlig egenandel.
 
Slik foregår undersøkelsen
Alle deltakere inviteres til en hovedundersøkelse som 
omfatter spørreskjema, intervju, blodprøver og under- 
søkelser. Et helt tilfeldig utvalg av deltakere inviteres  
tilbake til en spesialundersøkelse som omfatter flere  
prøver og mer omfattende undersøkelser. Alle under- 
søkelsene gjennomføres av helsepersonell.
Tilbakemelding
Noen uker etter undersøkelsen får du et brev med noen 
resultater, det vil si høyde, vekt, BMI, hemoglobin, blod-
trykk, kolesterolnivå og om du har diabetes. Det gis ikke 
rutinemessig tilbakemelding om resultater av andre blod-
prøver eller målinger. Dersom prøveresultatet viser at det 
er nødvendig med oppfølging av lege eller henvisning til 
spesialist, vil du få råd om det. Ved behov for henvisning 
til spesialist, sørger vi for å sende henvisning. 
 
Du kan reservere deg mot å få vite resultatene av prøvene 
dine. Men hvis et prøveresultat krever rask legebehandling, 
vil du likevel bli kontaktet.
Du vil også få informasjon om undersøkelsen underveis 
gjennom aviser, sosiale medier (Facebook, Twitter m.m) 
samt på arrangementer som “Lørdagsuniversitetet” og 
“Forskningsdagene”.
Frivillig deltakelse
Det er frivillig å delta i Tromsøundersøkelsen.  
Om du sier ja til å delta, kan du når som helst trekke 
tilbake samtykket.
Hva omfatter den sjuende 
Tromsøundersøkelsen?
Spørreskjema 
Deltakernes informasjon om egen helse er en svært viktig del av Tromsø- 
undersøkelsen. Vi ber deg derfor fylle ut to spørreskjema. Alle spørsmål  
kan besvares på nett. Det ene skjemaet er vedlagt i papirform, hvis du  
foretrekker det. Fyll det gjerne ut før du møter opp så sparer du tid under 
undersøkelsen. Hvis du trenger assistanse vil personalet hjelpe deg på 
undersøkelsen hvor det også er satt opp egne datamaskiner til dette.
Utfylte svar i spørreskjema er like viktig for forskningen som resultater  
fra blodprøver og kliniske undersøkelser.
Du kan delta på Tromsøundersøkelsen selv om du ikke ønsker å være  
med på alle deler av undersøkelsen.
Hva skal vi forske på? 
I denne runden av Tromsøundersøkelsen er det mer enn 50 prosjekter  
som skal forske på forekomst, forebygging og behandling av  
folkehelseproblemer.
 
Det skal blant annet forskes på hjerte- og karsykdommer, kreft, lunge- 
sykdommer, aldring og demens, fedme, diabetes, legemiddelbruk, psykisk 
helse, kronisk smerte, tannhelse, muskel- og skjelettplager, risikofaktorer 
som alkohol, fysisk aktivitet og kosthold, nyrer og urinveier, hudproblemer, 
miljøgifter, infeksjoner og antibiotikaresistens, nervesystemet, sosial ulikhet, 
samspill mellom arv og miljø, søvn og bruk av helsetjenester. 
Du finner mer informasjon om forskningen på vår internettside,  
www.tromsoundersokelsen.no
Hovedundersøkelsen  
Helsepersonell veileder deg gjennom  
undersøkelsen som varer ca. en time hvis  
du har fylt ut spørreskjemaene på forhånd.  
Du får også time til spesialundersøkelsen  
hvis du er valgt ut til denne.
Vi starter med noen enkle spørsmål knyttet  
til undersøkelsene du skal gjennomføre.  
Videre måler vi høyde, vekt, hofte- og livvidde, 
blodtrykk og puls. 
Det tas deretter prøver og gjøres noen  
kliniske undersøkelser: 
Blodprøve. Det tas blodprøver til bruk for 
forskning som samlet er mye mindre enn det  
en blodgiver gir. Det fryses ned prøver til bruk  
for senere analyser og forskning. Arvestoff  
(DNA/RNA) vil bli lagret til bruk for forskning.
Bakterieprøve fra nese og hals for å se etter  
gule stafylokokker, en bakterie som normalt  
finnes på hud og slimhinner hos mennesker, 
men som i enkelte tilfeller kan forårsake alvorlige 
infeksjoner. Prøvene tas med en fuktet vattpensel.
Spyttprøver til bruk for forskning knyttet til  
tannhelse, virusinfeksjon og kreft. 
Smertefølsomhet måles med to metoder.  
Først holder du hånden i kaldt vann i opptil 90 
sekunder,deretter får du en blodtrykksmansjett 
plassert rundt leggen som blåses opp. Underveis 
angir du hvor mye smerte du opplever, og kan 
avbryte testene når som helst hvis det blir for 
ubehagelig. 
Tannsjekk som omfatter et røntgenbilde av 
kjeven, registrering av hull i tennene og 
betennelsessykdom i tannkjøttet.
Fysisk aktivitet og kosthold. Utvalgte deltakere  
blir bedt om å registrere fysisk aktivitet ved bruk  
av aktivitetsmåler og registrering av kosthold i  
en periode. 
 
Du får også utdelt utstyr for innlevering av  
urin- og avføringsprøve hvis du er valgt ut til 
spesialundersøkelsen.
Spesialundersøkelsen
Et tilfeldig utvalg av deltakere inviteres til  
spesialundersøkelsen som gjennomføres noen 
uker etter hovedundersøkelsen. Denne varer 
totalt ca. 2 timer, avhengig av hvor mange  
deler du blir spurt om å være med på.
 
Ved oppmøte vil urinprøvene samles inn, og det tas 
noen nye blodprøver. Deler av blodprøvene fryses 
ned for senere forskning beskrevet i denne brosjyren.
 
Videre inviteres du til én eller flere av disse 
undersøkelsene:
EKG er en registrering av hjerterytmen  
som også kan gi informasjon om hjertesykdom.  
Ved registrering festes ledninger til kroppen. 
 
Kognitiv funksjon testes ved hjelp av enkle  
spørsmål knyttet til gjenkjenning av ord, kopling  
av symboler og tall samt grad av fingerbevegelighet.
Fysisk funksjon undersøkes ved å teste balanse,  
gange og gripestyrke. 
Ultralyd av halspulsåre gjøres for å se etter  
forkalkninger og innsnevringer av årene. Under- 
søkelsen kartlegger også blodforsyningen til hjernen.
Fotografering av øyebunnen gir bilder som både  
sier noe om synet og om tilstanden til blodkarene i 
kroppen. Det gis en øyendråpe i hvert øye en tid før 
fotografering for at pupillene skal utvide seg. Dette 
kan svi noe og synet kan forbigående bli noe uklart. 
Effekten går gradvis over, og er borte etter en time. 
I tillegg gjøres det en enkel synstest som du får svar 
på umiddelbart. 
Lungefunksjonen testes ved at du puster så hardt 
du klarer gjennom et munnstykke. Hvor mye  
luft som blåses ut pr. sekund, er et mål på lunge- 
funksjonen din. I tillegg vil det gjøres lydopptak  
av lungelyder og hjertelyder. 
Måling av beintetthet. Ved hjelp av ultralyd foretas 
det beintetthetsmåling som brukes til å undersøke 
risiko for beinskjørhet og brudd. 
Ultralyd av hjertet gjøres for å undersøke hjertets  
form og funksjon.
Hva omfatter den sjuende 
Tromsøundersøkelsen?
Spørreskjema 
Deltakernes informasjon om egen helse er en svært viktig del av Tromsø- 
undersøkelsen. Vi ber deg derfor fylle ut to spørreskjema. Alle spørsmål  
kan besvares på nett. Det ene skjemaet er vedlagt i papirform, hvis du  
foretrekker det. Fyll det gjerne ut før du møter opp så sparer du tid under 
undersøkelsen. Hvis du trenger assistanse vil personalet hjelpe deg på 
undersøkelsen hvor det også er satt opp egne datamaskiner til dette.
Utfylte svar i spørreskjema er like viktig for forskningen som resultater  
fra blodprøver og kliniske undersøkelser.
Du kan delta på Tromsøundersøkelsen selv om du ikke ønsker å være  
med på alle deler av undersøkelsen.
Hva skal vi forske på? 
I denne runden av Tromsøundersøkelsen er det mer enn 50 prosjekter  
som skal forske på forekomst, forebygging og behandling av  
folkehelseproblemer.
 
Det skal blant annet forskes på hjerte- og karsykdommer, kreft, lunge- 
sykdommer, aldring og demens, fedme, diabetes, legemiddelbruk, psykisk 
helse, kronisk smerte, tannhelse, muskel- og skjelettplager, risikofaktorer 
som alkohol, fysisk aktivitet og kosthold, nyrer og urinveier, hudproblemer, 
miljøgifter, infeksjoner og antibiotikaresistens, nervesystemet, sosial ulikhet, 
samspill mellom arv og miljø, søvn og bruk av helsetjenester. 
Du finner mer informasjon om forskningen på vår internettside,  
www.tromsoundersokelsen.no
Hovedundersøkelsen  
Helsepersonell veileder deg gjennom  
undersøkelsen som varer ca. en time hvis  
du har fylt ut spørreskjemaene på forhånd.  
Du får også time til spesialundersøkelsen  
hvis du er valgt ut til denne.
Vi starter med noen enkle spørsmål knyttet  
til undersøkelsene du skal gjennomføre.  
Videre måler vi høyde, vekt, hofte- og livvidde, 
blodtrykk og puls. 
Det tas deretter prøver og gjøres noen  
kliniske undersøkelser: 
Blodprøve. Det tas blodprøver til bruk for 
forskning som samlet er mye mindre enn det  
en blodgiver gir. Det fryses ned prøver til bruk  
for senere analyser og forskning. Arvestoff  
(DNA/RNA) vil bli lagret til bruk for forskning.
Bakterieprøve fra nese og hals for å se etter  
gule stafylokokker, en bakterie som normalt  
finnes på hud og slimhinner hos mennesker, 
men som i enkelte tilfeller kan forårsake alvorlige 
infeksjoner. Prøvene tas med en fuktet vattpensel.
Spyttprøver til bruk for forskning knyttet til  
tannhelse, virusinfeksjon og kreft. 
Smertefølsomhet måles med to metoder.  
Først holder du hånden i kaldt vann i opptil 90 
sekunder,deretter får du en blodtrykksmansjett 
plassert rundt leggen som blåses opp. Underveis 
angir du hvor mye smerte du opplever, og kan 
avbryte testene når som helst hvis det blir for 
ubehagelig. 
Tannsjekk som omfatter et røntgenbilde av 
kjeven, registrering av hull i tennene og 
betennelsessykdom i tannkjøttet.
Fysisk aktivitet og kosthold. Utvalgte deltakere  
blir bedt om å registrere fysisk aktivitet ved bruk  
av aktivitetsmåler og registrering av kosthold i  
en periode. 
 
Du får også utdelt utstyr for innlevering av  
urin- og avføringsprøve hvis du er valgt ut til 
spesialundersøkelsen.
Spesialundersøkelsen
Et tilfeldig utvalg av deltakere inviteres til  
spesialundersøkelsen som gjennomføres noen 
uker etter hovedundersøkelsen. Denne varer 
totalt ca. 2 timer, avhengig av hvor mange  
deler du blir spurt om å være med på.
 
Ved oppmøte vil urinprøvene samles inn, og det tas 
noen nye blodprøver. Deler av blodprøvene fryses 
ned for senere forskning beskrevet i denne brosjyren.
 
Videre inviteres du til én eller flere av disse 
undersøkelsene:
EKG er en registrering av hjerterytmen  
som også kan gi informasjon om hjertesykdom.  
Ved registrering festes ledninger til kroppen. 
 
Kognitiv funksjon testes ved hjelp av enkle  
spørsmål knyttet til gjenkjenning av ord, kopling  
av symboler og tall samt grad av fingerbevegelighet.
Fysisk funksjon undersøkes ved å teste balanse,  
gange og gripestyrke. 
Ultralyd av halspulsåre gjøres for å se etter  
forkalkninger og innsnevringer av årene. Under- 
søkelsen kartlegger også blodforsyningen til hjernen.
Fotografering av øyebunnen gir bilder som både  
sier noe om synet og om tilstanden til blodkarene i 
kroppen. Det gis en øyendråpe i hvert øye en tid før 
fotografering for at pupillene skal utvide seg. Dette 
kan svi noe og synet kan forbigående bli noe uklart. 
Effekten går gradvis over, og er borte etter en time. 
I tillegg gjøres det en enkel synstest som du får svar 
på umiddelbart. 
Lungefunksjonen testes ved at du puster så hardt 
du klarer gjennom et munnstykke. Hvor mye  
luft som blåses ut pr. sekund, er et mål på lunge- 
funksjonen din. I tillegg vil det gjøres lydopptak  
av lungelyder og hjertelyder. 
Måling av beintetthet. Ved hjelp av ultralyd foretas 
det beintetthetsmåling som brukes til å undersøke 
risiko for beinskjørhet og brudd. 
Ultralyd av hjertet gjøres for å undersøke hjertets  
form og funksjon.
Personvern 
All informasjon du gir til Tromsøundersøkelsen 
behandles med respekt for personvern og privat-
liv, og i samsvar med lover og forskrifter.  
Alle medarbeidere som jobber med undersøkel-
sen har taushetsplikt. Opplysningene som samles 
inn skal bare brukes til godkjente forsknings- 
formål. Det vil ikke være mulig å identifisere  
deg når resultatene av forskningen publiseres.
 
UiT Norges arktiske universitet ved universitets-
direktøren er ansvarlig for behandlingen av  
personopplysninger. Tromsøundersøkelsen har 
konsesjon fra Datatilsynet. Regional komité for 
medisinsk og helsefaglig forskningsetikk i Nord-
Norge (REK nord) har gjort en etisk og helsefag-
lig vurdering av undersøkelsene som gjennom- 
føres, samt godkjent innsamlingen av prøver.
Hvilke data lagres i 
Tromsøundersøkelsen?
I Tromsøundersøkelsen lagres opplysninger 
gitt av deltakere i de forskjellige rundene av 
Tromsøundersøkelsen. Det lagres også opplys-
ninger om kreftdiagnoser og dødsårsaker fra 
Kreftregisteret og Dødsårsaksregisteret.  
For deltakere som har eller får diagnoser innen 
hjerte- og karsykdom, diabetes og beinbrudd, 
innhentes opplysninger fra sykejournalen i spesi-
alist- og primærhelsetjenesten som er nødvendig 
for å kvalitetssikre aktuelle diagnoser. Dette for 
å sikre forskning av høy kvalitet. Tilsvarende vil 
også kunne bli aktuelt for andre sykdommer det 
forskes på i Tromsøundersøkelsen. 
Hvordan lagres dine  
opplysninger og prøver?
Alle opplysningene og prøvene lagres uten navn 
og fødselsnummer. 
En kode knytter deg til dine opplysninger og 
prøver. Det er kun noen få autoriserte personer 
som kan finne tilbake til deg gjennom en egen 
kodenøkkel. 
 
De biologiske prøvene lagres i godkjent 
forskningsbiobank ved Institutt for samfunns-
medisin, UiT. Leder av Tromsøundersøkelsen 
er ansvarlig for biobanken. Den er registrert i 
Folkehelseinstituttets Biobankregister (nr 2397). 
Det biologiske materialet kan bare brukes etter 
godkjenning fra REK. 
Utlevering av opplysninger  
og prøver til forskere
Hvis du sier ja til å delta i studien, samtykker  
du til at dine opplysninger og prøver kan  
brukes videre i forskning på ubestemt tid.  
Medisinsk forskning forandrer seg hele tiden,  
og i fremtiden kan data bli brukt i forsknings-
prosjekter forutsatt at det er i samsvar med 
gjeldende lover og forskrifter.
Alle forskningsprosjekter som får data fra  
Tromsøundersøkelsen må være i samsvar med 
lover og forskrifter. Prosjektleder må tilhøre en 
kompetent forskningsinstitusjon. Den enkelte 
forsker vil kun få tilgang til personidentifiserende 
opplysninger etter å ha innhentet nødvendige 
godkjenninger fra REK, og/eller Datatilsynet. 
I noen forskningsprosjekter kan prøver og  
avidentifiserte opplysninger bli utlevert til andre 
land. Det vil skje i en slik form at våre utenlandske 
samarbeidspartnere ikke kan knytte prøvene opp 
mot deg som person.
 
I noen prosjekter kan det bli aktuelt å kontakte  
deg igjen for å samle inn flere data, f.eks. ved  
spørreskjema, intervju eller kliniske undersøkelser. 
Du vil da få ny informasjon og bes om nytt  
samtykke til det konkrete prosjektet. 
Videre bruk av opplysninger  
og prøver i forskning
Sammenstilling med  
andre registre 
I noen forskningsprosjekter vil opplysninger  
om deg kunne bli sammenstilt med: 
 
Opplysninger du har gitt i tidligere runder  
av Tromsøundersøkelsen hvis du har deltatt  
i Tromsøundersøkelsen før.  
 
Opplysninger fra barn, søsken, foreldre og beste-
foreldre som har deltatt i Tromsøundersøkelsen. 
Opplysninger om deg i nasjonale helseregistre 
som Reseptregisteret, Medisinsk fødselsregister, 
Kreftregisteret, Norsk pasientregister, Hjerte-  
og karregisteret, Dødsårsaksregisteret,  
infeksjonsregistre og andre nasjonale  
sykdoms- og kvalitetsregistre. 
Helseopplysninger om deg fra primær- og  
spesialisthelsetjenesten.  
Opplysninger om sosiale forhold som arbeid, 
utdanning, inntekt, boforhold osv. fra registre 
hos bl.a. Statistisk sentralbyrå og NAV. 
Slike sammenstillinger krever som regel  
forhåndsgodkjenning av offentlige instanser,  
som REK og/eller Datatilsynet. 
Rett til innsyn og sletting av dine 
opplysninger og prøver 
Hvis du sier ja til å delta i studien, har du rett  
til å få innsyn i hvilke opplysninger som er  
registrert om deg. Du har også rett til å få  
korrigert eventuelle feil i opplysningene vi har 
registrert. Dersom du trekker deg fra studien, 
kan du kreve å få slettet innsamlede prøver  
og opplysninger, med mindre opplysningene 
allerede er inngått i analyser eller er brukt i  
vitenskapelige artikler.
Finansiering
Tromsøundersøkelsen er finansiert av  
UiT Norges arktiske universitet, Helse Nord 
RHF, Universitetssykehuset Nord-Norge (UNN)  
samt ulike forskningsfond.
Forsikring
Deltakere i Tromsøundersøkelsen er forsikret 
gjennom Norsk Pasientskadeerstatning.
Samtykke til deltakelse i studien
Hvis du vil delta i den sjuende Tromsø-
undersøkelsen, må du gi skriftlig samtykke  
ved oppmøte. Personalet vil gi mer informasjon 
og svare deg dersom du har spørsmål i forbindelse 
med samtykket. 
Du kan når som helst trekke tilbake  
samtykket ditt.
Ved å delta i Tromsøundersøkelsen bidrar du til viktig forskning på sykdom 
og helse, oppbygging av fagmiljøer og bedre pasientbehandling.
Personvern 
All informasjon du gir til Tromsøundersøkelsen 
behandles med respekt for personvern og privat-
liv, og i samsvar med lover og forskrifter.  
Alle medarbeidere som jobber med undersøkel-
sen har taushetsplikt. Opplysningene som samles 
inn skal bare brukes til godkjente forsknings- 
formål. Det vil ikke være mulig å identifisere  
deg når resultatene av forskningen publiseres.
 
UiT Norges arktiske universitet ved universitets-
direktøren er ansvarlig for behandlingen av  
personopplysninger. Tromsøundersøkelsen har 
konsesjon fra Datatilsynet. Regional komité for 
medisinsk og helsefaglig forskningsetikk i Nord-
Norge (REK nord) har gjort en etisk og helsefag-
lig vurdering av undersøkelsene som gjennom- 
føres, samt godkjent innsamlingen av prøver.
Hvilke data lagres i 
Tromsøundersøkelsen?
I Tromsøundersøkelsen lagres opplysninger 
gitt av deltakere i de forskjellige rundene av 
Tromsøundersøkelsen. Det lagres også opplys-
ninger om kreftdiagnoser og dødsårsaker fra 
Kreftregisteret og Dødsårsaksregisteret.  
For deltakere som har eller får diagnoser innen 
hjerte- og karsykdom, diabetes og beinbrudd, 
innhentes opplysninger fra sykejournalen i spesi-
alist- og primærhelsetjenesten som er nødvendig 
for å kvalitetssikre aktuelle diagnoser. Dette for 
å sikre forskning av høy kvalitet. Tilsvarende vil 
også kunne bli aktuelt for andre sykdommer det 
forskes på i Tromsøundersøkelsen. 
Hvordan lagres dine  
opplysninger og prøver?
Alle opplysningene og prøvene lagres uten navn 
og fødselsnummer. 
En kode knytter deg til dine opplysninger og 
prøver. Det er kun noen få autoriserte personer 
som kan finne tilbake til deg gjennom en egen 
kodenøkkel. 
 
De biologiske prøvene lagres i godkjent 
forskningsbiobank ved Institutt for samfunns-
medisin, UiT. Leder av Tromsøundersøkelsen 
er ansvarlig for biobanken. Den er registrert i 
Folkehelseinstituttets Biobankregister (nr 2397). 
Det biologiske materialet kan bare brukes etter 
godkjenning fra REK. 
Utlevering av opplysninger  
og prøver til forskere
Hvis du sier ja til å delta i studien, samtykker  
du til at dine opplysninger og prøver kan  
brukes videre i forskning på ubestemt tid.  
Medisinsk forskning forandrer seg hele tiden,  
og i fremtiden kan data bli brukt i forsknings-
prosjekter forutsatt at det er i samsvar med 
gjeldende lover og forskrifter.
Alle forskningsprosjekter som får data fra  
Tromsøundersøkelsen må være i samsvar med 
lover og forskrifter. Prosjektleder må tilhøre en 
kompetent forskningsinstitusjon. Den enkelte 
forsker vil kun få tilgang til personidentifiserende 
opplysninger etter å ha innhentet nødvendige 
godkjenninger fra REK, og/eller Datatilsynet. 
I noen forskningsprosjekter kan prøver og  
avidentifiserte opplysninger bli utlevert til andre 
land. Det vil skje i en slik form at våre utenlandske 
samarbeidspartnere ikke kan knytte prøvene opp 
mot deg som person.
 
I noen prosjekter kan det bli aktuelt å kontakte  
deg igjen for å samle inn flere data, f.eks. ved  
spørreskjema, intervju eller kliniske undersøkelser. 
Du vil da få ny informasjon og bes om nytt  
samtykke til det konkrete prosjektet. 
Videre bruk av opplysninger  
og prøver i forskning
Sammenstilling med  
andre registre 
I noen forskningsprosjekter vil opplysninger  
om deg kunne bli sammenstilt med: 
 
Opplysninger du har gitt i tidligere runder  
av Tromsøundersøkelsen hvis du har deltatt  
i Tromsøundersøkelsen før.  
 
Opplysninger fra barn, søsken, foreldre og beste-
foreldre som har deltatt i Tromsøundersøkelsen. 
Opplysninger om deg i nasjonale helseregistre 
som Reseptregisteret, Medisinsk fødselsregister, 
Kreftregisteret, Norsk pasientregister, Hjerte-  
og karregisteret, Dødsårsaksregisteret,  
infeksjonsregistre og andre nasjonale  
sykdoms- og kvalitetsregistre. 
Helseopplysninger om deg fra primær- og  
spesialisthelsetjenesten.  
Opplysninger om sosiale forhold som arbeid, 
utdanning, inntekt, boforhold osv. fra registre 
hos bl.a. Statistisk sentralbyrå og NAV. 
Slike sammenstillinger krever som regel  
forhåndsgodkjenning av offentlige instanser,  
som REK og/eller Datatilsynet. 
Rett til innsyn og sletting av dine 
opplysninger og prøver 
Hvis du sier ja til å delta i studien, har du rett  
til å få innsyn i hvilke opplysninger som er  
registrert om deg. Du har også rett til å få  
korrigert eventuelle feil i opplysningene vi har 
registrert. Dersom du trekker deg fra studien, 
kan du kreve å få slettet innsamlede prøver  
og opplysninger, med mindre opplysningene 
allerede er inngått i analyser eller er brukt i  
vitenskapelige artikler.
Finansiering
Tromsøundersøkelsen er finansiert av  
UiT Norges arktiske universitet, Helse Nord 
RHF, Universitetssykehuset Nord-Norge (UNN)  
samt ulike forskningsfond.
Forsikring
Deltakere i Tromsøundersøkelsen er forsikret 
gjennom Norsk Pasientskadeerstatning.
Samtykke til deltakelse i studien
Hvis du vil delta i den sjuende Tromsø-
undersøkelsen, må du gi skriftlig samtykke  
ved oppmøte. Personalet vil gi mer informasjon 
og svare deg dersom du har spørsmål i forbindelse 
med samtykket. 
Du kan når som helst trekke tilbake  
samtykket ditt.
Ved å delta i Tromsøundersøkelsen bidrar du til viktig forskning på sykdom 
og helse, oppbygging av fagmiljøer og bedre pasientbehandling.
Her finner du oss:
Heiloveien 6 (tidligere Langnes legesenter)
9015 Tromsø




esign Ferniss.no  Foto Lars Å
ke A
ndersen
Dine svar bidrar til  
bedre folkehelse for  
våre kommende  
generasjoner
Skjemaet skal leses optisk. Vennligst bruk blå eller sort 
penn. Bruk blokkbokstaver. Du kan ikke bruke komma.
Dato for utfylling:
1. HELSE OG SYKDOMMER








c c c c c
1.2  Hvordan synes du at helsen din er sammenlignet med 











c c c c c
1.3  Har du eller har du hatt?  









Høyt blodtrykk  .......................................................... c c c
Hjerteinfarkt  .................................................................. c c
Hjertesvikt ......................................................................... c c c
Atrieflimmer (hjerteflimmer)  ................ c c c
Angina pectoris (hjertekrampe)  ...... c c c
Hjerneslag/hjerneblødning  .................. c c
Diabetes  ............................................................................... c c c
Nyresykdom  
(unntatt urinveis infeksjon)  ........................ c c c
Kronisk bronkitt/emfysem/KOLS  .. c c c
Astma  ....................................................................................... c c c
Kreft ............................................................................................. c c c
Revmatoid artritt (leddgikt)  ................... c c c
Artrose (slitasjegikt)  ............................................ c c c
Migrene  ................................................................................. c c c
Psykiske plager  
(som du har søkt  hjelp for)  ......................... c c c
1.4  Har du langvarige eller stadig tilbakevendende smerter 
som har vart i 3 måneder eller mer?
c Nei c Ja
2. TANNHELSE
2.1  Hvordan vurderer du din egen tannhelse? 
1 2 3 4 5
Svært dårlig c c c c c Svært god
2.2  Hvor fornøyd eller misfornøyd er du med  tennene eller 
 protesene dine? 
Svært  
misfornøyd
1 2 3 4 5 Svært 
fornøydc c c c c
3. BRUK AV HELSETJENESTER
3.1  Har du, grunnet egen helse, i løpet av de siste 12  




Fastlege/allmennlege  .............................................................................. c c
Legevakt  ........................................................................................................................ c c
Psykiater/psykolog  ....................................................................................... c c
Legespesialist utenfor sykehus  
(utenom  fastlege/allmennlege/ psykiater)  .................... c c
Tannlege/tannpleier  ................................................................................... c c
Apotek (for kjøp/råd om medisiner/behandling) .... c c
Fysioterapeut  ......................................................................................................... c c
Kiropraktor  ................................................................................................................. c c
Akupunktør  ............................................................................................................... c c
Alternativ behandler  
(homøopat, sone terapeut, healer etc)  ............................... c c
Tradisjonell helbreder (hjelper, «læser» etc)  ............ c c
Har du kommunisert via internett med noen 
av tjenestene over?  ...................................................................................... c c




Innlagt på sykehus  .......................................................................................... c c
Konsultasjon ved sykehus uten innleggelse:
Ved psykiatrisk poliklinikk   .................................................................. c c
Ved annen sykehuspoliklinikk  ..................................................... c c
2015 – 2016
KONFIDENSIELT
4. BRUK AV MEDISINER
4.1  Bruker du, eller har du brukt, noen av følgende 








Medisin mot høyt blodtrykk  ............................ c c c
Kolesterolsenkende medisin  ........................... c c c
Vanndrivende medisin  .............................................. c c c
Annen medisin mot hjertesykdom 
 (f.eks. blodfortynnende, rytmestabili­
serende, nitroglycerin)  ................................................... c c c
Insulin  ................................................................................................... c c c
Tabletter mot diabetes .............................................. c c c
Stoffskiftemedisin (Levaxin/thyroxin) ... c c c
4.2  Hvor ofte har du i løpet av de siste 4 ukene brukt 











på resept  ....................................... c c c c
Smertestillende  
uten resept  ................................. c c c c
Magesyrehemmende 
medisiner  ..................................... c c c c
Sovemidler  ................................. c c c c
Beroligende  
medisiner  ..................................... c c c c
Medisin  
mot depresjon  ..................... c c c c
4.3  Skriv alle medisiner (reseptfrie og resept belagte) du har 
brukt regelmessig siste 4 uker. Ikke regn med reseptfrie  
vitamin­, mineral­ og kosttilskudd, urter, natur medisin etc.
Får du ikke plass til alle medisinene, bruk eget ark.
5. KOSTHOLD
5.1  Spiser du vanligvis frokost hver dag? 
c Nei c Ja
5.2  Hvor mange porsjoner frukt og grønnsaker  spiser du  
i  gjennomsnitt per dag? Med porsjon menes f.eks. et eple,  
en  salatbolle.
Antall porsjoner   
5.3  Hvor ofte spiser du vanligvis disse matvarene? 
















Rødt kjøtt (alle produkter 
av storfe, får, svin) .............................. c c c c c
Grønnsaker, frukt, bær  ............. c c c c c
Mager fisk (torsk, sei)  ................... c c c c c
Feit fisk (laks, ørret, uer  
makrell, sild, kveite)  ......................... c c c c c
5.4  Hvor mange glass/beger drikker/spiser du vanligvis av 















Actimel, BioQ)  ......................... c c c c c
Fruktjuice  ...................................... c c c c c
Brus/leskedrikker: 
med sukker  ................................. c c c c c
med kunstig søtning .... c c c c c
5.5  Hvor mange kopper kaffe og te drikker du  daglig?  
Sett 0 for de typene du ikke drikker daglig.
Antall kopper
Filterkaffe (trakterkaffe)  ........................................................................................................




Espressobasert kaffe (fra kaffemaskin, kapsler etc)  ...................
 
Sort te (f.eks. Earl Grey)  ...........................................................................................................
 
Grønn/hvit/oolong te  ..............................................................................................................
 
Urtete (f.eks. nype, kamille, Rooibos)  .................................................................
6. HELSEBEKYMRING
Ikke i det 
hele tatt Litt Noe En hel del Svært mye
6.1  Tror du at det er noe alvorlig galt med kroppen din? c c c c c
6.2  Er du svært bekymret over helsen din? c c c c c
6.3  Er det vanskelig for deg å tro på legen din dersom  
hun/han forteller deg at det ikke er noe å bekymre seg for?
c c c c c
6.4  Er du ofte bekymret for muligheten for at du har en  
alvorlig sykdom?
c c c c c
6.5  Hvis du blir gjort oppmerksom på en sykdom (f.eks. via TV, 
radio, internett, avis eller noen du kjenner), bekymrer du deg 
da for selv å få syk dommen?
c c c c c
6.6  Opplever du at du plages av mange ulike symp tomer? c c c c c
6.7  Har du tilbakevendende tanker (som er  vanskelig å bli 
kvitt) om at du har en sykdom?
c c c c c
7. FYSISK AKTIVITET
7.1  Hvis du er i lønnet eller ulønnet arbeid, hvordan vil du 
beskrive arbeidet ditt?  Sett kryss i den ruta som passer best.
c For det meste stillesittende arbeid  
(f.eks. skrivebords arbeid, montering)
c Arbeid som krever at du går mye  
(f.eks. ekspeditør arbeid, lett industriarbeid, undervisning)
c Arbeid der du går og løfter mye  
(f.eks. pleier, bygnings arbeider)
c Tungt kroppsarbeid
7.2  Angi bevegelse og kroppslig anstrengelse i din  fritid det 
siste året. Hvis aktiviteten varierer gjennom året, ta et gjennom­
snitt. Sett kryss i den ruta som passer best.
c Leser, ser på TV / skjerm eller annen stillesittende aktivitet 
c
Spaserer, sykler eller beveger deg på annen måte minst  
4 timer i uka (inkludert gang eller sykling til arbeidsstedet, 
søndagsturer etc)
c Driver mosjonsidrett, tyngre hagearbeid, snø måking etc 
minst 4 timer i uka
c Trener hardt eller driver konkurranseidrett regelmessig 
flere ganger i uka
7.3  Siste uka, omtrent hvor lang tid tilbrakte du sittende på 
en typisk hverdag og  fridag? F.eks. ved arbeidsbord, hos ven­
ner, mens du så på TV / skjerm.
 
timer sittende på en hverdag (både jobb og fritid)
 
timer sittende på en fridag 
8. ALKOHOL
8.1  Hvor ofte drikker du alkohol? 
c Aldri
c Månedlig eller sjeldnere
c 2–4 ganger hver måned
c 2–3 ganger per uke 
c 4 eller flere ganger per uke
8.2  Hvor mange enheter alkohol (flaske øl, glass vin eller 
drink) tar du vanligvis når du drikker?
1–2 3–4 5–6 7–9 10 eller flere
c c c c c
8.3  Hvor ofte drikker du 6 eller flere enheter  alkohol ved en 
anledning?
c Aldri
c Sjeldnere enn månedlig
c Månedlig
c Ukentlig
c Daglig eller nesten daglig
9. RØYK OG SNUS
9.1  Har du røykt/røyker du daglig?
c Aldri c Ja, nå c Ja, tidligere
9.2  Har du brukt/bruker du snus eller skrå daglig?
c Aldri c Ja, nå c Ja, tidligere
11. UTDANNING OG INNTEKT
11.1  Hva er din høyeste fullførte utdanning? Sett ett kryss.
c Grunnskole/framhaldsskole/folkehøyskole inntil 10 år
c Fagutdanning/realskole/videregående/gymnas  
minimum 3 år
c Høyskole/universitet mindre enn 4 år
c Høyskole/universitet 4 år eller mer
11.2  Hva var din husstands samlede bruttoinntekt siste år?  
Ta med alle inntekter fra arbeid, trygder,  sosialhjelp og  lignende.
c Under 150 000 kr c 451 000–550 000 kr
c 150 000–250 000 kr c 551 000–750 000 kr
c 251 000–350 000 kr c 751 000 –1 000 000 kr
c 351 000–450 000 kr c Over 1 000 000 kr
12. FAMILIE OG VENNER
12.1  Hvem bor du sammen med? 
Nei Ja Antall
Ektefelle/samboer  ............................................................................... c c
Andre personer over 18 år  .................................................... c c
Personer under 18 år  ...................................................................... c c
12.2  Har du nok venner som kan gi deg hjelp når du  trenger det?
c Ja c Nei
12.3  Har du nok venner som du kan snakke fortrolig med?
c Ja c Nei
12.4  Hvor ofte deltar du vanligvis i forenings virksomhet som 
syklubb, idrettslag,  politiske, religiøse eller andre foreninger?
Aldri, eller noen 




1 gang i uka
Mer enn 
1 gang i uka
c c c c
13. SPØRSMÅL TIL KVINNER
13.1  Hvor gammel var du da du fikk menstruasjon første gang? 
Alder    
13.2  Er du gravid nå?
c Nei c Ja c Usikker
13.3  Hvor mange barn har du født? 
Antall barn   
13.4  Hvis du har født, fyll ut for hvert barn: fødselsår og vekt 
samt hvor mange måneder du ammet. Angi så godt du kan.  
Hvis flere barn, bruk ekstra ark.









14. SPØRSMÅL TIL MENN
14.1  Har du fått behandling for betennelse i prostata eller 
urinblæra?
c Nei c Ja
14.2  Har du fått utført steriliseringsoperasjon?
c Nei c Ja Hvis ja:  hvilket år    
10. SPØRSMÅL OM KREFT
10.1  Har du noen gang fått
Nei Ja Hvis ja: alder første gang Hvis ja: alder siste gang
Utført mammografi  ................................................................................................................................................... c c
Målt PSA (prostataspesifikt antigen)  ............................................................................................ c c
Utført tykktarmsundersøkelse (koloskopi, avføringsprøve)  ................... c c
10.2  Har noen i din nære biologiske familie hatt
Egne barn Mor Far Mormor Morfar Farmor Farfar Tante Onkel Søsken
Brystkreft  ................................................ c c c c c c c c c c
Prostatakreft  ..................................... c c c c c c
Tykktarmskreft  .............................. c c c c c c c c c c
Tusen takk for ditt bidrag.






1 DIN HELSETILSTAND 
Under hver overskrift ber vi deg krysse av den ENE boksen som best beskriver helsen din I DAG.  
1.1 Gange  
Jeg har ingen problemer med å gå omkring 
Jeg har litt problemer med å gå omkring 
Jeg har middels store problemer med å gå omkring 
Jeg har store problemer med å gå omkring 
Jeg er ute av stand til å gå omkring 
1.2 Personlig stell 
Jeg har ingen problemer med å vaske meg eller kle meg 
Jeg har litt problemer med å vaske meg eller kle meg 
Jeg har middels store problemer med å vaske meg eller kle meg 
Jeg har store problemer med å vaske meg eller kle meg 
Jeg er ute av stand til å vaske meg eller kle meg 
1.3 Vanlige gjøremål 
(f.eks. arbeid, studier, husarbeid, familie- eller fritidsaktiviteter)  
Jeg har ingen problemer med å utføre mine vanlige gjøremål 
Jeg har litt problemer med å utføre mine vanlige gjøremål 
Jeg har middels store problemer med å utføre mine vanlige gjøremål 
Jeg har store problemer med å utføre mine vanlige gjøremål 
Jeg er ute av stand til å utføre mine vanlige gjøremål 
1.4 Smerter/ubehag  
Jeg har verken smerter eller ubehag 
Jeg har litt smerter eller ubehag 
Jeg har middels sterke smerter eller ubehag 
Jeg har sterke smerter eller ubehag 
Jeg har svært sterke smerter eller ubehag 
1.5 Angst/depresjon 
Jeg er verken engstelig eller deprimert 
Jeg er litt engstelig eller deprimert 
Jeg er middels engstelig eller deprimert 
Jeg er svært engstelig eller deprimert 
Jeg er ekstremt engstelig eller deprimert 
 
For å kunne vise hvor god eller dårlig din helsetilstand er, har vi laget en skala hvor den beste helsen 
du kan tenke deg er markert med 100 og den dårligste med 0. Hvor på denne skalaen vil du plassere 
din nåværende helse? 
 
















2 OPPVEKST OG TILHØRIGHET  
 
2.1 Hvor bodde du størstedelen av din oppvekst?  
(Sett ett kryss) 
 Tromsø  
 Troms, andre kommuner enn Tromsø  
 Finnmark  
 Nordland  
 Resten av Norge 
Utlandet  
  
2.2 Hvor lenge har du bodd i din nåværende bolig? 
Antall år___ 
 
2.3 Hvordan var de økonomiske forhold i familien under din oppvekst? 
 Meget gode 
 Gode 
 Vanskelige 
 Meget vanskelige 
2.4 Hvilken betydning har religion i ditt liv? 
Stor betydning 
En viss betydning 
Ingen betydning 
 
2.5 Hva regner du deg selv som?  




 Annet  
 
2.6 Hvor mange søsken har du/har du hatt? 
 Antall søsken 
    
Hvor mange barn har du/har du hatt? 
    Antall 





2.11 Lever din mor? 
Nei Ja 
   
Hvis Ja, hopp til spm 2.9. 
Hvis Nei:  





2.11.1 Hva var din mors alder ved død? 
Alder ved død __  
    
2.12 Lever din far?  
Nei Ja 
  
Hvis Ja, hopp til spm 2.10. 
Hvis Nei:  
2.12.1 Hva var din fars alder ved død? 
Alder ved død__  
 
Hva var/er den høyeste fullførte utdanning til dine foreldre og din ektefelle/samboer? 
 
Grunnskole/framhaldsskole/folkehøyskole inntil 10 år   
Fagutdanning/realskole/videregående/gymnas minimum 3 år 
Høyskole/universitet, mindre enn 4 år 
Høyskole/universitet, 4 år eller mer 
12.13 Mor  
12.14 Far  
12.15 Ektefelle/samboer 
3 TRIVSEL OG LIVSFORHOLD 
 
Nedenfor står tre utsagn om tilfredshet med livet som et hele. Deretter står fem utsagn om syn på 
din egen helse, og mestring av egen helse. Vis hvor enig eller uenig du er i hver av påstandene ved å 
sette et kryss i rubrikken for det tallet du synes stemmer best for deg. 
    Helt uenig      Helt enig 
     1 2 3 4 5 6 7 
3.1 På de fleste måter er livet mitt nær idealet mitt     
3.2 Mine livsforhold er utmerkede     
3.3 Jeg er tilfreds med livet mitt     
3.4 Jeg ser lyst på min framtidige helse     
3.5 Ved å leve sunt kan jeg forhindre alvorlige sykdommer    
3.6 Jeg vet hvordan jeg skal forebygge forverring av min helsetilstand 
3.7 Jeg kan finne løsninger når det oppstår nye situasjoner eller problemer 
med min helsetilstand 
3.8 Når alt kommer til alt er jeg selv ansvarlig for å ta hånd om min egen 
helse 
 
Angi hvor godt følgende påstander beskriver deg og familien din: 
Helt uenig     Helt enig  
1 2 3 4 5 





3.9 Jeg stoler fullt ut på mine vurderinger og avgjørelser  
3.10 Jeg trives svært godt i familien min  
3.11 Troen på meg selv får meg gjennom vanskelige perioder  
3.12 Det er godt samhold i familien min  
3.13 I motgang klarer jeg å finne noe bra å vokse på 
3.14 Familien min ser positivt på fremtiden selv i vanskelige perioder  
 






4 ARBEID OG YRKE 
4.1 Hvilken arbeids- eller livssituasjon er du i?  











Hvis Yrkesaktiv heltid, Yrkesaktiv deltid, Hjemmeværende, Alderspensjonist, 
Student/militærtjeneste, hopp til spørsmål 4.2. 
Hvis Sykemeldt, Uføretrygdet/mottar arbeidsavklaringspenger, Mottar sosialstønad, Arbeidsledig: 
4.1.1 Hvor lenge har du vært uten lønnet arbeid? 






10 år eller mer 
 
4.2 Jeg opplever at yrket mitt har/hadde følgende sosiale status i samfunnet 
(dersom du ikke er i arbeid nå, tenk på det yrket du hadde sist): 
Meget høy status 
Ganske høy status 
Middels status 
Ganske lav status 
Meget lav status 






Hvis ikke Yrkesaktiv heltid eller Yrkesaktiv deltid på spm 4.1 hopp til spm 4.1.3. 
Hvis Yrkesaktiv heltid eller Yrkesaktiv deltid på spm 4.1: 
4.1.2 Hvilken av følgende yrkesfelt beskriver best ditt nåværende arbeid?   
(Sett ett kryss)  
Administrativ leder, politiker 
Akademisk yrke (minst 4 års høyskole- eller universitetsutdanning) 
Yrke med kortere høyskole- eller universitetsutdanning (1-3 år) og teknikere 
Kontor- og kundeserviceyrker 
Salgs-, service- og omsorgsyrker 
Jordbruks-, skogbruks- og fiskeyrker 
Håndverker, bygningsarbeider, fagarbeider o.l. 
Prosess- og maskinoperatør, sjåfør o.l. 
Yrke uten formelt krav til utdanning 
 
4.1.2.1 Beskriv virksomheten på det arbeidstedet (avdelingen) der du utførte 
inntektsgivende arbeid i lengst tid de siste 12 mnd (f.eks. regnskapsbyrå, ungdomsskole, 
sykehus, snekkerverksted, bilverksted, bank, dagligvarehandel eller lignende): 
Virksomhet: ____________________________________ 
4.1.2.2 Hvilket yrke/tittel har eller hadde du på dette arbeidsstedet? (f.eks. sekretær, 
lærer, barnepleier, møbelsnekker, avdelingsleder, selger, sjåfør eller lignende) 
Yrke:_________________________________________ 
4.1.4 På en skala fra 0 til 10, hvordan vil du beskrive din arbeidsprestasjon siste 7 dager? 
0 Jeg har prestert svært dårlig   10 Jeg har prestert svært godt 
 
Hvis Yrkesaktiv heltid eller Yrkesaktiv  på spm 4.1 deltid hopp til spm 5.1.  
Hvis ikke Yrkesaktiv heltid eller Yrkesaktiv deltid på spm 4.1: 
4.1.3 Hvilken av følgende yrkesfelt beskriver best ditt siste arbeid?   
(Sett ett kryss)  
Administrativ leder, politiker 
Akademisk yrke (minst 4 års høyskole- eller universitetsutdanning) 
Yrke med kortere høyskole- eller universitetsutdanning (1-3 år) og teknikere 
Kontor- og kundeserviceyrker 
Salgs-, service- og omsorgsyrker 
Jordbruks-, skogbruks- og fiskeyrker 
Håndverker, bygningsarbeider, fagarbeider o.l. 
Prosess- og maskinoperatør, sjåfør o.l. 
Yrke uten formelt krav til utdanning 
4.1.3.1 Beskriv virksomheten på det arbeidstedet (avdelingen) der du utførte 
inntektsgivende arbeid siste periode du var i arbeid. (f.eks. regnskapsbyrå, 
ungdomsskole, sykehus, snekkerverksted, bilverksted, bank, dagligvarehandel eller 
lignende) 
Virksomhet: ____________________________________ 





4.1.3.2 Hvilket yrke/tittel hadde du på dette arbeidsstedet? (f.eks. sekretær, lærer, 
barnepleier, møbelsnekker, avdelingsleder, selger, sjåfør eller lignende) 
Yrke: _________________________________________ 
5 SYKDOMMER OG SYMPTOMER 
 
Har du hatt følgende sykdommer eller plager? 
Nei Ja Alder første gang 
5.1 Har du gjennomgått operasjon (bypass) av trange blodårer (kransårer) 
til hjertet? 
 
5.2 Har du gjennomgått utblokking (stenting) av trange blodårer 
(kransårer) til hjertet? 
 
5.3 Har du eller har du hatt trange blodårer i beina (åreforkalkning, 
“røykebein”)? 
 
Hvis Nei på spm 5.1-5.3, hopp til spm 5.4. 
Hvis Ja på spm 5.1: 
5.1.1 Hvis du har gjennomgått operasjon (bypass) av trange blodårer (kransårer) til 
hjertet, hva var din alder første gang? 
Alder første gang___ 
 
Hvis Ja på spm 5.2: 
5.2.1 Hvis du har gjennomgått utblokking (stenting) av trange blodårer (kransårer) til 
hjertet, hva var din alder første gang? 
Alder første gang___ 
 
Hvis Ja på spm 5.3: 
5.3.1 Hvis du har eller har hatt trange blodårer i beina (åreforkalkning, “røykebein”), hva 
var din alder første gang? 
Alder første gang___ 
 
Får du smerter i tykkleggen når du 
Nei Ja 
5.4 Går? 
5.5 Er i ro? 
 
Hvis Nei på 5.4 og 5.5, hopp til spm 5.6. 
Hvis Ja på 5.4: 
 
Hvis du får smerter i tykkleggen når du går 
         Nei Ja 
5.4.1 Forverres smertene ved raskere tempo eller i bakker? 
5.4.2 Gir smertene seg når du stopper? 
 
Får du smerter eller ubehag i brystet når du går 







5.6 I bakker, trapper eller fort på flat mark 
5.7 I vanlig takt på flat mark 
 
Hvis Nei på 5.6 og 5.7, hopp til spm 5.8. 
Hvis Ja på 5.6 eller 5.7 eller begge: 
 
5.6.1 Hvis du får smerter eller ubehag i brystet ved gange, pleier du å 
Stanse 
Saktne farten 
Fortsette i samme takt 
 
5.6.2 Hvis du stanser eller saktner farten, forsvinner smertene etter  
10 minutter eller mindre 
Mer enn 10 minutter 
5.8 Har du merket anfall med plutselig endring i pulsen eller hjerterytmen 
siste året?       
Nei Ja 
5.9 Hoster du omtrent daglig i perioder av året? 
Nei Ja 
 
Hvis Nei, hopp til spm 5.14. 
Hvis Ja: 
 
Hvis du hoster omtrent daglig i perioder av året 
Nei Ja 
5.9.1 Er hosten vanligvis ledsaget av oppspytt? 
5.9.2 Har du hatt slik hoste så lenge som i en 3 måneders periode i begge de to siste 
årene?  
 
Blir du tungpustet når du 
Nei Ja 
5.10 Går hurtig på flatmark eller svak oppoverbakke?  
5.11 Spaserer i rolig tempo på flatmark? 
5.12 Vasker deg eller kler på deg? 
5.13 Er i hvile? 
 
5.14 Har du Crohns sykdom eller ulcerøs kolitt? 
Nei Ja 
 
5.15 Har du vært smittet med leverviruset hepatitt C?  
Nei Ja Vet ikke 
 
Hvis Nei eller Vet ikke, hopp til spm 6.1. 
Hvis Ja: 






5.15.1 Har du fått behandling for hepatitt C?  
Nei Ja Vet ikke 
6 MUSKEL- OG LEDDSMERTER 
 
Har du i løpet av det siste året vært plaget med smerter og/eller stivhet i muskler og ledd som har 
vart i minst 3 måneder sammenhengende?   
(Sett ett kryss for hver linje) 
Ikke plaget En del plaget Sterkt plaget 
6.1 Nakke, skuldre 
6.2 Armer, hender 
6.3 Øvre del av ryggen 
6.4 Korsryggen 
6.5 Hofter, ben, føtter 
6.6 Andre steder 
 
Har du vært plaget av smerter og/eller stivhet i muskler og ledd i i løpet av de siste fire ukene? 
(Sett ett kryss for hver linje) 
Ikke plaget En del plaget Sterkt plaget 
6.7 Nakke, skuldre 
6.8 Armer, hender 
6.9 Øvre del av ryggen 
6.10 Korsryggen 
6.11 Hofter, ben, føtter 
6.12 Andre steder 
7 HODEPINE 
7.1 Har du vært plaget av hodepine det siste året? 
Nei Ja  
 
Hvis Nei, hopp til spm 8.1. 
Hvis Ja:  
7.1.1 Hva slags hodepine er du plaget av? 
Migrene  
Annen hodepine 
7.1.2 Omtrent hvor mange dager per måned har du hodepine? 
Mindre enn 1 dag 
1-6 dager 
7-14 dager 
Mer enn 14 dager 
7.1.3 Hvor sterk er hodepinen vanligvis? 
Mild (hemmer ikke aktivitet) 





Moderat (hemmer aktivitet) 
Sterk (forhindrer aktivitet) 
7.1.4 Hvor lenge varer hodepinen vanligvis? 
Mindre enn 4 timer 
4 timer – 1 døgn 
1-3 døgn 
Mer enn 3 døgn 
 
Er hodepinen vanligvis preget eller ledsaget av: 
Nei Ja 
7.1.5 Bankende/dunkende smerte? 
7.1.6 Pressende smerte? 
7.1.7 Ensidig smerte (høyre eller venstre)? 
7.1.8 Forverring ved fysisk aktivitet? 
7.1.9 Kvalme og/eller oppkast? 
7.1.10 Lys- og/eller lydskyhet? 
 
Før eller under hodepinen, kan du ha forbigående: 
Nei Ja 
7.1.11 Synsforstyrrelse (takkede linjer, flimring, tåkesyn, lysglimt)? 
7.1.12 Nummenhet i halve ansiktet eller i hånden? 
 
7.1.13 Angi hvor mange dager du har vært borte fra arbeid eller skole siste måned på 
grunn av hodepine: 
Antall dager borte ___ 
8 PLAGER 
8.1 Hvor ofte har du vært plaget av halsbrann og/eller sure oppstøt i løpet 
av de siste tre måneder? 
Aldri Månedlig Ukentlig Daglig 
 
Hvis Aldri, hopp til spm 8.2. 
Hvis > Aldri: 
8.1.1 Hvor plaget har du vært av halsbrann og/eller sure oppstøt? 
Ikke noe  Litt Mye 
8.1.2 Hvor lenge har du vært plaget av halsbrann og/eller sure oppstøt? 
 Mindre enn 3 måneder  
3-5 måneder 
6-12 måneder 
Mer enn 1 år 
 
8.2 Har du falt siste året? 
Nei 
En gang     
Mer enn en gang 






8.3 Er du redd for å falle? 
Ikke i det hele tatt    
Noe redd    
Svært redd 
8.4 Hvordan har du opplevd følelse av tretthet og utmattelse den siste 
uken? 
Marker på linjen nedenfor det punktet som best passer med den følelse av tretthet og utmattelse 
som du har opplevd siste uke. 
 




Nedenfor ber vi deg besvare noen spørsmål om din hukommelse:  
(Sett ett kryss for hvert spørsmål) 
Nei Ja 
9.1 Synes du at din hukommelse har blitt dårligere?  
9.2 Glemmer du ofte hvor du har lagt tingene dine?  
9.3 Har du problemer med å finne vanlige ord i en samtale?  
9.4 Har du fått problemer med daglige gjøremål som du mestret tidligere?  
9.5 Har du vært undersøkt for sviktende hukommelse?  
 
Hvis Nei på 9.1-9.4, hopp til spm 10.1. 
Hvis Ja på ett eller flere av 9.1-9.4: 
9.1.1 Er din hukommelse et problem i hverdagen?  
Nei Ja 
10 UFRIVILLIG BARNLØSHET 
 
10.1 Har du opplevd ufrivillig barnløshet i mer enn 1 år? 
Nei Ja 
 
Hvis Nei, hopp til spørsmål 11.1.   
Hvis Ja: 
 
Dersom du har opplevd ufrivillig barnløshet i mer enn 1 år      
Nei Ja Vet ikke 
10.1.1 Skyldtes dette forhold hos deg selv?     
10.1.2 Skyldtes dette forhold hos din partner? 
   
10.1.3 Har du/dere fått behandling for ufrivillig barnløshet?  
Nei Ja 
 





Hvis Nei, hopp til spm 11.1. 
Hvis Ja:  
 
Hvis du/dere har fått behandling for ufrivillig barnløshet, hva slags behandling har du eller din 
partner fått?        
Antall ganger 
10.1.3.1 Stimulering med tabletter 
10.1.3.2 Stimulering med tabletter og sæddonasjon (ikke ektemann/samboer) 
10.1.3.3 Sæddonasjon (ikke ektemann/samboer) 
10.1.3.4 Prøverørsbefruktning (IVF/ICSI) 
10.1.3.5 Annet 
 
Hvor mange barn har du/dere fått ved infertilitetsbehandling?   
Antall barn 
10.1.3.6 Ved Universitetssykehuset Nord-Norge 
10.1.3.7 Annet sted i Norge 
10.1.3.8 I utlandet  
11 DINE SLEKTNINGERS SYKDOMMER 
 
Kryss av for de slektningene som har eller har hatt noen av sykdommene: 
        Mor    Far     Barn       Søsken       Ingen av disse                                                                  
11.1 Hjerteinfarkt før fylte 60 år 
11.2 Angina pectoris (hjertekrampe) 
11.3 Hjerneslag/hjerneblødning 
11.4 Astma 
11.5 Diabetes  
11.6 Psykiske plager 
11.7 Rusproblemer 
 
12  SØVN 
 
Hvor mange dager pr uke  
(marker antall dager)  Antall dager pr uke 0  1  2  3  4  5  6  7 
12.1 bruker du mer enn 30 minutter for å sovne inn etter at lysene ble 
slukket? 
12.2 er du våken mer enn 30 minutter innimellom søvnen? 
12.3 våkner du mer enn 30 minutter tidligere enn du ønsker uten å få sove 
igjen?  
12.4 føler du deg for lite uthvilt etter å ha sovet? 
12.5 er du så søvnig/trett at det går ut over skole/jobb eller privatlivet? 
12.6 er du misfornøyd med søvnen din? 
 
12.7 Om du har søvnplager, hvor lenge har de vart? 
 Mindre enn 1 uke 
1-3 uker 












Mer enn 10 år 
Har ikke søvnplager 
 
12.8 Har du vanligvis skiftarbeid/nattarbeid? 
Nei  Ja 
 
Når pleier du vanligvis å legge deg for å sove? 
12.9 På arbeidsdager/hverdager 
kl. 00:30-24:00 (rullegardinmeny) 
12.10 På fridager/helgedager 
kl. 00:30-24:00 (rullegardinmeny) 
 
Hvor lenge ligger du våken før du sovner? 
12.11 På arbeidsdager/hverdager 
Antall minutter___ 
12.12 På fridager/helgedager 
Antall minutter___ 
 
Når pleier du vanligvis å våkne? 
12.13 På arbeidsdager/hverdager 
kl. 00:30-24:00 (rullegardinmeny) 
12.14 På fridager/helgedager 
kl. 00:30-24:00 (rullegardinmeny) 
 
12.15 Hvor ofte tar du deg en lur på dagtid? 
Aldri eller sjeldnere enn en gang i måneden 
Sjeldnere enn en gang i uken 
1-2 dager i uken 
3-5 dager i uken 
Hver dag eller nesten hver dag 
 
Hvis Aldri eller sjeldnere enn en gang i måneden, hopp til spm 12.16. 
Hvis > Aldri eller sjeldnere enn en gang i måneden: 
12.15.1 Hvis du tar deg en lur, hvor lenge pleier den vanligvis å vare? 
Antall minutter___ 
12.16 Snorker du når du sover?  
Aldri eller sjeldnere enn en natt i måneden 





Sjeldnere enn en natt i uken 
1-2 netter i uken 
3-5 netter i uken 
Hver natt eller nesten hver natt 
Vet ikke 
12.17 Har du opplevd pustestopp (søvnapné) når du sover? 
Aldri eller sjeldnere enn en natt i måneden 
Sjeldnere enn en natt i uken 
1-2 netter i uken 
3-5 netter i uken 
Hver natt eller nesten hver natt 
Vet ikke 
 
Hvor sannsynlig er det at du døser av eller sovner i følgende situasjoner? 
Bruk skalaen fra 0 til 3 for hver situasjon: 
0=ville aldri døse/sovne 
1=liten sjanse for å døse/sovne 
2=moderat sjanse for å døse/sovne 
3=stor sjanse for å døse/sovne 
 
Situasjon        Sjanse for å døse/sovne (0-3) 
12.18 Sitte og lese  
12.19 Se på TV 
12.20 Sitte, inaktiv på et offentlig sted (f.eks. på teater eller et møte) 
12.21 Som passasjer på en en-times biltur uten pause 
12.22 Legge deg for å hvile om ettermiddagen hvis omstendighetene tillater 
det 
12.23 Sitte og snakke med noen 
12.24 Sitte stille etter lunsj (uten å ha inntatt alkohol) 
12.25 I en bil, som har stoppet for noen få minutter i trafikken 
14 MAGE 
14.1 Hvor ofte har du hatt ubehag eller smerte i mageregionen de siste 3 
månedene? 
Aldri 
Mindre enn en dag i måneden 
En dag i måneden 
To til tre dager i måneden 
En dag i uken 
Mer enn en dag i uken 
Hver dag 
 
Hvis Aldri, hopp til spm 14.2. 
Hvis > Aldri og mann, hopp til spm 14.1.2. 
Hvis >Aldri og kvinne: 






14.1.1 Har du hatt dette ubehaget eller denne smerten kun under menstruasjon og ikke 
på andre tidspunkt? 
Nei Ja Jeg har ikke hatt menstruasjon siste 3 måneder 
 
Hvis Ja, hopp til spm 14.2. 
Hvis Nei eller Jeg har ikke hatt menstruasjon siste 3 måneder: 
MAGESMERTER 
14.1.2 Har du hatt dette ubehaget eller disse smertene i 6 måneder eller mer? 
Nei Ja 
 




Aldri eller sjelden Av og til Ofte Nesten alltid Alltid 
14.1.2.1 Hvor ofte har ubehaget eller smerten blitt bedre eller helt borte etter at du har hatt 
avføring?  
14.1.2.2 Hadde du oftere avføring da ubehaget eller smerten begynte?  
14.1.2.3 Hadde du sjeldnere avføring da ubehaget eller smerten begynte?  
14.1.2.4 Hadde du løsere avføring da ubehaget eller smerten begynte?  
14.1.2.5 Hvor ofte hadde du hardere avføring da ubehaget eller smerten begynte?  
14.1.2.6 Hvor ofte har du hatt hard eller klumpete de siste 3 månedene?  
14.1.2.7 Hvor ofte har du hatt løs, grøtaktig eller vandig avføring de siste 3 månedene? 
14.2 Hvor ofte har du vanligvis avføring?  
4 ganger eller mer per dag 
1-3 ganger per dag  
4-6 ganger per uke 
1-3 ganger per uke 
Sjeldnere enn 1 gang per uke 
15 HELSETJENESTER 
15.1 Hvor lenge har du hatt din nåværende fastlege?  
Mindre enn 1 år 
1-2 år 
3-4 år 
Mer enn 4 år 
 
15.2 Har du vært hos fastlegen siste 12 måneder? 
Nei Ja 
 
Hvis Nei, hopp til spm 15.3. 
Hvis Ja: 
15.2.1 Ved siste konsultasjon hos fastlegen, ble du henvist til  
(Sett ett eller flere kryss)  
fysioterapeut  









legespesialist utenfor sykehus 
annen henvisning 
ble ikke henvist 
15.2.2 Har du de siste 12 måneder bedt om eller ønsket å bli henvist til 
røntgenundersøkelse eller spesialist, men ikke blitt henvist av fastlegen?  
Ja, en gang 
Ja, flere ganger 
Nei, jeg har blitt henvist når jeg har bedt om eller ønsket det 
Nei, henvisning har ikke vært aktuelt 
 
Hvis Nei, jeg har blitt henvist når jeg har bedt om eller ønsket det eller Nei, henvisning har ikke 
vært aktuelt, hopp til spm 15.3. 
Hvis Ja: 
 
15.2.2.1 Hvis du ikke ble henvist av fastlegen, fikk det konsekvenser for din helse at du ikke 
ble henvist? 
Nei Ja, forbigående konsekvenser Ja, varige konsekvenser 
 
Hvor ofte det siste året har du benyttet internett til informasjon og råd om helse og sykdom? 
Aldri En gang Noen ganger Ofte  
15.3 Apper for smarttelefon eller nettbrett  
15.4 Søkemotorer (som Google)  
15.5 Sosiale medier (som Facebook e.l.)  
15.6 Videotjenester (som Youtube)  
 
Hvis Aldri på alle de foregående, hopp til spørsmål 16.1. 
Hvis >Aldri: 
 
På grunnlag av informasjon du har funnet via internett, har du: 
Aldri En gang Noen ganger Ofte  





15.3.1 Bestemt deg for å oppsøke lege? 
15.3.2 Bestemt deg for ikke å oppsøke lege?  
15.3.3 Diskutert informasjonen med lege? 
15.3.4 Endret din medisin uten å snakke med lege?  
15.3.5 Blitt usikker på om du har fått riktig diagnose? 
15.3.6 Blitt usikker på om du har fått riktig behandling? 
15.3.7 Bestemt deg for å oppsøke alternativ behandler?  
15.3.8 Endret din livsstil?  
15.3.9 Følt deg engstelig? 
15.3.10 Følt deg betrygget?  
15.3.11 Følt deg mer kunnskapsrik?  
15.3.12 Følt deg mer forvirret? 
16 ALTERNATIV MEDISIN 
16.1 Har du i løpet av de siste 12 måneder brukt urtemedisin, naturmidler 
eller naturlegemidler? 
Nei  Ja 
 
16.2 Har du i løpet av de siste 12 måneder brukt meditasjon, yoga, qi gong 
eller thai chi som egenbehandling? 
Nei  Ja 
17 SMERTESTILLENDE OG BETENNELSESDEMPENDE MEDISINER 
17.1 Har du det siste året regelmessig brukt smertestillende og/eller 
betennelsesdempende medisiner (f.eks. acetylsalicylsyre, paracetamol, 
ibuprofen, diklofenak, naproxen)?  
 
Dette inkluderer både reseptfrie og reseptbelagte legemidler, også acetylsalisylsyre som brukes i lav 
dose som blodfortynnende middel. 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1. 
Hvis Ja: 
 
Hvilke smertestillende/betennelsesdempende medisiner har du brukt siste året?  
(Sett ett eller flere kryss) 
 
17.1.1 Acetylsalisylsyre lav dose som brukes som blodfortynnende middel 
(75 mg eller 160 mg per tablet, f.eks. Acetylsalisylsyre® Albyl-E® Asasantin Retard®) 
Nei Ja 
 
17.1.2 Acetylsalisylsyre høy dose  




(f.eks. Pamol® Panodil® Paracet® Paracetamol® Pinex® Paracetduo®) 







17.1.4 Paracetamol kombinert med kodein/tramadol 
(Paralgin forte® Codaxol® Paralgin major® Paralgin minor® Paramax Comp Vitabalans® Pinex Forte® 




(Fanalgin® Fenazon-koffein® Fenazon-koffein sterke®) 
Nei Ja 
 
17.1.6 Ibuprofen og lignende 




17.1.7 Diklofenak og lignende  





(f.eks. Napren-E® Naproxen-E® Naproxen® Vimovo®) 
Nei Ja 
 
17.1.9 Andre smertestillende og/eller betennelsesdempende medisiner 
(f.eks. Brexidol® Piroxicam® Meloxicam® Migea® Celebra® Dynastat® Arcoxia® Relifex®) 
Nei Ja 
 
Hvis Nei på spm 17.1.1, hopp til spm 18.1. 
Hvis Ja på spm 17.1.1: 
 
17.1.1.1 Har du brukt lavdose acetylsalisylsyre ukentlig eller oftere siste år? 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt acetylsalisylsyre lavdose ukentlig eller mer siste år 
 

















17.1.1.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
 
Hvis Nei på spm 17.1.2, hopp til spm 18.1. 
Hvis Ja på spm 17.1.2: 
 
17.1.2.1 Har du brukt høydose acetylsalicylsyre ukentlig eller oftere siste år? 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt acetylsalisylsyre høydose ukentlig eller mer siste år 
 












17.1.2.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
 
Hvis Nei på spm 17.1.3, hopp til spm 18.1. 
Hvis Ja på spm 17.1.3: 
 
17.1. 3.1 Har du brukt paracetamol ukentlig eller mer oftere år? 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt paracetamol ukentlig eller mer siste år 
 

















17.1.3.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
 
Hvis Nei på spm 17.1.4, hopp til spm 18.1. 
Hvis Ja på spm 17.1.4: 
 




Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt paracetamol med kodein/tramadol ukentlig eller mer siste år 
 












17.1.4.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
 
Hvis Nei på spm 17.1.5, hopp til spm 18.1. 
Hvis Ja på spm 17.1.5: 
 
17.1.5.1 Har du brukt fenazon ukentlig eller oftere siste år? 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt fenazon ukentlig eller mer siste år 
 

















17.1.5.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
 
Hvis Nei på spm 17.1.6, hopp til spm 18.1. 
Hvis Ja på spm 17.1.6: 
 
17.1.6.1 Har du brukt ibuprofen og lignende ukentlig eller oftere siste år? 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt ibuprofen og lignende ukentlig eller mer siste år 
 












17.1.6.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
 
Hvis Nei på spm 17.1.7, hopp til spm 18.1. 
Hvis Ja på spm 17.1.7: 
 
17.1.7.1 Har du brukt diklofenak og lignende ukentlig eller oftere siste år? 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt diclofenac og lignende ukentlig eller mer siste år 
 

















17.1.7.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
 
Hvis Nei på spm 17.1.8, hopp til spm 18.1. 
Hvis Ja på spm 17.1.8: 
 
17.1.8.1 Har du brukt naproksen ukentlig eller oftere siste år? 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt naproksen ukentlig eller mer siste år 
 












17.1.8.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
 
Hvis Nei på spm 17.1.9, hopp til spm 18.1. 
Hvis Ja på spm 17.1.9: 
 
17.1.9.1 Har du brukt andre smertestillende og/eller betennelsesdempende medisiner 
ukentlig eller oftere siste år? 
Nei Ja 
 
Hvis Nei, hopp til spm 18.1.  
Hvis Ja: 
 
Hvis du har brukt andre smertestillende og/eller betennelsesdempende medisiner ukentlig eller mer 
siste år 
 






17.1.9.1.2 Hvor mange tabletter totalt per uke? 
1-2 
3-5  








17.1.9.1.3 Hvor mange år har du hatt dette forbruket? 
Antall år__   
18 INFORMASJON OM MEDISINER 
18.1 Har du brukt medisiner (reseptfrie og reseptbelagte) regelmessig siste 
4 uker? 
(Ikke regn med reseptfrie vitamin-, mineral- og kosttilskudd, urter, naturmedisin etc) 
Nei Ja 
 
Hvis Nei, hopp til spm 19.1. 
Hvis Ja: 
 
Tenk på informasjonen om dine medisiner som du får hos din fastlege. Angi i hvilken grad du er enig i 
følgende utsagn. 
 
Jeg får informasjon om…    Helt uenig Uenig Usikker Enig Helt enig 
18.1.1 Hvorfor jeg skal bruke medisinene 
18.1.2 Hvordan jeg skal bruke medisinene (antall tabletter, inntak, med eller uten mat 
osv) 
18.1.3 Hvilke bivirkninger medisinene kan ha 
18.1.4 Hvilke andre medisiner eller matvarer som kan påvirke effekten av mine 
medisiner 
 
Tenk på informasjonen om dine medisiner som du får når du er på apoteket. Anig i hvilken grad er er 
enig i følgende utsagn. 
 
Jeg får informasjon om…   Helt uenig Uenig Usikker Enig Helt enig 
18.1.5 Hvorfor jeg skal bruke medisinene 
18.1.6 Hvordan jeg skal bruke medisinene (antall tabletter, inntak, med eller uten mat 
osv.) 
18.1.7 Hvilke bivirkninger medisinene kan ha  
18.1.8 Hvilke andre medisiner eller matvarer som kan påvirke effekten av mine 
medisiner 
 
18.1.9 Har du hjelp med dine medisiner? 
Nei Ja 
18.1.10 Uavhengig av om du har hjelp eller ikke med dine medisiner, trenger du mer 
hjelp? 
Jeg trenger ikke mer hjelp  
Jeg trenger litt mer hjelp  
Jeg trenger mye mer hjelp 
18.1.11 Trenger du mer informasjon om dine medisiner? 
Jeg trenger ikke mer informasjon  





Jeg trenger litt mer informasjon   
Jeg trenger mye mer informasjon 
18.1.12 Generelt sett, hvor viktig mener du at dine medisiner er for deg? 
Ikke viktig i det hele tatt  
Ikke veldig viktig  
Viktig  
Veldig viktig 
18.1.13 Er du bekymret for dine medisiner? 




Hvis Ikke bekymret i det hele tatt, hopp til spm 18.1.13. 
Hvis Bekymret eller Veldig bekymret:  
18.1.13.1 Kryss av for hvilke bekymringer du har for dine medisiner 
(Sett ett eller flere kryss) 
Jeg er bekymret for 
Langtids-effekter av mine medisiner 
Bivirkninger av mine medisiner 
At medisinene skal ha negativ innvirkning på livet mitt 
At jeg ikke tar mine medisiner på rett måte 
Å bli avhengig av mine medisiner 
At medisinene mine skal miste effekten 
At medisinene mine gjør mer skade enn nytte 
Kostnader med mine medisiner 
Annet 
 
Mange mennesker tar ikke sine medisiner hele tiden, enten fordi de ikke kan, glemmer, eller fordi de 
ikke vil. De følgende spørsmålene omhandler hvordan du tar dine medisiner. 
18.1.14 Hvor mange ganger i uka glemmer du å ta dine medisiner? 
Sjeldnere enn 1 gang per uke  
1 gang per uke  
2-4 ganger per uke  
5 ganger per uke eller mer 
18.1.15 Hvor mange ganger i uka bestemmer du deg for å ikke ta dine medisiner? 
Sjeldnere enn 1 gang per uke 
1 gang per uke 
2-4 ganger per uke 
5 ganger per uke eller mer 
19 FYSISK AKTIVITET 
19.1 Hvor ofte driver du mosjon?  
(Med mosjon mener vi gå en tur, gå på ski, svømme eller drive trening/idrett) 
Aldri 
Sjeldnere enn en gang i uken 
En gang i uken 





2-3 ganger i uken 
Omtrent hver dag 
 
Hvis Aldri, hopp til spm 20.1. 
Hvis >Aldri: 
19.1.1 Hvor hardt mosjonerer du i gjennomsnitt? 
Tar det rolig uten å bli andpusten eller svett 
Tar det så hardt at jeg blir andpusten og svett 
Tar meg nesten helt ut   
19.1.2 Hvor lenge mosjonerer du per gang i gjennomsnitt? 
Mindre enn 15 minutter 
15-29 minutter  
30 minutter – 1 time  
Mer enn 1 time 
20 MATVANER 
 
Hvor ofte spiser du vanligvis følgende?  
Sett ett kryss for hver linje 
  0-1 g per mnd 2-3 g per mnd  1-3 g per uke Mer enn 3 g per uke 
20.1 Ferskvannsfisk (ikke oppdrett)    
20.2 Saltvannsfisk (ikke oppdrett)    
20.3 Oppdrettsfisk (laks, røye, ørret)    
20.4 Tunfisk (fersk eller hermetisert)    
20.5 Fiskepålegg    
20.6 Skjell    
20.7 Den brune innmaten i krabbe    
20.8 Hvalkjøtt/sel/kobbekjøtt    
20.9 Innmat fra rein eller elg   
20.10 Innmat fra rype    
20.11 Tomater og tomatbaserte produkter (f.eks. tomat, ketchup) 
     
Hvor mange ganger i året spiser du/spiste du vanligvis følgende?  
   Som voksen: antall ganger i året I din barndom: antall ganger i året 
20.12 Mølje   
20.13 Måsegg    
20.14 Reinsdyrkjøtt   
20.15 Elgkjøtt  
20.16 Villsopp (for eksempel kantarell) og villbær (for eksempel 
blåbær/tyttebær/multe) 
 
Bruker du følgende kosttilskudd? 
(Sett ett kryss per linje) 
      Nei  Iblant Daglig i vinterhalvåret  Daglig   





20.17 Tran, trankapsler   
20.18 Omega 3 (fiskeolje, selolje)  
20.19 Kalktabletter   
20.20 Vitamintilskudd med vitamin D 
 
Nei  Iblant Kun ved reiser Daglig  
20.21 Melkesyrebakterier/probiotika 
21 SOLING 
21.1 Har du vært på solferie siste 2 måneder?  
Nei Ja 
21.2 Tar du solarium?  
Ja, ukentlig Ja, iblant  Aldri 
22  VEKTEN DIN 
22.1 Hvilken vekt ville du være tilfreds med (din trivselsvekt)? 
Antall kg___ 
22.2 Er du fornøyd med vekta di nå? 
Ja  Nei  
22.3 Anslå din vekt da du var 25 år gammel 
Antall kg___ 
22.4 Har du ufrivillig gått ned i vekt siste 6 måneder? 
Ja  Nei      
 
Hvis Nei, hopp til spm 23.1 eller 24.1 avhengig av kjønn. 
Hvis Ja: 
22.4.1 Hvis du har gått ufrivillig ned i vekt siste 6 måneder, hvor mange kilo har du gått 
ned? 
Antall kg___ 
23 MENNS HELSE 
 
23.1 Har du i løpet av de siste 3 mnd hatt problemer med ereksjonsevnen? 
Nei Ja 
 
Hvis Nei, hopp til spm 23.2. 
Hvis Ja: 
 
23.1.1 Hvordan rangerer du tilliten din til å oppnå og opprettholde en ereksjon  
Veldig lav Lav Moderat Høy Veldig høy 
 





23.1.2 Når du har hatt ereksjoner med seksuell stimulering, hvor ofte var ereksjonene 
stive nok for penetrering (innføring i partner)? 
(Nesten) aldri Noen få ganger  Noen ganger Oftest (Nesten) alltid 
 
23.1.3 Når du forsøkte å ha samleie, hvor ofte klarte du å vedlikeholde ereksjonen etter 
penetrering (innføring) hos partner?  
(Nesten) aldri Noen få ganger  Noen ganger De fleste ganger Oftest (alltid) 
 
23.1.4 Når du forsøkte samleie, hvor vanskelig var det å vedlikeholde din ereksjon til 
fullendt samleie? 
Store vansker Veldig vanskelig Vanskelig Litt vanskelig Ikke vanskelig 
 
23.1.5 Når du forsøkte samleie, hvor ofte var det tilfredsstillende for deg?  
(Nesten) aldri Noen få ganger  Noen ganger De fleste ganger Oftest (alltid) 
23.2 Har noen av dine partnere blitt gravid med deg og spontanabortert? 
Nei Ja Vet ikke 
 
Hvis Nei eller Vet ikke, hopp til spm 25.1. 
Hvis Ja: 
23.2.1 Antall ganger dine partnere har blitt gravid med deg og spontanabortert 
Antall ganger__ 
24 KVINNERS HELSE 
 
24.1 Har du spontanabortert? 
Nei Ja Vet ikke   
 
Hvis Nei eller Vet ikke, hopp til spm 24.2. 
Hvis Ja: 
24.1.1 Antall ganger du har spontanabortert 
Antall ganger__ 
MENSTRUASJON 
24.2 Har du menstruasjon fremdeles?  
Nei Ja 
 
Hvis Ja, hopp til spm 24.3. 
Hvis Nei: 
 
24.2.1 Hvorfor stoppet menstruasjonen? 
(sett ett kryss) 
Den stoppet av seg selv 
Operasjon på livmoren  
Operert bort begge eggstokkene  
Satte inn hormonspiral  
Annen grunn (for eksempel stråling, cellegiftbehandling)  
 





24.2.2 Hvor gammel var du da menstruasjonen stoppet? 
Alder___ 
  
24.3 Har du i løpet av livet vært plaget av menstruasjonssmerter?   
Nei Ja 
 
Hvis Nei, hopp til spm 24.4.  
Hvis Ja på spm 24.3 + Nei på spm 24.2: 
 
Hvor gammel var du da menstruasjonssmertene var mest plagsomme?  
24.3.1 Fra alder__ 
24.3.2 Til alder __ 
 
24.3.3 Hvor lenge varte menstruasjonssmertene vanligvis da?  
Mindre enn 1 dag 




mer enn 4 dager 
 
24.3.4 På en skala fra 0 til 10, der 0 er ingen smerte og 10 er sterkest tenkelige smerte, 
hvor sterke var menstruasjonssmertene vanligivis?  
Ingen smerte 0 1 2 3 4 5 6 7 8 9 10 Sterkest tenkelige smerte 
 
24.3.5 Hendte det at du var borte fra skole eller jobb på grunn av menstruasjonssmerter? 
Aldri Sjelden Ganske ofte Svært ofte 
 
Hvis Ja på spm 24.3 + Ja på spm 24.2: 
24.3.6 Hvor lenge varer menstruasjonssmertene vanligvis nå?  





mer enn 4 dager 
 
24.3.7 På en skala fra 0 til 10, der 0 er ingen smerte og 10 er sterkest tenkelige smerte, 
hvor sterke er menstruasjonssmertene vanligivis?  
Ingen smerte 0 1 2 3 4 5 6 7 8 9 10 Sterkest tenkelige smerte 
 
24.3.8 Hender det at du er borte fra skole eller jobb på grunn av menstruasjonssmerter? 
Aldri Sjelden Ganske ofte Svært ofte 
BRUK AV PREVENSJON MED HORMONER 
24.4 Bruker du nå, eller har du brukt prevensjon med hormoner (p-
piller/minipiller/plaster/hormonspiral/implantat)?  
Nei Ja, før Ja, nå 
 





Hvis Nei, hopp til spm 24.5.  
Hvis Ja, før på spm 24.4:  
24.4.1 Alder første gang du brukte prevensjon med hormoner 
Alder første gang __  
24.4.2 Alder når du sluttet med prevensjon med hormoner 
Alder når sluttet __ 
24.4.3 Hvor mange år har du til sammen brukt prevensjon med hormoner? 
Antall år__ 
 
Hvis Ja, nå på spm 24.4: 
24.4.1 Alder første gang du brukte prevensjon med hormoner 
Alder første gang __  
24.4.3 Hvor mange år har du til sammen brukt prevensjon med hormoner? 
Antall år__ 
24.4.5 Hvilken type p-pille/minipille/p-plaster/hormonspiral/implantat bruker du nå? 
P-piller (Loette Microgynon Oralcon Marvelon Mercilon Yasmin Yasminelle Yaz Zoely Synfase Qlaira)  
Minipille (Conludag  Cerazette) 
Plaster (Evra ) 
Implantat (Depo-Provera Nexplanon)  
Hormonspiral/skjedeinnlegg (Jaydess Mirena NuvaRing)  
HORMONBEHANDLING VED NEDGANG I EGNE KJØNNSHORMONER 
24.5 Bruker du nå, eller har du brukt østrogenpreparater 
(tabletter/plaster/vaginalring/tabletter/kremer) for enten plager i 
overgangsalderen eller av andre årsaker som behandling av beinskjørhet 
etc? 
Nei Ja, før Ja, nå 
 
Hvis Nei, hopp til spm 24.6. 
Hvis Ja, før på spm 24.5: 
24.5.1 Alder første gang du brukte østrogenpreparater 
Alder første gang __  
24.5.2 Alder når du sluttet med østrogenpreparater 
Alder når sluttet __ 
24.5.3 Hvor mange år har du til sammen brukt østrogenpreparater? 
Antall år__ 
 
Hvis Ja, nå på spm 24.5: 
24.5.1 Alder første gang du brukte østrogenpreparater 
Alder første gang __    
24.5.3 Hvor mange år har du til sammen brukt østrogenpreparater? 
Antall år__ 





24.5.4 Hvilke hormonpreparater bruker du nå? 
Plaster (Evorel Estalis Estradot Sequidot) 
Tabletter (Activelle Cliovelle  Eviana Indivina Novofem Trisekvens Progynova Livial) 
Ovesterin tabletter 
Ring/tablett til skjeden (Estring Vagifem) 
Ovesterin vaginalkrem, Ovesterin vagitorier  
 
Ja, helt klart Ja, noen ganger Nei, ikke så mye Nei, ikke i det hele tatt 
24.6 Har du eller har du hatt hetetokter? 
24.7 Er du eller har du vært plaget av nattesvette? 
 
FRAMFALL I SKJEDEN 
24.8  Kjenner du et framfall i skjeden? 







Hvis Ikke, hopp til spm 25.1. 
Hvis Litt, Ganske mye eller Svært mye: 
FRAMFALL I SKJEDEN 
Ikke Litt Ganske mye Svært mye 
24.8.1 Har du nedtrykk-følelse i skjeden eller underlivet som blir verre utover dagen?  
24.8.2 I hvor stor grad har fremfallet innflytelse på ditt liv?     
24.8.3 Har framfallet en innflytelse på dine fysiske aktiviteter (for eksempel: å spasere, 
sykle, gå på trim)? 
24.8.4 Må du presse for å tømme blæren?  
24.8.5 Har du følelse av at framfallet er sjenerende under samleie? 
 
24.8.6 Hvis behov, kan du presse framfallet tilbake i skjeden? 
Aldri 
Av og til 
Ofte 
Alltid 




Som oftest ikke 
24.8.8 Har du søkt hjelp for framfall/prolaps 
Nei Ja 






25.1 Har du i løpet av de siste 12 måneder vært seksuelt aktiv ? 
Nei Ja 
25.2 Hvor mange seksualpartnere har du hatt totalt (Sett 0 dersom du ikke 
har hatt seksualpartner)? 
Antall seksualpartnere__ 




Hvis Nei, hopp til spm 26.1. 
Hvis Ja: 
25.3.1 Har du i løpet av de siste 12 måneder praktisert munnsex (utført på partner 
og/eller mottatt)? 




26.1 Har du hatt vannlatningsbesvær i løpet av den siste måneden? 
(f.eks. svak stråle, følelse av ufullstendig blæretømning eller hyppig vannlatning) 
Nei Ja 
 




Aldri Mindre enn 1 av 5 ganger Mindre enn halvparten av gangene Omtrent 
halvparten av gangene Mer enn halvparten av gangene Nesten alltid 
 
26.1.1 Hvor ofte har du hatt følelsen av at blæren ikke er fullstendig tømt etter avsluttet 
vannlatning? 
26.1.2 Hvor ofte har du måttet late vannet på nytt mindre enn to timer etter forrige 
vannlatning? 
26.1.3 Hvor ofte har du måttet stoppe og starte flere ganger mens du lot vannet? 
26.1.4 Hvor ofte har det vært vanskelig å utsette vannlatningen? 
26.1.5 Hvor ofte har du hatt svak stråle 
26.1.6 Hvor ofte har du måttet trykke eller presse for å late vannet? 
26.1.7 Hvor ofte har du vanligvis måttet stå opp i løpet av natten for å late vannet? 
27 URINLEKKASJE 
27.1 Hvor ofte lekker du urin? 
(Sett ett kryss) 
Aldri    
Omtrent en gang i uken eller sjeldnere 
2-3 ganger i uken   





ca 1 gang per dag 
Flere ganger per dag  
Hele tiden 
 
Hvis Aldri, hopp til spm 28.1. 
Hvis >Aldri: 
URINLEKKASJE 
27.1.1 Hvor mye urin lekker du vanligvis? 
(Sett ett kryss) 
Ikke noe    
En liten mengde                      
En moderat mengde   
En stor mengde  
27.1.2 Hvor mye påvirker urinlekkasje ditt hverdagsliv? 
Sett kryss for et tall mellom 0 (ikke i det hele tatt) og 10 (svært mye). 
 
Ikke i det hele tatt       0     1      2      3      4      5      6      7      8      9     10    Svært mye 
27.1.3 Når lekker du urin  
(Sett ett eller flere kryss) 
Aldri, jeg lekker ikke urin 
Lekker før jeg når toalettet 
Lekker når jeg hoster eller nyser 
Lekker når jeg sover 
Lekker når jeg er fysisk aktiv/trimmer 
Lekker når jeg er ferdig med å late vannet og har tatt på meg klærne 
Lekker uten noen opplagt grunn 
Lekker hele tiden 
27.1.4 Har du søkt hjelp for urinlekkasje   
Nei Ja 
28 PSYKISK HELSE 
 
Under finner du en liste over ulike problemer. Har du opplevd noe av dette den siste uken (til og med 
i dag)?  
(Sett ett kryss for hver plage) 
 
      Ikke     Litt      Ganske  Veldig 
      plaget  plaget    mye       mye 





28.1 Plutselig frykt uten grunn 
28.2 Føler deg redd eller engstelig 
28.3 Matthet eller svimmelhet 
28.4 Føler deg anspent eller oppjaget 
28.5 Lett for å klandre deg selv 
28.6 Søvnproblemer 
28.7 Nedtrykt, tungsindig 
28.8 Følelse av å være unyttig, lite verd 
28.9 Følelse av at alt er et slit 
28.10 Følelse av håpløshet mht. framtida 
 
Her kommer noen spørsmål om hvorledes du føler deg. For hvert spørsmål setter du kryss for 
ett av de fire svarene som best beskriver dine følelser den siste uken. Ikke tenk for lenge på svaret 
– de spontane svarene er best. 
28.11 Jeg føler meg nervøs og urolig 
Mesteparten av tiden 
Mye av tiden 
Fra tid til annen 
Ikke i det hele tatt 
28.12 Jeg gleder meg fortsatt over tingene slik jeg pleide før 
Avgjort like mye 
Ikke fullt så mye 
Bare lite grann 
Ikke i det hele tatt 
28.13 Jeg har en urofølelse som om noe forferdelig vil skje 
Ja, og noe svært ille 
Ja, ikke så veldig ille 
Litt, bekymrer meg lite 
Ikke i det hele tatt 
28.14 Jeg kan le og se det morsomme i situasjoner 
Like mye nå som før 
Ikke like mye nå som før 
Avgjort ikke som før 
Ikke i det hele tatt 
28.15 Jeg har hodet fullt av bekymringer 
Veldig ofte 
Ganske ofte 
Av og til 
En gang i blant 




For det meste 





28.17 Jeg kan sitte i fred og ro og kjenne meg avslappet 
Ja, helt klart 
Vanligvis 
Ikke så ofte 
Ikke i det hele tatt 
28.18 Jeg føler meg som om alt går langsommere 
Nesten hele tiden 
Svært ofte 
Fra tid til annen 
Ikke i det hele tatt 
28.19 Jeg føler meg urolig som om jeg har sommerfugler i magen 
Ikke i det hele tatt 
Fra tid til annen 
Ganske ofte 
Svært ofte 
28.20 Jeg bryr meg ikke lenger om hvordan jeg ser ut 
Ja, jeg har sluttet å bry meg 
Ikke som jeg burde 
Kan hende ikke nok 
Bryr meg som før 
28.21 Jeg er rastløs som om jeg stadig må være aktiv 
Uten tvil svært mye 
Ganske mye 
Ikke så veldig mye 
Ikke i det hele tatt 
28.22 Jeg ser med glede frem til hendelser og ting 
Like mye som før 
Heller mindre enn før 
Avgjort mindre enn før 
Nesten ikke i det hele tatt 
28.23 Jeg kan plutselig få en følelse av panikk 
Uten tvil svært ofte 
Ganske ofte 
Ikke så veldig ofte 
Ikke i det hele tatt 
28.24 Jeg kan glede meg over gode bøker, radio og TV 
Ofte 
Fra tid til annen 
Ikke så ofte 
Svært sjelden 
29 BEKYMRINGER 
Hvor typisk er utsagnene for deg: 
(Sett ett kryss for hver påstand, fra 1=Ikke typisk til 5=Meget typisk) 





Ikke typisk Noe typisk Meget typisk 
1 2 3 4 5 
29.1 Jeg bekymrer meg hele tiden  
29.2 Mange situasjoner får meg til å bli bekymret 
29.3 Jeg bekymrer meg alltid for et eller annet 
30 TRAUMER 
 
Har du noen gang opplevd noen av disse hendelsene?  
(Sett ett eller flere kryss for hver linje) 
 
Nei Ja, før fylte 18 år Ja, etter fylte 18 år Ja, siste året 
30.1 En livstruende sykdom eller vært utsatt for en alvorlig ulykke (f.eks. 
brann, arbeids- eller bilulykke) 
30.2 Blitt utsatt for vold (f. eks. slått, sparket, banket opp, ranet, eller truet 
med skytevåpen) 
30.3 Blitt utsatt for seksuelle overgrep, det vil si utsatt for seksuelle 
handlinger uten at du selv ønsket det 
30.4 Blitt kalt noe negativt, holdt utenfor, truet eller plaget av medelever, 
studiekamerater eller arbeidskollegaer over lengre tid 
30.5 Vært vitne til at noen som står deg nær er blitt utsatt for vold eller 
seksuelle overgrep (f. eks. slått, sparket, banket opp, ranet, truet med 
skytevåpen, eller drept) 
30.6 Opplevd noe annet som har vært skremmende, farlig eller voldelig 
(f.eks. naturkatastrofe, krig, terrorhandlinger, holdt fanget, etc) 
30.7 Dødsfall hos noen som stod deg nær og har vanskelig for å akseptere 
tapet, lengter etter den avdøde og opplever intens følelsesmessig smerte 
knyttet til tapet 
30.8 Fått smertefull eller skremmende medisinsk behandling da du var på 
sykehus fordi du var syk eller alvorlig skadet 
30.9 Fått smertefull eller skremmende behandling hos tannlege 
30.10 At noen som står deg nær har vært livstruende syk eller utsatt for en 
alvorlig ulykke (f. eks. brann, arbeids- eller bilulykke) 
30.11 Omsorgssvikt under oppveksten, det vil si ikke fått det nødvendige av 
mat, klær, beskyttelse og omsorg/kjærlighet fra foreldre/foresatte 
Nei Ja  
 
 
Hvis Nei på alle 30.1-30.11, hopp til spm 31.1. 
Hvis Ja på minst ett av 30.1-30.11:  
30.1.1 Tenker du fortsatt mye på det som skjedde? 
Nei Ja  






31.1 Har du drukket alkohol det siste året? 
Nei Ja 
 
Hvis Nei, hopp til spm 31.1.1.15. 
Hvis Ja: 
 






Hvor ofte har du det siste året: 
Aldri Sjeldnere enn månedlig  Månedlig Ukentlig Daglig eller nesten 
daglig 
31.1.1.9 Ikke klart å stoppe og drikke alkohol når du først har begynt? 
31.1.1.10 Ikke klart å gjøre det som normalt forventes av deg fordi du har drukket? 
31.1.1.11 Trengt alkohol om morgenen for å få komme i gang etter en rangel? 
31.1.1.12 Følt skyld eller anger etter at du har drukket? 
31.1.1.13 Ikke klart å huske hva som skjedde kvelden før på grunn av at du hadde 
drukket? 
31.1.1.14 Drukket så mye at du har kjent deg sterkt beruset (full)? 
 
Aldri Ja, men ikke det siste året Ja, det siste året 





31.1.1.15 Har du eller andre noen gang blitt skadet på grunn av at du har drukket? 
31.1.1.16 Har en slektning, venn, lege, eller annet helsepersonell vært bekymret for din 
drikking, eller foreslått at du reduserer inntaket? 
32 ANDRE RUSMIDLER 
32.1 Bruker du eller har du brukt andre rusmidler enn alkohol (f.eks hasj, 
amfetamin, kokain, heroin, hallusinogener, løsemidler, GHB)? 
 
Nei         Ja, nå    Ja, tidligere 
 
Hvis Nei hopp til spm 32.2. 
Hvis Ja, nå eller Ja, tidligere: 
32.1.1 Hva var din alder første gang du brukte andre rusmidler enn alkohol (f.eks. 
amfetamin, kokain, heroin, hallusinogener, løsemidler, GHB)? 
Alder første gang__ 
32.1.2 I løpet av det siste året, hvor ofte har du brukt andre rusmidler enn alkohol (f.eks 
hasj, amfetamin, kokain, heroin, hallusinogener, løsemidler, GHB)?  
Ikke brukt siste 12 måneder 
1 gang i måneden eller sjeldnere 
2-4 ganger i måneden 
2-3 ganger i uken 
4 ganger i uken eller mer 
32.2 Bruker du eller har du brukt reseptbelagte legemidler for å oppnå rus 
(f.eks beroligende medisin, sovemedisin, smertestillende medisin, ADHD-
medisin)?  
Nei         Ja, nå    Ja, tidligere 
 
Hvis Nei hopp til spm 33.1. 
Hvis Ja, nå eller Ja, tidligere: 
32.2.1 Hva var din alder første gang du brukt reseptbelagte legemidler for å oppnå rus 
(f.eks beroligende medisin, sovemedisin, smertestillende medisin, ADHD-medisin)? 
Alder første gang__ 
32.2.2 I løpet av de siste 12 måneder, hvor ofte har du brukt reseptbelagte legemidler for 
å oppnå rus (f.eks beroligende medisin, sovemedisin, smertestillende medisin, ADHD-
medisin)?  
Ikke brukt siste 12 måneder 
1 gang i måneden eller sjeldnere 
2-4 ganger i måneden 
2-3 ganger i uken 
4 ganger i uken eller mer 
33 RØYK OG SNUS 
 






33.1 Røyker du daglig eller har du tidligere røykt daglig? 
Aldri Ja, nå Ja, tidligere   
 
Hvis Aldri, hopp til spm 33.2. 
Hvis Ja, nå eller Ja, tidligere: 
DAGLIG RØYKING 
33.1.1 Hvor gammel var du da du begynte å røyke daglig?     
Alder__ 
33.1.2 Hvor mange år til sammen har du røykt daglig?      
Antall år__ 
 
33.1.3 Hvor mange sigaretter røyker/røykte du vanligvis daglig? 
Antall sigaretter__ 
 
Hvis Ja, tidligere på spm 33.1: 
DAGLIG RØYKING 
33.1.4 Hvis du har røykt daglig tidligere, hvor lenge er det siden du sluttet?   
Antall år__ 
AV-OG-TIL RØYKING 
33.2 Røyker du av og til men ikke daglig, eller har du tidligere røykt av og til 
men ikke daglig?       
Aldri Ja, nå Ja, tidligere 
 
Hvis Aldri, hopp til spm 33.3. 
Hvis Ja, nå eller Ja, tidligere: 
AV-OG-TIL RØYKING 
33.2.1 Hvor mange sigaretter røyker/røykte du vanligvis per uke?    
Antall sigaretter__ 
DAGLIG SNUSING 
33.3 Bruker du eller har du tidligere brukt snus eller skrå daglig? 
Aldri Ja, nå Ja, tidligere 
 
Hvis Aldri, hopp til spm 33.4. 
Hvis Ja, nå eller Ja, tidligere: 
DAGLIG SNUSING 
33.3.1 Hvor gammel var du da du begynte å snuse daglig?  
Alder__ 
33.3.2 Hvor mange år til sammen har du snust daglig? 
Antall år__ 
33.3.3 Hvis du snuser daglig nå eller har snust daglig tidligere, hvor mange porsjoner 
snus bruker/ brukte du vanligvis daglig? 
Antall porsjoner__ 
 





Hvis Ja, tidligere på spm 33.3: 
DAGLIG SNUSING 
33.3.4 Hvis du har snust daglig tidligere, hvor lenge er det siden du sluttet? 
Antall år__ 
AV-OG-TIL SNUSING 
33.4 Bruker du eller har du tidligere brukt snus av og til, men ikke daglig?   
Aldri Ja, nå Ja, tidligere  
 
Hvis Aldri, hopp til spm 34.1. 
Hvis Ja, nå eller Ja, tidligere: 
AV-OG-TIL SNUSING 




Hvor følsom er du for støy? Sett kryss ved det utsagnet som passer best. 







34.2 Har du nedsatt hørsel (ett/begge ører)? 
Nei Ja 
34.3 Har du i løpet av de siste 12 måneder hatt øresus i perioder som varer 
lengre enn 5 minutter? 
  Nei Ja 
 
Hvis Nei hopp til spm 34.4. 
Hvis Ja: 
ØRESUS 
34.3.1 Hvor ofte har du øresus? 
(Sett ett kryss) 
Sjeldnere enn hver uke 
Hver uke, men ikke hver dag 
Hver dag, men ikke hele tiden 
Nesten alltid  
34.3.2 Hvor lenge varer vanligvis periodene med øresus? 
(Sett ett kryss) 
Noen få minutter 
10 minutter til 1 time 
Lengre enn 1 time 





34.3.3 Noen bryr seg ikke om lyden, for andre oppleves det svært plagsomt å ha øresus. 
Angi hvor plaget du er av øresusen  med det tall mellom 0 og 10, der 0 er inger plager og 
10 er verst tenkelige plager. 
0 Ingen plager   10 Verst tenkelige plager 
  
Hvis du tenker på de siste 12 månedene, hvor plaget er du av støy hjemme fra kildene nedenfor?  
(Sett ett kryss for hver linje) 





34.8 Bygge- og anleggsvirksomhet 
34.9 Industri- og næringsvirksomhet  
34.10 Nabo/andre utenfor din bolig  
34.11 Andre innenfor din bolig (f. eks. som spiller høy musikk, snorkende 
partner, barn som våkner og skriker om natten o.l.) 
34.12 Annen støykilde 
 
34.13 Hvor mange år til sammen har du arbeidet på steder med støy der det 
har vært nødvendig å rope for å bli hørt? 
Antall år___ 
 
Hvis ikke Yrkesaktiv heltid eller Yrkesaktiv deltid på spm 4.1 hopp til spm 35.1. 
Hvis Yrkesaktiv heltid eller Yrkesaktiv deltid på spm 4.1: 
34.13.1 Hvis du tenker på de siste 12 månedene, hvor plaget er du av støy (fra musikk, 









Her kommer noen spørsmål om hvordan tennenes og munnhulens tilstand kan påvirke deg i dine 
daglige gjøremål. Først vil vi stille noen spørsmål om ulike plager med tennene, eventuelt gebiss, 
løstenner eller tannprotese. 
PLAGER MED TENNER/TANNPROTESER 
Hver dag eller nesten hver dag En til to ganger i uka En til to ganger i måneden
 Sjeldnere enn en gang i måneden Aldri 
 





35.1  I løpet av de siste 6 månedene, hvor ofte har slike plager gjort det 
vanskelig for deg å spise og nyte maten?  
35.2  I løpet av de siste 6 månedene, hvor ofte vil du si at slike plager har 
gjort det vanskelig for deg å snakke og uttrykke deg tydelig?  
35.3  I løpet av de siste 6 månedene, hvor ofte har slike plager gjort 
tannrengjøringen vanskelig?  
35.4  I løpet av de siste 6 månedene, vil du si at slike plager har gjort det 
vanskelig for deg å sove og slappe av?  
35.5  I løpet av de siste 6 månedene, hvor ofte vil du si at slike plager har 
gjort det vanskelig for deg å smile og vise tenner uten å bli brydd?  
35.6  I løpet av de siste 6 månedene, hvor ofte vil du si at slike plager har 
gjort det vanskelig for deg å være følelsesmessig stabil uten å bli irritabel?  
35.7 I løpet av de siste 6 månedene, hvor ofte vil du si at slike plager har 
gjort det vanskelig for deg å glede deg over samvær med andre mennesker?  
35.8 I løpet av de siste 6 månedene, hvor ofte vil du si at slike plager har 
gjort det vanskelig for deg å utføre daglig gjøremål?  
35.9  Hvor ofte pusser du vanligvis tennene dine?  
Sjeldnere enn 1 gang per uke 
Noen ganger i uka 
En gang daglig 
To eller flere ganger daglig 
35.10 Går du regelmessig til tannlege/tannpleier? 
Ja, mer enn en gang i året 
Ja, hvert år    
Ja, hvert annet år    
Ja, med lengre mellomrom enn 2 år 
Nei, bare for akutte problemer 
Nei, går aldri 
 
 
Bruker du selv noen av følgende hjelpemidler og i tilfelle hvor ofte?  
Aldri/Sjelden Noen ganger i måneden Noen ganger i uka Daglig 
35.11 Fluortannkrem 
35.12 Tanntråd, mellomromsbørste og eller tannstikker 
35.13 Fluortabletter 
35.14 Fluorskyllevæske (Flux; Fluorid tannskyll; Nicodent) 
35.15 Antibakteriell skyllvæske (Listerine, Corsodyl, Klorhexidin) 
 
 
Her kommer noen spørsmål om hvordan du opplever tannlegebesøk. Føler du, eller føler du ikke 
engstelse ved tannlegebesøk? 
 
Ikke engstelig i det hele tatt Litt engstelig Ganske engstelig Meget engstelig
 Ekstremt engstelig 





35.16 Dersom du skulle til tannlegen i morgen, hvordan vil du føle deg? 
35.17 Når du sitter i tannlegens venteværelse og venter på tur, hvordan føler du deg? 
35.18 Hvordan føler du det når du sitter i tannlegestolen og venter på at tannlegen skal 
bore i tannen/tennene dine? 
35.19 Tenk deg at du sitter i tannlegestolen og venter på at tannlegen skal får rengjort 
tennene dine. Hvordan føler du deg når tannlegen tar fram instrumentene for å fjerne 
tannsten? 
35.20 Hvis du måtte ta bedøvelse («sprøyte») for behandling av en jeksel i overkjeven, 
hvordan vil du føle deg? 
36 HUD- OG LEDDPLAGER 
 
Har du eller har du noen gang hatt følgende hud- eller leddsykdommer? 
Nei Ja 
36.1 Psoriasis 
36.2 Psoriasis artritt (psoriasis leddgikt) 
36.3 Atopisk eksem (barneeksem) 
36.4 Tilbakevendende (kronisk) håndeksem 
36.5 Tilbakevendende, store, smertefulle kuler (verkebyller) som ofte 
tilheler med arr, i armhuler, lysker eller under brystene (sykdom kalt 
hidradrenitis)?  
 
Hvis Ja på spm 36.1: 
PSORIASIS  
36.1.1 Har du fått diagnosen psoriasis av lege? 
Nei Ja 
36.1.2 Har du vært plaget av psoriasis i løpet av de siste 12 månedene? 
Nei Ja 
 
Hvis Ja på spm 36.2: 
36.1.2.1 Hvilken beskrivelse passet/passer best til din psoriasis siste 12 måneder?  
(Sett ett kryss) 
Plutselige, bitte små flekker over hele kroppen (mindre enn 1 cm) 
Flekker på albuer/knær/hodebunn som kommer av og til 
Flekker på albuer/knær/hodebunn som er nærmest konstant til stede  
Flekker på albuer/knær/hodebunn men også enkelte flekker på overkroppen, som nærmest 
konstant er til stede  
Utslett på større områder på kroppen som kommer av og til 
Utslett på større områder på kroppen som er nærmest konstant til stede 
 
Hvis Ja på spm 36.2: 
PSORIASIS ARTRITT (PSORIASIS LEDDGIKT) 
36.2.1 Har du vært plaget av psoriasis artritt i løpet av de siste 12 månedene? 
Nei Ja 
 
Hvis Nei på spm 36.3 





ATOPISK EKSEM (BARNEEKSEM) 
36.3.1 Har du vært plaget av atopisk eksem i løpet av de siste 12 månedene? 
Nei Ja 
 
Hvis på spm 36.4: 
TILBAKEVENDENDE (KRONISK) HÅNDEKSEM 




Hvis Ja på spm 36.5: 
VERKEBYLL (HIDRADRENITIS) 
36.5.1 Har du vært plaget av verkebyll i løpet av de siste 12 månedene? 
Nei Ja 
 
Har du eller har du hatt: 
(Sett ett eller flere kyss) 
 








36.6.1 Har du hatt slikt utslett på huden i løpet av de siste 12 månedene? 
Nei Ja 
 














36.7.1 Har du hatt slike negleforandringer i løpet av de siste 12 månedene? 
Nei Ja 
 




Hvis Nei, hopp til spm 36.9. 
Hvis Ja: 
 







36.8.1 Har du hatt slikt utslett i hodebunnen i løpet av de siste 12 månedene? 
Nei Ja 
 













36.10 Har du hatt utslett eller rødhet/irritasjon i lyskene, under/mellom 
rumpeballene eller under armene som har vart i mer enn 2 uker?  
Nei Ja 





37 REISER UTENFOR NORDEN 
  
37.1 I løpet av de siste 12 måneder, hvor mange reiser har du hatt utenfor 
Norden med varighet lengre enn en uke?  
(Sett 0 dersom du ikke har reist lengre enn en uke utenfor Norden siste 12 måneder) 
Antall reiser i rullegardinmeny (1-20 reiser) 
  
Hvis Reiser =0, hopp til spm 38.1. 
Hvis Reiser >0: 
  
For hver reise utenfor Norden med varighet lengre enn en uke, kryss av for landet du opphold deg 
lengst i, om du hadde diare i forbindelse med reisen, og dersom du var sykehusinnlagt, hvor mange 
ganger: 
 
For reise 1-20: 
37.1.1 Land 
Rullegardinmeny land alfabetisk (200 land) 
37.1.2 Diare 
Nei Ja 
37.1.3 Antall ganger sykehusinnlagt  
(Sett 0 dersom du ikke var sykehusinnlagt i forbindelse med oppholdet) 
Antall ganger__ 
 
Hvis Antall ganger sykehusinnlagt =0, hopp til spm 38.1. 
Hvis Antall ganger sykehusinnlagt >0: 
  
For hver sykehusinnleggelse i land utenfor Norden siste 12 måneder, i hvilket land var du 
sykehusinnlagt, hvilken måned du ble sykehusinnlagt, og hvor mange dager var du sykehusinnlagt:  
37.1.3.1 Land 
Rullegardinmeny land alfabetisk (200 land) 
37.1.3.2 Måned sykehusinnlagt 
 Mars 2015 etc 
37.1.3.3 Varighet sykehusinnleggelse 
Antall dager__ 
38 ANTIBIOTIKAKJØP I UTLANDET 
38.1 Har du kjøpt antibiotika i utlandet i løpet av de siste 12 måneder 
(penicillinlignende medisin til behandling av infeksjon)?   
Nei Ja 
 
Hvis Nei, ferdig med skjema. 
Hvis Ja:  
  





38.1.1 Hvordan foregikk kjøpet? 
Behandlingen var etter resept fra lege/tannlege 
Kjøpte direkte fra apotek uten resept 
